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The Role of the Gp41 Membrane-Proximal Tyrosine Motif in Simian
Immunodeficiency Virus Pathogenesis
Abstract
A tyrosine-dependent sorting signal in membrane-proximal region of the envelope protein cytoplasmic tail
domain is conserved across all primate lentiviruses. It is known to be involved in mediating endocytosis
of envelope from the cell surface and in directing sorting of envelope to the basolateral membrane in
polarized cells, and its strict conservation implies that this motif is critical for viral function. Our
laboratory has previously shown that ablation of two amino acids from this motif produces a virus,
SIVmac239∆GY, that replicates well in rhesus (RhM) and pig-tailed macaques (PTM), but fails to infect
macrophages in vivo and spares CD4+ T cells in gastrointestinal lamina propria. Further, while 90% of
SIVmac239∆GY-infected PTM control the virus to undetectable levels, a small subset of PTM and all RhM
progressed to AIDS without evidence of increased gut damage and microbial translocation, uncoupling
this source of immune activation from development of AIDS. Additional mutations in the gp41
cytoplasmic tail in progressors were correlated with development of disease.
In this thesis, we identify in vitro properties that distinguish SIVmac239∆GY from its parent and evaluate
a number of putative compensatory mutations for their ability to restore a wildtype phenotype to
SIVmac239∆GY in these assays. We
determined that SIVmac239∆GY virions have reduced envelope levels on virions that are partially rescued
by addition of one of two compensatory mutations, S727P or R722G. Growth of SIVmac239∆GY was
reduced in macaque PBMCs and modulated by mutations that arose in vivo during chronic
SIVmac239∆GY infection. We also identified differences in Env cellular localization and impaired
endocytosis and basolateral sorting resulting from the ∆GY mutation. A novel ∆QTH mutation that arose
in vivo produced functional tyrosine-dependent motifs that restored basolateral sorting and endocytic
function to SIVmac239∆GY, the latter in an AP-2 dependent manner. Compared to SIVmac239,
SIVmac239∆GY-containing mutants also exhibited differences in cell surface distribution of envelope that
may contribute to reduction in envelope content of virions.
To test if putative compensatory mutations were sufficient to reconstitute an SIVmac239-like phenotype
in animals, we then inoculated naïve PTM with SIVmac239∆GY R722G or SIVmac239∆GY R722G + ∆QTH
(YFQL). We assessed key differentiators of SIVmac239 and SIVmac239∆GY, including the ability to infect
macrophages and to deplete gut CD4+ T cells. Although full pathogenicity and macrophage infection
were not restored, 3/6 animals became progressors and developed high peak viral loads, with trends
toward increased depletion of gut CD4+ T cells, and two died. Engineered mutations were stable
throughout infection, and in progressing SIVmac239∆GY + R722G infected animals, additional mutations
arose that appear to reconstitute endocytosis signals. These findings serve to further highlight the
exceptional importance of the membrane-proximal tyrosine motif to optimal function of SIV in vivo.
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ABSTRACT
THE ROLE OF THE GP41 MEMBRANE-PROXIMAL TYROSINE MOTIF IN
SIMIAN IMMUNODEFICIENCY VIRUS PATHOGENESIS

Samra E. Elser
James A. Hoxie, M.D.
A tyrosine-dependent sorting signal in membrane-proximal region of the
envelope protein cytoplasmic tail domain is conserved across all primate lentiviruses.
It is known to be involved in mediating endocytosis of envelope from the cell surface
and in directing sorting of envelope to the basolateral membrane in polarized cells,
and its strict conservation implies that this motif is critical for viral function. Our
laboratory has previously shown that ablation of two amino acids from this motif
produces a virus, SIVmac239∆GY, that replicates well in rhesus (RhM) and pigtailed macaques (PTM), but fails to infect macrophages in vivo and spares CD4+ T
cells in gastrointestinal lamina propria. Further, while 90% of SIVmac239∆GYinfected PTM control the virus to undetectable levels, a small subset of PTM and all
RhM progressed to AIDS without evidence of increased gut damage and microbial
translocation, uncoupling this source of immune activation from development of
AIDS. Additional mutations in the gp41 cytoplasmic tail in progressors were
correlated with development of disease.
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In this thesis, we identify in vitro properties that distinguish SIVmac239∆GY
from its parent and evaluate a number of putative compensatory mutations for their
ability to restore a wildtype phenotype to SIVmac239∆GY in these assays. We
determined that SIVmac239∆GY virions have reduced envelope levels on virions that
are partially rescued by addition of one of two compensatory mutations, S727P or
R722G. Growth of SIVmac239∆GY was reduced in macaque PBMCs and modulated
by mutations that arose in vivo during chronic SIVmac239∆GY infection. We also
identified differences in Env cellular localization and impaired endocytosis and
basolateral sorting resulting from the ∆GY mutation. A novel ∆QTH mutation that
arose in vivo produced functional tyrosine-dependent motifs that restored basolateral
sorting and endocytic function to SIVmac239∆GY, the latter in an AP-2 dependent
manner. Compared to SIVmac239, SIVmac239∆GY-containing mutants also
exhibited differences in cell surface distribution of envelope that may contribute to
reduction in envelope content of virions.

To test if putative compensatory mutations were sufficient to reconstitute an
SIVmac239-like phenotype in animals, we then inoculated naïve PTM with
SIVmac239∆GY R722G or SIVmac239∆GY R722G + ∆QTH (YFQL). We assessed
key differentiators of SIVmac239 and SIVmac239∆GY, including the ability to infect
macrophages and to deplete gut CD4+ T cells. Although full pathogenicity and
macrophage infection were not restored, 3/6 animals became progressors and
developed high peak viral loads, with trends toward increased depletion of gut CD4+
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T cells, and two died. Engineered mutations were stable throughout infection, and in
progressing SIVmac239∆GY + R722G infected animals, additional mutations arose
that appear to reconstitute endocytosis signals. These findings serve to further
highlight the exceptional importance of the membrane-proximal tyrosine motif to
optimal function of SIV in vivo.
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CHAPTER 1

General Introduction
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Overview
Since its identification in 1983, human immunodeficiency virus (HIV) and the
associated acquired immune syndrome (AIDS) has become one of the most
significant infectious diseases of the era. The Centers for Disease Control estimate
about 50,000 new cases of HIV currently occur in the United States per year.1 Despite
substantial improvements in diagnosis and treatment, efforts to develop a vaccine
against HIV have been disappointing. Of the nearly 200 vaccine trials to date, just
five have progressed to efficacy studies, and only one of these demonstrated any level
of protection against acquisition of HIV.2 Factors contributing to the difficulty in
vaccine development include the remarkable sequence diversity of HIV-1, the
inability of most infected individuals to naturally clear or suppress the virus, and
failure of researchers to identify immune correlates of protection against infection.3,4

As known methods for vaccine development have failed to produce an
effective HIV vaccine, a goal for the field has been to increase our understanding of
viral pathogenesis, with the idea that successful drug or vaccine strategies should
target vulnerable aspects of the viral life cycle.5 These discoveries have led to the
development of multiple classes of antiretroviral drugs that act at distinct points in the
HIV reproductive pathway, allowing multidrug therapy regimens that inhibit virus
replication by several different mechanisms.6 Antiretroviral therapy (ART) has
greatly improved the quality and duration of life for HIV-positive individuals, but
treatment is expensive, lifelong, and inaccessible to a large percentage of infected
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individuals, particularly those in developing countries.7 In addition, ART does not
eliminate the chronic immune activation induced by HIV infection, and long-term
sequelae of infection and side effects of treatment continue to plague many patients.8
As such, the need for a prophylactic vaccine remains urgent.

Prevention of infection appears to require blocking viral replication prior to
establishment of a latent reservoir.9 Ideally, early steps of the viral life cycle should
be targeted, as clearance of the virus from infected individuals has thus far proven
nearly impossible.10 The envelope protein (Env), which HIV uses to enter cells, is
functional during early stages of infection and contains conserved sequences that are
critical to pathogenesis.11 Understanding how these domains contribute to natural
history in hosts and their importance to the virus allows both development of antiviral
agents that exploit these regions and identification of aspects of pathogenesis that
should be targeted by vaccines. Additionally, these motifs may drive immunogen
design as we determine what components of Env are most effective in eliciting
protective responses against pathogenic challenge.

Vaccines often aim to target antigens on the virion surface, allowing for
neutralization of the pathogen before it interacts with target cells.12–15 HIV Env,
present on the virion surface, is an attractive vaccine target for several reasons. It is
critical for the virus to enter permissible cells, it is present and exposed on the virion
surface at the earliest stages of infection, and it has conserved regions that are
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relatively consistent across strains. In the 1970s, researchers induced protective
humoral immune responses against hepatitis B virus (HBV) by administration of
purified, inactivated HBV surface antigen (HBsAg) from sera of infected humans.15
This approach resulted in the licensing of a successful vaccine against HBV.14,15
Shortly thereafter, a system to produce HBsAg in yeast yielded the first recombinant
vaccine, still relying on induction of antibody responses against the HBV surface
protein.16 However, similar approaches were not effective against HIV, prompting the
need for additional research to identify the role of conserved motifs in pathogenesis
and to improve our understanding of how immunogens can be designed to elicit
relevant immune responses.17

Primate Lentivirus Structure and Life Cycle
HIV and its evolutionary precursor simian immunodeficiency virus (SIV)
have analogous virion structures typical of retroviruses. Virions are roughly 100 nm
in diameter, enveloped, and contain all constituents necessary for infection and
reproduction by the virus, including an RNA genome.18 Approximately 7-14 Env
trimers stud the surface of the virion.19,20 Env spikes are trimers of heterodimers,
consisting of a gp120 surface domain and a gp41 transmembrane domain. Env is
heavily glycosylated co-translationally with N-linked and O-linked
oligosaccharides.21,22 These glycans, which contribute half of the molecular mass of
gp120, aid in shielding epitopes from recognition by the immune system.11 The first
step in the viral life cycle involves the virus binding to cells, which may initially
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occur via attachment factors such as DC-SIGN or proteoglycans on the cell surface.23
Following nonspecific attachment, the Env gp120 binds to the primary cellular
receptor, CD4.24,25 Engagement of CD4 causes conformational changes in Env that
allow binding of the gp120 V3 loop and the newly formed bridging sheet domain to a
coreceptor, most commonly CCR5.26,27 While HIV uses CCR5 or sometimes CXCR4,
SIV relies primarily on CCR5, but can also utilize alternative coreceptors such as
GPR15 and CXCR6.28–30 Coreceptor binding exposes the fusion peptide region of
gp41, which inserts into the cell membrane and undergoes a conformational change
that brings the virion and cell membranes into apposition.31 Membrane mixing allows
delivery of the virion contents into the host cell.32 Following entry, uncoating of
capsid releases the positive-sense RNA genome, from which DNA is reverse
transcribed by the viral reverse transcriptase.33 A pre-integration complex forms and
undergoes nuclear import, and viral DNA is integrated into the host genome,
mediated by the viral integrase protein.34 In a subset of cells, typically resting cells,
the virus may remain dormant. These latently infected cells contain the viral
reservoir, a sequestered population of virus that has been a significant obstacle to
cure, as identification and eradication of latently infected cells remains a challenge
for clinicians and researchers.9,34 However, most infected cells are in an activated
state and are undergoing transcription, and integrated DNA is transcribed by host
enzyme RNA Pol II into viral mRNA, giving rise to all viral proteins.35 Finally,
various host factors are exploited to direct virion assembly and trafficking of viral
proteins to sites of budding, primarily at the plasma membrane.36 Immature virions
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are released, and viral capsid protein is cleaved by viral protease post-budding to
form the mature, infectious virion.37

Virus Assembly and Budding
HIV and SIV assembly and budding involve interactions between the viral
Gag and Env proteins and recruitment of host proteins to facilitate production of
virions (Fig. 1). Importantly, budding can occur in the absence of Env, implying that
Gag and Env targeting to assembly sites may occur through separate mechanisms.38
The Gag polyprotein precursor (PrGag) is synthesized in the cytosol. This molecule
has four major components: matrix (MA), capsid (CA), nucleocapsid (NC) and the p6
domain, as well as two spacer peptides (Fig. 1).36 Following synthesis, PrGag is
targeted to the plasma membrane through interaction of a basic region in MA with
host phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].39,40 Binding of a second
region of the MA domain to PI(4,5)P2 induces a conformational change in MA that
exposes a myristyl group at the N-terminus of of the domain.41 This myristyl group
aids in targeting and binding of PrGag to the plasma membrane, and mutation of the
myristoylation target glycine impairs these functions.42 PI(4,5)P2 binding both
exposes the myristyl and serves as a direct anchor for MA to the plasma membrane,
promoting association of PrGag with the membrane. Saturated fatty acids such as
myristyl preferentially target lipid raft domains, providing further evidence for the
current hypothesis that HIV-1 release occurs at lipid raft microdomains.41
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NC contains sequences called zinc knuckle domains that bind a packaging
signal at the 5’ end of the viral genomic RNA, effectively capturing the genome
within the assembling virion. Viral assembly is initiated by interactions between
PrGag and RNA, but the primary driver of multimerization is CA. As PrGag
accumulates, it assembles into hexamers, which form a lattice at the inner leaflet of
the plasma membrane.43 The CA domains assemble deep to this lattice, and although
the precise structure of this region and of interactions between CA monomers is not
fully resolved, there is some evidence in for a similar organization of the MA and CA
domains.44,45
Following assembly of the PrGag lattice, the virus recruits components of the
cellular ESCRT complex to facilitate virion budding. Late domains in PrGag bind,
specifically a PTAP motif in the p6 region, bind the host protein TSG101, a
component of the ESCRT-1 complex.46 A second late domain, YPXL, binds the
accessory protein ALIX, enhancing viral release.47,45 Ubiquitylation of viral Gag may
also aid in recruitment of ESCRT complexes, although this function is not fully
understood. Targeting of ESCRT family members to sites of budding is critical for
membrane scission, though conflicting hypotheses exist for a mechanism. One model
involves ESCRT-III protein assembly into rings that pinch off membranes by
constriction, but some imaging suggests that ESCRT proteins localize into the virion
head and promote fission from the interior of the virion.48,49 Additionally, ESCRT-III
recruitment of VPS4, an ATPase, is an energy source for scission and also recycles
ESCRT following budding.45 Incorporation of Env into virions, which is dispensible
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for the process of assembly and budding, appears to occur through a separate
mechanism and will be discussed below. The process of viral assembly and release
thus requires appropriation of multiple cellular pathways to organize viral
components for production of new virions.

Envelope Glycoprotein Structure and Trafficking
The envelope protein of primate lentiviruses has been of interest to the field as
an immunogen and therapeutic target. The earliest studies of candidate HIV vaccines
used recombinant Env immunogens to induce neutralizing antibody responses in
humans.50 These approaches modeled similar designs for Herpes Simplex Virus and
Hepatitis B (glycoprotein D and Hepatitis B surface antigen, respectively), which
targeted viral surface antigens and elicited a humoral immune response.15,51 HIV
neutralizing antibodies (NAb), which are directed against the Env protein, had been
shown to protect macaques from SIV acquisition, and induction of such responses
was the prime goal of initial vaccine designs.52–55 A limitation of this approach is that
the majority of antibodies that develop in HIV-infected individuals are strain specific;
that is, they target regions of Env that are highly variable.56 The ability of HIV to
mutate the exposed Env variable loops while maintaining protein function is a key
strategy for the virus to evade humoral immunity.57 Over time, patients may develop
serum antibodies that are capable of neutralization, but these typically neutralize the
viral strain that initiated infection in the individual, and do not extend neutralization
to heterologous strains of HIV, or even to chronic virus from the same individual,
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severely limiting their clinical relevance.58 In contrast, a much smaller proportion of
patients develop broadly neutralizing antibodies (BNAbs), which neutralize multiple
strains of HIV and target conserved regions of Env.5 Design of an Env immunogen
that elicits BNAbs has proved elusive, but would be an effective antibody-based
strategy for vaccine design.

The HIV and SIV envelope is synthesized in the rough endoplasmic reticulum
as a 160kDa protein precursor, which is co-translationally glycosylated.11,59 The
precursor oligomerizes, primarily forming trimers, and is transported to the Golgi
apparatus, where it is cleaved by host furin into mature gp120 (surface, SU) and gp41
(transmembrane, TM).60 The processed subunits remain associated as a trimer of
heterodimers, forming a single Env spike, 7-14 of which are typically incorporated
into each virion.19,20,61

The gp41 cytoplasmic tail domains of HIV and SIV Envs contain motifs that
mediate endocytosis of the protein from the cell surface and direct protein trafficking
within infected cells. These motifs are similar in structure to cellular trafficking
signals, allowing viral proteins to hijack cellular machinery for use in production and
assembly of nascent virions. 62 At least two endocytosis signals have been identified
in the SIV cytoplasmic tail. The first, a tyrosine-dependent signal located proximal to
the membrane spanning region of gp41, is conserved across all HIV and SIV
isolates.63 The second known endocytosis motif in gp41 is a C-terminal dileucine,
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Figure 1-1: Schematic of primate lentivirus assembly and budding.
Envelope synthesis occurs in the RER and the protein is trafficked to the plasma membrane through
the Golgi and TGN via the secretory pathway. Sites of budding are targeted through a mechanism
thought to involve the membrane-proximal tyrosine motif, as well as interactions of the gp41
cytoplasmic tail domain with matrix and host factors, including TIP47. The polyproteins PrGag and
GagPol are synthesized from genomic RNA in the cytoplasm and targeted and bound to lipid rafts on
the plasma membrane through interactions of MA with PIP(4,5)P2 and of the MA myristyl group
with the membrane. The RNA genome is recruiting and packaged by interaction with CA. The host
ESCRT complexes and ALIX are recruited to facilitate membrane scission and viral release.

	
  

10	
  

characterized in the Env of HIV HXB2. This motif functions as efficiently as, and
independently of, the membrane-proximal tyrosine motif.64 It has been shown both in
HIV and SIV that these two motifs bind to the cellular adapter complex AP-2 and
mediate clathrin-dependent endocytosis.64–66

The membrane-proximal tyrosine motif is of particular note due to its strict
conservation and implication in a multitude of Env functions. Tyrosine-dependent
domains of this structure have been well characterized in eukaryotic cells as
multifunctional sorting signals. This motif is present in a diverse set of cellular
proteins, including the lysosomal LAMP family, cell adhesion molecules, and the
protease furin.62 The sequence in eukaryotic proteins is YxxΦ, in which x represents
any amino acid and Φ represents an amino acid with a bulky hydrophobic sidechain.67
In primate lentiviruses, a glycine preceding the tyrosine has also been shown to be
important in mediating efficient endocytosis. While the specific amino acid sequence
varies between viruses, e.g. GYRPV in SIVmac239 and SIV BK28 and GYSPL in
HIV-1 HXB2,63,66,68 the glycine, tyrosine, proline, and bulky hydrophobic residue are
consistently present.69 Endocytosis signaling has also been attributed to the
corresponding tyrosine residue in HIV-1, implying that this motif is both structurally
and functionally conserved across primate lentiviruses.70 Mapping experiments using
alanine substitution or other mutational analysis have localized endocytic function to
the glycine, tyrosine, and a proline at the Y+2 site, with endocytosis rate being
significantly decreased when the relevant residues are replaced.65,66
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Multiple groups have shown binding of this motif, in lentiviral and eukaryotic
proteins, to the µ subunits of the cellular adapter complexes AP-1 and AP-2.71,72
Within eukaryotic cells, AP-1 is located in the trans-Golgi network (TGN) and
believed to mediate trafficking of cargo to endosomes or lysosomes. AP-2 is found
primarily at the plasma membrane and functions in clathrin dependent endocytosis,
removing transmembrane proteins from the surface of the cell.62,72–75 Our
laboratory has previously shown that an SIV with a Y723C mutation at the tyrosine
residue and a cytoplasmic tail truncation has roughly 25-fold increased expression of
Env on the cell surface.63 In SIVmac239, which expresses a full length cytoplasmic
tail, Y723C confers a four-fold increase of Env expression, consistent with the
presence of additional endocytosis signals downstream from the membrane-proximal
tyrosine motif.63 Other groups have demonstrated that HIV and SIV Env are first
expressed on the cell surface,76,77 and following internalization via clathrin-mediated
endocytosis, appear to co-localize with lysosomal markers, though this may represent
a recycling rather than a degradative pathway.66,76,78–80

In addition to its role in endocytosis, the membrane-proximal tyrosine motif
also directs sorting of proteins trafficking to the cell surface. Within eukaryotes, some
cells have distinct regions or domains of the plasma membrane with unique
biochemical properties. For example, epithelial cells are frequently polarized and
have dissimilar compositions on their apical or lumenal versus basolateral surfaces
that contribute to the function of the tissue.81 Leukocytes, particularly T cells in
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Figure 1-2: Intracellular envelope trafficking and host protein interactions.
Synthesis of the envelope precursor gp160 occurs in the rough endoplasmic reticulum, where the
protein is co-translationally glycosylated. gp160 is transported to the Golgi apparatus, cleaved by
host furin into gp120 and gp41, and trafficked through the trans-Golgi network. The protein follows
the secretory pathway to endosomes, where it is targeted to lipid rafts on the plasma membrane and
preferentially to the basolateral membrane in polarized cells by association with the adapter complex
AP-1. Palmitoylation and the LLP domains are thought to be involved in lipid raft association. Env
is then either incorporated into new virions, likely through interactions with viral MA, or removed
from the plasma membrane by clathrin dependent endocytosis. The latter is mediated by AP-2
binding and results in targeting of the protein either to lysosomes for degradation or to endosomes
for return to the plasma membrane.
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lymph nodes, are also polarized, with distinct localization of actin, adhesion
molecules, and other surface proteins to aid in migration and adhesion.82,83 AP-1
adapter complexes bind cellular sorting signals and direct relevant proteins from the
TGN to the basolateral membrane in such cells.81,84,85 It has long been known that
tyrosine-based motifs in cellular proteins and in the surface glycoprotein G of
vesicular stomatitis virus (VSV) can direct proteins to the basolateral surface.86
Similarly, in polarized cell lines and in lymphocytes, wildtype HIV Env preferentially
targets the lymphocyte pole that is analogous to the basolateral surface of epithelial
cells, and is thought to determine in part the sites from which virions bud from the
plasma membrane.87–89 Further investigation localized the determinant of polarized
budding to gp41 and specifically the membrane-proximal tyrosine motif.89,90
Although Env is dispensable for budding of virions (this is determined by
components of the Gag polyprotein), there is evidence for an interaction between Env
and matrix (MA) during viral assembly that suggests Env is responsible for directing
specific sites of budding at the plasma membrane.61,87,91–94 While the membraneproximal tyrosine motif has not been a candidate motif for interaction with MA, it has
been shown to be a regulator of Env incorporation into virions, strengthening the case
for its role in correctly targeting Env to assembly sites on the plasma membrane.95–97

As mentioned above, Env targeting to assembly sites is not required for viral
budding and release, but, predictably, is necessary for production of infectious
virions. The Env cytoplasmic tail has been implicated in directing incorporation into
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Figure 1-3: Location of the membrane-proximal tyrosine motif in SIVmac239 gp41
The membrane spanning domain (MSD) of gp41 is indicated by the gray box. Amino acids of the
cytoplasmic tail domain from the membrane spanning domain to the stop codon are numbered
according to the SIVmac239 sequence. The membrane-proximal tyrosine motif (GYxx!) is
highlighted in yellow.
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virions, and several studies have provided evidence that interactions between the Env
tail and MA are determinants of this function.94,98,99 In HIV-1, interactions between
Env and MA have been mapped by demonstrating that point mutations in MA can
prevent incorporation of Env into virions, and that deletions in the Env tail that
abrogate Env incorporation can be rescued by additional MA mutations.100,101,91,102
Interestingly, in viruses with MA mutations that block Env incorporation into virions,
Env incorporation is restored if the cytoplasmic tail is truncated.92,102,91,100
Interactions between Env and MA are less well characterized for SIV, and for both
viruses, the exact nature of the association remains controversial. One study found a
direct interaction between the proteins when produced in prokaryotic cells.103 More
recent work demonstrated that TIP47, a eukaryotic trafficking protein, was a mediator
of interaction between Env and MA, but not required for their binding or for
incorporation of Env into virions.99,104,105 With regard to trafficking of Env to sites of
viral budding, the cytoplasmic tail also contains signals that confer localization to
lipid raft microdomains at the plasma membrane. As mentioned earlier, these regions
of the membrane are rich in cholesterol, glycosphingolipids, and GPI-anchored
proteins, and are thought to be preferred budding locations for HIV assembly and
release.106,107 The signals that dictate localization to lipid rafts, the lentiviral lytic
peptides (LLP) 1-3, are amphipathic α-helices at the C-terminus of the gp41
cytoplasmic tail domain.107
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Incorporation of Env is a critical step in formation of infectious virions; Env
levels on HIV virions have been shown to correlate with particle infectivity and as
such, regulation of this feature is a critical determinant of productive infection.91,95 At
least one study of SIV found that an increase in Env on virions correlated with
increased infectivity, which may be due in part to greater resistance to antibodymediated neutralization.108,109 Consequently, the function of the membrane-proximal
tyrosine motif in directing sorting of Env may be critical to production of fully
infectious particles. However, the direct role of this motif in Env incorporation into
virions is not fully understood. A second possible implication for this region of gp41
is in directing Env to aid in creation of the virological synapse, a mechanism by
which cell-to-cell spread occurs in infected tissues.110 Interestingly, as for viral
budding and release, lipid rafts have been associated with virological synapses,
further implicating Env targeting in their formation.111

Direct cell-to-cell, rather than cell-free spread of infection is advantageous to
the virus for a number of reasons; it is more efficient, requiring fewer infectious
particles, it limits exposure of the virus to the host immune system, particularly
neutralizing antibodies, and it may reduce the effectiveness of restriction factors such
as tetherin.110 Cell-to-cell spread commonly occurs between T cells, but infected
dendritic cells and macrophages can also transfer virus to uninfected T cells.112,113
This transfer is thought to be important in the spread of virus from sites of
transmission at mucosal surfaces, such as the GI tract, to secondary lymphoid
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tissue.113,114 In both types of interaction, virological synapses, named for their
structural resemblance to an immunological synapse, form via interaction between
HIV Env expressed on an infected cell and CD4 on an uninfected cell.115 A slightly
different, CD4-independent mechanism, allows formation of a virological synapse
that mediates spread of HIV from T cells to epithelial cells in the GI tract and renal
tubules, which may contribute to viral reservoirs.116 In the canonical virological
synapse, high concentrations of HIV Gag are recruited to the uropod membrane of
polarized T cells, a region rich in characteristic adhesion molecules.115 After EnvCD4 binding, these adhesion molecules are thought to further stabilize the interaction
between the cells.113 Once the connection has been established, HIV particles
assemble and bud from the plasma membrane within the synapse, efficiently
transferring large numbers of particles to the recipient cell.113,117 As cell-to-cell
transfer via the virological synapse may be the main mediator of spreading infection
in tissues, targeting of Env to sites of budding is likely critical to productive infection
in vivo, and particularly relevant at mucosal sites where cell-to-cell spread may be the
dominant mechanism of viral propagation.110,113,117 It is possible that disruption of
Env targeting could impair the ability of the virus to efficiently spread in GALT and
have serious repercussions for pathogenicity.

Pathogenicity
Within the Retroviridae family, HIV and SIV are classed as lentiviruses, from
the Latin lente, meaning slow, as their pathological effects occur over extended time
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periods.118–120 Both cause disease by depleting subsets of lymphocytes that are critical
to immune function, as well as by inducing a chronic state of inflammation and
immune activation in the host.121 CD4+ cells, particularly those expressing high levels
of CD4 and CCR5, are the primary targets of HIV.122 These cells are predominantly
CD4+ T lymphocytes, but can also include monocytes and macrophages, which have
lower CD4 density, as well as high levels of CCR5.123–125 Specifically, memory CD4+
T cells express the highest levels of CCR5, with effector memory T cells representing
the primary subset for replication, although resting and naïve CD4+ T cells (which
express higher levels of CXCR4) can also be infected.10,123,126,127 Similarly, there is
increased contribution to viral production from macrophages and monocytes later in
the disease course, and these cells are infected by variants of HIV that are capable of
using lower CD4 densities for entry.123,124,126

During acute infection, large numbers of CD4+ T cells are killed by multiple
mechanisms, the details of which are an area of ongoing investigation and include
direct infection, apoptosis, and bystander pyroptosis resulting from abortive
infection.128–130 Cell-mediated immune responses are also important in killing of
infected cells and thus controlling viral replication in the acute phase. HIV-specific
CD8+ T cell precursors are present as early as three weeks post-infection, and their
presence correlates with decreases in viremia.131 There is also evidence for HIVspecific CD4+ T cell responses, which may provide help to CD8+ cytotoxic T
lymphocytes (CTLs) or function in a direct antiviral role as cytotoxic CD4+ cells.132
	
  

19	
  

Further evidence for the importance of CTL responses in control of viremia is
provided by nonhuman primate models, in which the evolution of escape variants
with mutations in Tat CTL epitopes is seen immediately following the acute phase of
SIV infection.133 During chronic infection, viral replication decreases as adaptive
immune responses arise, and the host is able to reconstitute sufficient CD4+ T cells
for immune function.134 Over time, control of viremia cannot be maintained, plasma
viral load rises, and CD4+ cells in peripheral blood gradually decline, eventually
reaching a level that permits opportunistic infections and contributes to the death of
the host.135

The majority of CD4+ T cells are found in lymphoid tissues, rather than in
peripheral blood, and thus the majority of viral replication appears to occur in these
sites.136 Infected activated CD4+ T cells are commonly found in the lymph node
paracortex, as well as in peripheral blood.137,138 The gut-associated lymphoid tissue
(GALT), the largest compartment of lymphoid tissue, is an essential site of early viral
replication.139,140 CD4+ T cells in GALT are rapidly and irreversibly depleted very
early in infection, in conjunction with GI inflammation that leads to epithelial damage
and translocation of bacteria from the gut lumen into the lamina propria.140–143
Microbial translocation is thought to be a major contributor to the chronic immune
activation that is a hallmark of AIDS.144
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Immune activation leads to increased recruitment of activated CD4+ T cells,
fueling viral replication. Studies of both HIV and SIV have shown an increase in
circulating microbial products such as lipopolysaccharide (LPS) in chronically
infected hosts. Notably, Brenchley et al.145 demonstrated an association between
circulating LPS and intestinal bacterial load in SIV-infected macaques, suggesting
that LPS in plasma is primarily derived from translocation of bacteria from the
intestine through a damaged gut epithelium. They also identified a correlation
between plasma LPS and plasma soluble CD14 (sCD14), the soluble form of the
surface LPS receptor CD14, which is shed by activated CD14+ monocytes following
LPS stimulation.145,146 Further, natural hosts of SIV such as sooty mangabeys, which
do not develop persistent immune activation or AIDS despite chronically high plasma
viral loads, do not have increased plasma LPS or sCD14 compared to uninfected
control animals.147 Microbial translocation also appears to be related to variations in
disease course across species of macaques. Pig-tailed macaques (PTM), discussed in
greater detail below, appear to be more susceptible than rhesus to the pathologic
effects of SIV infection in that they progress more quickly to AIDS despite similar or
even slightly lower average plasma viremia.148 Investigation of the gastrointestinal
health of PTM revealed damage to the epithelium of the gastrointestinal tract in the
absence of SIV infection, leading to high baseline levels of microbial translocation.
This correlated with increased immune activation as measured by T cell turnover and
proliferation, and more memory and effector T cells, including a higher percentage of
CCR5+ T cells.149
	
  

21	
  

SIV models
Simian immunodeficiency virus (SIV) shares a common ancestor with HIV-1
and, like HIV-1, can induce immunopathology following infection of a susceptible
host.150 HIV-1 originated from three independent cross-species transmission of
SIVcpz from chimpanzees to humans, likely due to ingestion of nonhuman primate
products (bushmeat) by humans in western equatorial Africa.151,152 Non-human
primate (NHP) models recapitulate many features of HIV-1 infection in humans and
have been implemented in vaccine development and pathogenesis research. The two
most common species currently used in HIV research are the rhesus macaque
(Macaca mulatta) and the pig-tailed macaque (Macaca nemestrina).153 Inoculation
via intravenous (IV) or mucosal routes with swarm or molecularly cloned pathogenic
SIV induces AIDS-like pathology in an accelerated model, mimicking human
infection with HIV-1 and providing a biologically relevant model for studies of
pathogenesis.153–158

The rhesus macaque model has been extensively studied using a variety of
SIV strains, the best characterized being SIVmac239, an infectious molecular clone
originating from the SIVmac251 swarm.159–161 SIVs were first noted after several
cases of lymphoma and opportunistic infections occurred in macaques at multiple
primate centers.162 Contemporaneously, experimental induction of leprosy via tissue
transfer from sooty mangabeys (SM) to rhesus macaques resulted in AIDS in
macaques at Tulane National Primate Research Center.163 SIVs were isolated from
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these animals and later shown via phylogenetic analysis to have originated from
asymptomatic SMs.150 The discovery of a pathogenic lentivirus infection in nonhuman primates suggested that macaques were, analogous to humans, non-natural
hosts of SIV, and could represent a new model for HIV pathogenesis.164

When SIV infects a non-natural host such as the rhesus macaque, animals
develop simian AIDS, a syndrome that closely mirrors AIDS in humans. Disease is
characterized by high viremia followed by a decrease to set-point, early depletion of
CD4+ T cells in the GALT, declining CD4+ T cells in peripheral blood, chronic
immune activation, opportunistic infections, neoplasias, weight loss, and eventual
death.148,159 Unlike HIV-associated AIDS in humans, which manifests over a period
of years to decades, within the macaque model, simian AIDS develops within 1-2
years, greatly accelerating the course of disease and facilitating studies of
pathogenesis.148

In addition to more general studies of pathogenesis, the rhesus macaque model
has also been used to study variations in susceptibility to SIV transmission throughout
the menstrual cycle in females.165,166 Studies of viral transmission dynamics,
including identification and characterization of transmitted founder viruses, have also
been performed in rhesus macaques, as animals can be experimentally infected with
quantified inocula and with genetically modified tagged viruses.156,157,167 These early
infection events, which are critical to understanding viral kinetics and dissemination,
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are difficult or sometimes impossible to perform in human subjects. Studies of dose
and route of infection in rhesus macaques have optimized our ability to recapitulate
mucosal HIV transmission in a consistent animal model.158

While many seminal discoveries have been made in rhesus, in the early 2000s
a shortage of this species due to their popularity for vaccine and pathogenesis
research prompted investigation into alternative models.168,169 Early studies
comparing pig-tailed to rhesus macaques suggested that they would represent
similarly appropriate models for HIV infection.170 Subsequently, pig-tailed macaques
gained popularity for pathogenesis studies due to their larger size, cooperation in oral
dosing of ART, and resilience under stress. They also progress more rapidly to AIDS
(average 42 weeks versus 69 weeks for rhesus macaques) in association with
thrombocytopenia, a characteristic hematologic change observed in human
patients.148 Initially, major histocompatibility complex (MHC) alleles had not been
characterized in pig-tailed macaques. Given that certain MHC alleles in humans and
rhesus are associated with a long term nonprogressor (LTNP) phenotype, concern
arose over consistency of phenotype in PTM models.171 Similar protective alleles in
pig-tailed macaques have now been identified, though there remains some
controversy regarding their contribution to phenotype.172–174 An additional advantage
of the PTM model is that while the majority of rhesus macaques express Trim5α, a
host restriction factor that blocks HIV replication in macaques, pig-tailed macaques
instead express a TRIM5α-Cyclophilin A fusion termed TRIM-Cyp, which is more
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permissive to HIV infection.175–177 As a result, minimal modifications to HIV allow it
to replicate in pig-tailed macaques, that has shown some promise for creating a novel
model for vaccine studies as an alternative to SHIVs.178

SIV live attenuated vaccines (LAVs) are historically the most effective
immunogens in eliciting protective responses in macaque models.179 Although the
risk of reversion to pathogenicity precludes the use of LAVs in humans, models of
protection are useful for identifying immune responses that correlate with protection
from challenge, as well as testing novel immunogens.180 Genetically modified SIVs
also provide an elegant system in which to examine the roles of various proteins or
domains in pathogenesis, as the effect of removing or mutating portions of the
genome can be studied in vitro or in animal models. Several modifications to the
pathogenic molecular clone SIVmac239 have been examined as LAVs. These altered
viruses result in nonpathogenic infection in rhesus macaques, which are then
protected against challenge with homologous or heterologous pathogenic SIV.
SIVmac239 deletion mutants include those with deletions in nef (SIVmac239Δnef);
in nef, vpr, and upstream U3 sequences of the long terminal repeat (SIVmac239Δ3);
nef, vpx, and U3 (SIVmac239Δ3x); and nef, vpr, vpx, and US (SIVmac239Δ4).181,182
Another method of producing an attenuated vaccine strain involves engineering SIVs
limited to single-round infection (single cycle SIV, scSIV).183
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A myriad of studies have characterized SIV mutants to determine the effect of
various mutations on pathogenesis. As early as the mid-1990s, researchers have
engineered mutations into SIVmac239 and other SIV molecular clones and evaluated
their effect on viral structure and function.63,184–186 The most comprehensively studied
SIVmac239 mutant is Δnef. While Nef, an accessory protein, is not required for
replication in most cell culture systems, elimination of the functional gene product
decreases replicative capacity and has a substantial effect on viral growth in
vivo.187,188 Throughout infection, rhesus macaques infected with SIVmac239Δnef
exhibit plasma viral loads approximately 100-fold lower than those infected with the
SIVmac239 parent, although virus persists after inoculation.187 Despite persistent
virus, animals typically remain clinically well for up to three years post-inoculation,
though there has been documentation of pathogenic SIVmac239Δnef infection in both
adult and neonatal rhesus maacques.189–192 Most SIVmac239Δnef infections, however,
do not cause clinical disease, and many groups have reported the development of
protective immune responses against SIV in these animals.187,189,193–198 In one study,
27 months after infection with SIVmac239Δnef, four rhesus macaques resisted a
high-dose intravenous (IV) homologous challenge with either SIVmac239 or
SIVmac251. These animals did not display detectable viral antigen (p27, Gag) in
plasma and remained healthy, while control animals became infected by challenge
virus and succumbed to AIDS.197 A second study intravenously challenged 10
SIVmac239Δnef-infected animals with a heterologous strain, SIVsmE660. In contrast
to the results of the homologous challenge, eight of 10 vaccinated animals became
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infected with the heterologous challenge virus and exhibited detectable SIVsmE660
in plasma; the remaining two animals showed increased viremia post-challenge, but
only the vaccine strain could be detected. No animals had neutralizing antibody
activity against SIVsmE660.199 The same group also performed a heterologous
intrarectal challenge of SIVmac239Δnef-infected animals, finding delayed acquisition
and improved control of viremia in vaccinees.195 In both studies, multiple animals
experienced recombination between the vaccine strain and the challenge strain.195,199

Comparisons between SIVmac239Δnef and other deletion mutants
(SIVmac239Δ3, Δ3x, Δ4) demonstrate that additional deletions result in greater
attenuation as measured by peak plasma viral load.182 Mutations in vif have been
shown to render viral particles less infectious and attenuate replication in vitro.184
There is evidence that vpx is important for macrophage tropism in animal models, but
that AIDS can develop in the absence of this phenotype.200 Deletion of vpr did not
prevent development of AIDS in rhesus macaques, but disease progression was
delayed, and two animals remained healthy, suggesting some degree of attenuation
for a Δvpr virus.186 A large subset of mutagenesis studies have focused on alterations
to env. Multiple groups have evaluated mutations in the constant regions of env,
including their effects on entry, replication, and gp160 processing.185,201 Importantly,
these studies have also mapped residues that are determinants for interaction of Env
with CD4 and made comparisons to analogous residues in HIV-1.201,202 This work led
to identification of amino acid determinants of CD4-independent entry and
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macrophage tropism in SIV by comparison of SIVmac239 Env sequence with the
CD4-independent, macrophage-tropic SIVmac316.203 Determinants of coreceptor
tropism have also been identified using similar techniques of site-directed
mutagenesis.204

HIV and SIV Envs are known to have long cytoplasmic tail domains (CTDs)
relative to other retroviruses.205 An unexpected finding during study of SIVs was that
the Env CTD spontaneously truncates when these viruses are propagated in human
cell lines, and revert to full-length sequence when grown in NHP cells.206,207 As such,
there has been interest in studying truncations of the CTD to determine its
contribution to viral phenotype. Tail truncations enhance replication in the context of
some SIV gp120s, but not all; SIVmac239 replication in vivo is not enhanced by this
mutation, and truncated SIVs quickly revert to full-length tails in animals.207–210
Additionally, some viruses with short CTDs have increased surface expression of Env
on infected cells, likely owing to the removal of endocytosis motifs present toward
the C-terminus of gp41.63,66,211,212 Studies of HIV and SIV have also demonstrated a
relationship between tail truncation and conformational changes to the gp120
ectodomain, which may have implications for immunogen design and interaction of
gp120 with cellular receptors.212,213 Short-tail SIVs have also provided evidence for
interaction between the Env and matrix proteins; viruses with matrix mutations that
are defective in virion Env incorporation are rescued by Env tail truncation.91,102
Further, tail-truncated SIVs often display increased Env on virions and improved
	
  

28	
  

infectivity.97,214 Paradoxically, mutations at the C terminus of Env can dramatically
decrease Env incorporation into virions and therefore particle infectivity, implying
that the CTD contains both positive and negative regulators of Env incorporation into
virions.96,214 The large body of work on engineered SIVs has yielded valuable insight
to viral factors important for pathogenicity as well as characteristics of effective
immunogens and goals for relevant protective immune responses.

Goals of This Thesis
The strict conservation of the gp41 membrane-proximal tyrosine motif among
primate lentiviruses implies that this domain is a critical component of the structure
or function of the envelope protein. While it has been implicated in a variety of
functions, including endocytosis, intracellular trafficking, plasma membrane
localization, and incorporation of Env into virions, the specifics of its effect on
virologic and pathogenic properties have not been well characterized. Here I present a
comprehensive investigation of a mutant SIVmac239 lacking this signal, together
with viruses containing possible compensatory mutations. In Chapter 2, I address in
vitro virologic properties such as growth in primary macaque cells, Env quantification
on virions, and Env distribution on the cell surface, as well as cell-dependent
phenotypes of total Env production, subcellular localization, and endocytosis and
sorting function. This SIVmac239 mutant virus is rapidly controlled and nonpathogenic in an in vivo model in pig-tailed macaques, lacking pathogenic signatures
of SIVmac239 infection, and induces immune responses that allow resistance or
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control of pathogenic challenge viruses. In Chapter 3, I assess whether putative
compensatory mutations added to this virus can restore pathogenicity in pig-tailed
macaques. In Chapter 4, I summarize these findings and propose further experiments
to continue the investigation of this motif and its role in viral pathogenesis. Mutation
of this highly conserved sequence, and subsequent evolution by the virus to restore its
function, provides a valuable tool to study determinants of pathogenicity in SIV and
to characterize protective immune responses elicited by a novel live-attenuated
vaccine.
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CHAPTER 2

In vitro Characterization of an SIVmac239 Variant With a Deletion in the TyrDependent Trafficking Signal of the Env Cytoplasmic Tail
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Abstract
The envelope (Env) protein of primate lentiviruses contains a tyrosinedependent trafficking motif in the cytoplasmic tail domain of gp41 that is strictly
conserved. To investigate the function of this GYxxΦ domain, we deleted glycine720 and tyrosine-721 from the SIVmac239 infectious molecular clone (IMC) to
produce a virus termed SIVmac239∆GY. In vivo, SIVmac239∆GY replicated acutely
to peaks comparable to SIVmac239, but failed to infect macrophages and spared gut
CD4+ T cells. Most pig-tailed macaques (19/21) controlled SIVmac239∆GY and
remained healthy. However, 4/4 rhesus macaques and 2/21 pig-tailed macaques
developed intermediate set-points and progressed to AIDS. Envelope cytoplasmic tail
mutations in progressors included R722G, S727P, and ∆QTH, a deletion of amino
acids 734-736, which produced novel YxxΦ motifs. We assessed in vitro properties
of SIVmac239∆GY and these putative compensatory mutations that could explain the
unique phenotype of this virus in macaques.

Mutations that arose in vivo mitigated the effects of SIVmac239∆GY, which
included reduced envelope on virions and impaired Env trafficking, as demonstrated
in assays for endocytosis and basolateral sorting. Infection of macaque peripheral
blood mononuclear cells (PBMCs) by IMCs revealed slight attenuation of
SIVmac239∆GY and variable effects of additional mutations. By imaging flow
cytometry in CEMx174 cells, a decreased proportion of SIVmac239∆GY-infected
cells exhibited clustered distribution of Env, which might represent alterations in Env
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surface expression in microdomains and possibly explain the decreased Env content
on virions. This effect was not changed by addition of R722G or ∆QTH, though the
former did increase surface envelope expression and restored Env content on virions.
Together, these results indicate important functions of the membrane-proximal
tyrosine motif of SIV in directing envelope protein trafficking within the cell and
potentially to sites of virion budding that are necessary for optimal viral function.
Further understanding of its role may provide insight to the mechanism by which
SIVmac239∆GY is controlled in pig-tailed macaques. In Chapter 3, we will assess the
ability of mutations arising in vivo to restore pathogenicity to SIVmac239∆GY.
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Introduction
Infection of non-natural hosts by human immunodeficiency virus (HIV) and
the closely related simian immunodeficiency virus (SIV) is characterized by several
pathologic features. These include high and persistent viremia, chronic immune
activation, rapid and sustained depletion of CD4+ T cells in the gastrointestinal
lamina propria, infection of tissue macrophages, and eventual loss of CD4+ T cells in
peripheral blood.8,159,163,215–219 Humans are a non-natural host of HIV, while
analogous hosts of SIVmac are Asian macaque species, including rhesus (RhM,
Macaca mulatta) and pig-tailed macaques (PTM, Macaca nemestrina).153,220 Infection
of these species by SIVmac239 recapitulates many features of HIV-1 natural history:
animals typically lose peripheral CD4+ T cells and develop AIDS within one year,
with PTM being particularly rapid progressors.148 It has been hypothesized that the
more rapid progression seen in PTM may be due in part to the greater levels of gut
microbial translocation, immune activation, and T cell turnover in this species prior to
SIV infection.149

We have described the virus SIVmac239∆GY, which is identical in sequence
to SIVmac239 except for a deletion of glycine-720 and tyrosine-721 in the envelope
protein cytoplasmic tail.221,222 This deletion ablates two key residues in the
membrane-proximal tyrosine motif, which is conserved across all HIVs and SIVs.66
In eukaryotic proteins, the YxxΦ motif, in which x is any amino acid and Φ is an
amino acid with a bulky hydrophobic sidechain, is known to mediate clathrin
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dependent endocytosis via the adaptor complex AP-2.71 In primate lentiviruses, the
motif extends to include an upstream glycine (GYxxΦ).76 This motif mediates
endocytosis of Env from the surface of infected cells, decreasing Env expression on
the cell surface, and the tyrosine residue has been implicated in directing basolateral
sorting of Env in polarized epithelial cells.63–66,90 Some cellular GYxxΦ motifs,
particularly those just downstream of transmembrane domains, are involved in
lysosomal targeting of transmembrane proteins.62 Additionally, the cytoplasmic tail of
Env has been associated with modulating incorporation of Env into virions, although
the underlying mechanism is unclear.92,96 The conservation of these features points to
this SIV membrane-proximal tyrosine motif as an important player in the modulation
of Env expression and targeting within infected cells. As described further below, the
∆GY mutation produces a virus with a strikingly different natural history in RhM and
PTM compared to SIVmac239.222,223

In RhM, infection with either SIVmac239 or SIVmac239∆GY produced a
peak viremia of equivalent magnitude. However, SIVmac239∆GY had a lower setpoint viremia and only transient infection and mild depletion of CD4+ T cells in the
GI lamina propria, in contrast to the profound and sustained depletion seen in
SIVmac239 infection.139,224 Additionally, SIVmac239∆GY showed markedly
decreased infection of macrophages and absence of virus in the central nervous
system infection at all stages of infection.222,225 Despite lack of gut damage,
SIVmac239∆GY-infected RhM eventually developed increased plasma viremia, loss
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of peripheral CD4+ T cells, and systemic immune activation, with progression to
AIDS. In progressing animals, novel mutations arise in the Env cytoplasmic tail that
we hypothesized were compensatory for ∆GY. These include point mutations R722G
and S727P, as well as a remarkable deletion of nine nucleotides (∆QTH 734-736),
which overlaps with the second exon open reading frame of rev and tat (Fig. 1B) and
produces novel YxxΦ motifs YFQI and YFQL. This deletion affects the sequence of
all three proteins and is an unusual development in a relatively conserved region of
the SIV genome. As such, in this species, the SIVmac239∆GY mutation was not
sufficient to render the virus nonpathogenic.222 In PTM, there is evidence for greater
baseline immune activation and T cell turnover, as well as more rapid progression to
AIDS following SIVmac239 infection.148 In this species, as in RhM, SIVmac239∆GY
had an acute peak viremia of equivalent magnitude and kinetics to SIVmac239, but
failed to deplete GI lamina propria CD4+ T cells or to infect macrophages throughout
the course of infection. However, by 20 weeks post-infection, 19/21 PTM controlled
viremia to a set-point of <100 copies/ml. These animals maintained normal levels of
CD4+ and CD8+ T cells in GI lamina propria as well as in peripheral blood and did
not develop systemic immune activation or progress to AIDS over extended periods
of time.223 Remarkably, SIVmac239∆GY-controlling PTM have been shown to
become resistant to intravenous challenge with SIVmac239, and a majority of animals
resist or control challenges with heterologous SIVsmE660 and the pathogenic SHIV
SF162P3N, making protection afforded by control of this virus one of the most
effective described to date (A. Lackner & J. Hoxie, unpublished data). Accordingly,
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there are compelling reasons to understand 1) the virologic effects of the ∆GY
mutation; 2) the mechanism for its control by the host; and 3) how host immune
responses that control SIVmac239∆GY can confer broad protection to pathogenic
challenge viruses.

In this study, we evaluated the effect of the ∆GY mutation in SIVmac239 on a
variety of virologic parameters in an effort to understand how a minor sequence
alteration so drastically alters the ability of the virus to cause disease in a susceptible
host. We then addressed the ability of novel gp41 mutations that arose in vivo to
compensate for ∆GY by mediating functions of the GYxxΦ. These findings elucidate
a role for this gp41 membrane-proximal tyrosine motif in the incompletely
understood process of Env incorporation into virions and provide evidence that this is
likely to be an active process requiring coordination between viral proteins and
cellular machinery.

Methods
Env mutagenesis, cloning, and plasmid generation
Relevant mutations (ΔGY, R722G, S727P, ΔQTH YFQI and ΔQTH YFQL) were
introduced into env genes in pVP2 plasmids using QuikChange PCR (Agilent
Technologies) as previously described.63,221 Env DNA was isolated from bacteria
using the QIAamp DNA minikit (Qiagen) as per the manufacturer’s protocol, and
sequenced with env specific primers to identify clones with the correct sequence.
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Proviral constructs were produced by linearizing digestion of pVP2 and p239Spsp5’
plasmids with SphI followed by gel purification and ligation with T4 ligase.
Successful ligation was confirmed by restriction enzyme digestion and gel
electrophoresis, followed by full genome sequencing of each construct.

Cell lines & primary cells
Viral stocks for growth assays and infection of cell lines were produced in HEK293T
cells. Virions were produced in HEK293T cells, CEMx174 cells, or rhesus macaque
peripheral blood mononuclear cells (PBMCs). CF2-Luc cells, a modified Cf2th cell
line stably expressing the luciferase gene under the HIV-1 long terminal repeat, were
used for coreceptor dependence assays.226,227 HeLa cells were used for Env
localization and endocytosis assays. Madin-Darby canine kidney II (MDCKII) cells, a
subclone of the MDCK cell line (Sigma, 85011435) were used for polarized
trafficking assays. Rhesus and pig-tailed macaque cells were obtained from Gregory
del Prete, Specimen Support Core, Leidos Biomedical Research, Inc., Frederick
National Laboratory for Cancer Research; additional pig-tailed macaque cells were
obtained via Tulane National Primate Research Center and Washington National
Primate Research Center. HEK293T and CF2-Luc cells were grown in Dulbecco’s
Modified Eagle’s Media (DMEM) supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 1% L-glutamine. CEMx174 cells and PBMCs were
grown in Roswell Park Memorial Institute (RPMI) media supplemented with 10%
fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine. RPMI for
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PBMCs was supplemented with rHu IL-2 as described for growth assays. MDCKII
cells were grown in RPMI with Hepes, pH 7.0 and supplemented with 0.2% bovine
serum albumin (BSA).
Virions & western blotting
Rhesus macaque PBMCs were infected with each virus as for growth assays above.
On Day 6 post-infection, cultures were centrifuged and cell-free supernatant was
removed. Virions were pelleted through a 20% sucrose gradient by ultracentrifugation
for 120 minutes. Supernatant was removed and virus resuspended in 1X TNE buffer
and quantified by p27 ELISA. Virion preps were reduced by combining NuPAGE
10X Reducing Agent (Life Technologies) and NuPAGE 4X LDS Sample Buffer (Life
Technologies) and incubating at 95°C for 10 minutes. Equal quantities of p27 were
loaded into individual wells for PAGE. Protein was transferred to a PVDF membrane
by semi-dry transfer and blocked with 5% NFM for 1 hour at room temperature. The
membrane was then cut in half and the top (gp120) half remained in blocker
overnight. The bottom (p27) half was incubated overnight with mouse anti-Gag
monoclonal 3A8 at 1:1000 dilution. On day 2, the top half was incubated with mouse
monoclonal anti-gp120 (DA6) at 1:2000 dilution for one hour. Blots were then
washed 4x 5 minutes and incubated with goat anti-mouse HRP conjugated secondary
antibody for 1 hour, washed 4x 5 minutes, and developed with Luminata Forte
Western HRP Substrate (Merck Millipore).

CD4-SIV Env chimeras
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(Assays performed by Dr. Scott Lawrence, University College London, in the
Laboratory of Dr. Mark Marsh)
CD4-SIV Env chimeras were constructed by fusing the ecto- and membrane-spanning
domains of human CD4 to a short section of the cytoplasmic domain of SIVmac239
Env (residues 716-745) as previously described.66 The cytosolic domain of the CD4SIV Env chimera included amino acids from the cytoplasmic domain of CD4 to place
the SIV endocytosis signal (YxxΦ) the requisite distance from the membrane for
functional activity.76 CD4-SIV Env constructs with relevant point mutations and
deletions as shown in Figure 1 were constructed by site-directed mutagenesis as
described above. The structure of CD4-SIV Env chimeras is shown in Figure 4.

CD4-SIV Env construct subcellular localization
(Scott Lawrence, University College London)
HeLa cells expressing CD4-SIV Env chimeras (Fig. 4) were fixed with 3%
formaldehyde in PBS, permeabilized with 0.05% saponin and 0.2% bovine serum
albumin in PBS, and immunolabeled with 5 µg/ml anti-CD4 antibody (Q4120,
NIBSC, ARP318) at 37°C for 3 hours. Free antibody was washed away and cells
incubated with secondary anti-mouse antibody conjugated to Alexa-Fluor 488
(Molecular Probes, Invitrogen). For antibody feeding experiments, cells were
incubated with Q4120 before permeabilization. Images were acquired using a Zeiss
Axioplan2 with 40x neofluar objective and a Hamamatsu camera (C4742-95).

	
  

40	
  

Endocytosis assays
(Scott Lawrence, University College London)
HeLa cells expressing CD4-SIV Env chimeras (Fig. 4 & Fig. 7) were selected with
400 µg/ml G418 and incubated with an anti-CD4 antibody (Q4120, NIBSC, ARP318)
at 4°C. Free antibody was washed away with ice cold RPMI + 0.2% BSA and
endocytosis was initiated by incubating the cells in 37°C media. After incubation for
specified times, the cells were cooled to 4°C and then incubated with a 1:1000
dilution of secondary antibody on ice (anti-mouse IgG HRP conjugate (G-21040,
Invitrogen). Cells were washed with ice cold RPMI + 0.2% BSA followed by PBS.
Cells were lysed and Amplex Red (Molecular Probes, Invitrogen) was added. Amplex
Red (HRP) signal was read on an EnVision® Multilabel Reader.

AP-2 depletion & protein quantification
(Scott Lawrence, University College London)
HeLa cells expressing CD4-SIV Env chimeras (Fig. 4) were selected with 400 µg/ml
G418 and transfected once with an siRNA targeting the µ2 subunit of adaptor-related
protein complex 2 (AP-2) as previously described.228 48 hours after transfection total
cell protein (30 µg) was separated by SDS-PAGE and transferred to nitrocellulose
membranes. Membranes were incubated with antibodies to AP-2 subunits (anti-ɑadaptin, BD Biosciences 610502 or anti-µ2, AP50, BD Biosciences 611350), or with
a loading control (anti-VDAC, Abcam ab15895). Membranes were then washed and
incubated with secondary antibodies (IRDye680 or IRDye800, Li-COR®) and
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imaged and quantified using the LiCOR® Odyssey. The percentage AP-2 subunit
depletion was calculated by comparison to mock conditions for all cell lines.
Measurement of endocytosis rates of CD4-SIV Env chimeras in AP-2 depleted cells
was performed as described for previous endocytosis assays.

Polarized Env trafficking in MDCKII cells
(Scott Lawrence, University College London)
MDCKII mixed stable cell lines that express CD4-SIV Env constructs with
SIVmac239 sequence or mutant chimeras with a short Env (Fig. 4) or full-length
cytoplasmic tail were selected with 400 µg/ml G418. MDCKII cell lines were seeded
at 2.7x105/cm2 on polyester Transwell 0.4 µm clear filters (Corning) and cultured for
6 days to establish a polarized epithelial monolayer (trans-epithelial resistance of 80100 Ω/cm2). Cells were fixed with 3% formaldehyde in PBS, quenched and stained
with an anti-CD4 antibody (Q4120) either with (total) or without (surface) 0.05%
saponin for permeabilization. Antibody was washed away and cells were then
incubated with an anti-mouse secondary antibody conjugated to Alexa-Fluor 488. Z
stacks of cell monolayers were acquired on a Leica SPE-3 with consistent settings.
Images shown are of the orthogonal projection and white vertical lines separate
different images. The ratio of apical to basolateral CD4 staining of the images was
quantified from the orthogonal sections using Image J to measure intensity of CD4
staining (arbitrary units) in the apical and basolateral membranes.
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Preparation of viral stocks
Viral stocks were produced in HEK-293T cells using a standard 5 hour calcium
phosphate transfection protocol with full length viral genome constructs. Stocks were
harvested 48 hours post-transfection and quantified using the SIV p27 Antigen
Capture Assay (Advanced Bioscience Laboratories). All stocks were stored at -80°C.

Viral replication assays
Viably cryopreserved rhesus or pig-tailed macaque peripheral blood mononuclear
cells (PBMCs) were thawed, counted, and cultured for 72 hours in RPMI + 5 µg/ml
Concanavalin A (Sigma-Aldrich #L7647) at a concentration of 2-3 x 106 cells/ml.
After 72 hours cells were washed, counted, and resuspended at 1 x 106 cells/ml in
RPMI + rHu IL-2 (Aldesleukin, Prometheus Laboratories, Inc.). Five million cells
were infected with 250 ng p27 of each virus and allowed to incubate for 24 hours.
After 24 hours (Day 0), excess virus was washed off and 1 ml of culture supernatant
was ultracentrifuged at 45,000 RPM for 30 minutes. The resulting supernatant was
removed and the viral pellet resuspended in 50 µl Tris buffer for reverse transcriptase
(RT) assay. Every 3 days, cells were counted and the concentration maintained at ~2
x 106 cells/ml, adding IL-2 and RPMI as needed. RT assay measurements were taken
at Day 0, 3, 6, 10, and 14 post-infection.

Serial passaging assays for viral evolution in vitro
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CEMx174 cells were counted and plated at a concentration of 1 x 106 cells/ml. 293T
viral stocks (SIVmac239, SIVmac239∆GY, or SIVmac239∆GY + ∆QTH) were
added to 5 ml of cell culture at a ratio of 50 ng viral p27 per 1 x 106 cells. After 24
hours (Day 0), excess virus was washed off and cultures were monitored visually for
development of cytopathic effect (CPE). When this was observed (typical, 3-4 days
for SIVmac239, 4-7 days for others), cell-free supernatant was collected and added to
uninfected CEMx174 cells (1 ml supernatant per 5 x 106 cells). After 10 or 20
passages, cells were collected and DNA was isolated using the QIAamp DNA Mini
Kit (Qiagen) per the manufacturer’s protocol. Purified DNA was then amplified by
PCR with SIV Env-specific primers and bulk sequencing was performed.

Imaging flow cytometry & image capture
CEMx174 cells were infected with each virus at 100 ng p27/million cells. Cultures
were visually monitored for CPE. At peak infection, as determined by CPE (day 6-7
post-infection for SIVmac239∆GY, day 3-4 for others), 10 ml of CEMx174 cells
were centrifuged at 5,000 rpm for 5 minutes. Cells were washed with FACS buffer
(1X PBS + 0.1% BSA) and resuspended in 500 µl FACS buffer. 100 µl cells were
incubated with 10 µg/ml primary anti-Env antibody (7D3, Julian Bess, Leidos
Biomedical Research, NCI.) for 30 minutes on ice. Cells were washed with FACS
buffer, resuspended in 50 µl FACS buffer, and incubated with 0.1 µl FITC-conjugated
goat anti-mouse secondary antibody (Santa Cruz Biotechnology) for 30 minutes on
ice. Cells were then washed and fixed by resuspension in 100 µl Fix & Perm Medium
	
  

44	
  

A (Thermo Fisher Scientific) for 15 minutes at room temperature. Cells were washed
with FACS buffer + 0.01% saponin and resuspended in 100 µl Fix & Perm Medium
B. 0.5 µl Alexa-Fluor 647-conjugated FA2 Anti-Gag229 (NIH AIDS Reagent
Repository, conjugation performed in-house with Thermo Fisher Scientific kit) and
0.2 µg/ml DAPI were added and cells were incubated for 15 minutes, covered, at
room temperature. Cells were washed with FACS buffer + 0.01% saponin and
resuspended in 50 µl FACS buffer + 0.01% saponin. 200 µl 2% paraformaldehyde
was added and cells were allowed to settle overnight. 150 µl of supernatant was
removed and cells were vortexed to resuspend in the residual 100 µl of buffer.
Imaging flow cytometry was performed on an ImageStreamX (Amnis, EMD
Millipore) with 3 active lasers (405, 488, and 658 nm). Acquisition was performed at
60X magnification using an extended depth of field (EDF) filter. A minimum of
30,000 events were collected for each sample. Uninfected cells were stained as a
negative control.

Envelope distribution gating
IDEAS Software version 6.1 was used for offline analysis. Single cells that were in
focus were selected based on brightfield images (see Supplemental Figure 1-3 for
details on gating parameters). Cells with single nuclei were selected based on DAPI
images. Gag positive cells were then gated, and of those, Env positive cells were
selected (Supp. Fig. 2). Gag and Env gates were maintained across samples within
each experiment via file batching to ensure consistency. Single, focused, and DAPI
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gates were applied to each sample individually to accurately represent the appropriate
cell populations.

Following selection of DAPI+Gag+Env+ singlets (minimum 500 cells per
sample), masking of cell regions based on fluorescent signal was used to determine
median pixel intensity of Env in the region of the plasma membrane versus the
interior of the cells (see Supp. Fig 1B) as well as area of plasma membrane that was
positive for Env. Area of Env intensity vs. median pixel intensity of Env in the
plasma membrane was charted and cells were gated into punctate, diffuse, or
intermediate Env distribution phenotype (Supp. Fig. 3). Masking and phenotype gates
as shown in Supplemental Figures 1 and 3 were batched across all experiments to
ensure unbiased comparisons.

CF2-Luc entry assay for coreceptor dependence
CF2-Luc cells were plated in 6-well plates at 1x106 cell/well in DMEM + 10% fetal
bovine serum (FBS) without antibiotic. After 24 hours, cells were transfected with
RhM CD4 and RhM CCR5 using a standard lipofectamine transfection protocol and
incubated overnight. Cells were then replated into 48-well plates, allowed to recover
for 4-6 hours, and spinoculated with equivalent quantities of SIVmac239,
SIVmac239ΔGY, or vesicular stomatitis virus as a positive control. The next day,
virus was washed off and replaced with fresh media. 48 hours after infection, cells
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were lysed and luciferase activity was read on a Luminoskan AscentTM (Thermo
Labsystems, Thermo Scientific). This assay has been described previously.226,227

Statistical analysis
All statistical analyses were performed with GraphPad Prism v6.0g (GraphPad
Software, Inc., La Jolla, CA). Pairwise comparisons were conducted using nonparametric tests (Kruskal-Wallis or Friedman tests), as samples sizes were
insufficient to assess normality. Dunnett’s or Holm-Sidak tests were used to adjust pvalues for multiple comparisons. Where applicable, results are expressed as mean ±
standard error of mean.

Results
Mutations in gp41 modulate Env incorporation into virions
Because ∆GY disrupts a highly conserved trafficking motif in the cytoplasmic
tail of gp41, we evaluated the effect of this mutation on Env incorporation into
virions. Virions were produced by infection of rhesus macaque PBMCs with
SIVmac239 or mutant infectious molecular clones (Fig. 1A) and harvested at day 6
post-infection, the previously determined peak of replication.

A representative western blot is shown in Figure 2A. Compared to
SIVmac239, SIVmac239∆GY virion Env content was significantly decreased, to 45%
of SIVmac239 (Fig. 2B). We next evaluated whether Env content was affected by
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Figure 2-1: gp41 cytoplasmic tail mutations selected for study in vitro
(A) Partial Env cytoplasmic tail sequences of SIVmac239 mutants selected for study in
vitro. Mutations were originally identified in !GY-infected rhesus or pig-tailed
macaques that developed AIDS. All mutations were either identified in at least 2 animals
or appeared to reconstitute YXX" motifs. (B) Nucleotide sequence of !QTH mutants
creating YFQI and YFQL motifs. YFQI and YFQL were created by deletions of nine
nucleotides from env that overlapped the second exon open reading frame of rev and
tat. YFQI versus YFQL sequence was determined by a one basepair frameshift of the
mutation. Both !QTH mutations were observed in vivo only in the presence of R722G.
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gp41 mutations that arose in vivo during SIVmac239∆GY infection. In rhesus
macaque PBMCs, only the R722G mutation had a significant effect on Env content of
virions; SIVmac239∆GY R722G virion Env content was 2.0 times greater than
SIVmac239∆GY (p<0.01, Fig. 2B). Other mutations did not increase Env
significantly over SIVmac239∆GY alone. This is in contrast to our observations in
293T-produced virions, in which all mutations arising in vivo conferred an increase in
virion Env content (Fig. 3A). The findings for SIVmac239∆GY R722G YFQI or
YFQL were somewhat less consistent in CEMx174 cells, though the reduction in Env
for with ∆GY and its restoration by R722G remained clear (Fig. 3B).

gp41 mutations regulate intracellular Env trafficking
If the trafficking mediated by GYxxΦ is important for efficient viral
replication or evasion of host immune responses, there might be in vivo selection for
Env mutations that restore the function of this sequence. To determine whether any of
the putative compensatory mutations rescue the trafficking function lost in
SIVmac239∆GY, we constructed CD4-SIV Env chimeras as previously described and
generated stable cell lines (Fig. 4).76 These chimeras encode a truncated Env
cytoplasmic domain containing only the membrane-proximal GYxxΦ trafficking
motif, excluding any downstream endocytosis signals. As trafficking signals can alter
the cellular distribution of a protein, we first determined the steady state localization
of the chimeras. Constructs with the SIVmac239 wildtype sequence GYRPV had an
intracellular perinuclear distribution and a small amount of the CD4 reporter at the
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Figure 2-2: Env incorporation into virions produced in
rhesus macaque PBMCs
(A) Representative western blot of purified virions produced
in RhM PBMCs. Virions were pelleted through a sucrose
cushion, depleted of CD45 to remove microvesicles,
denatured, and blotted using anti-gp120 and anti-p27
antibodies. n!9 for all samples.
Top band: gp120 Env; bottom band: p27 Gag
(B) p27 values by densitometry were normalized and the
fold change determined in the gp120:p27 ratio relative to
SIVmac239. n!9 for all samples.
* denotes significant difference from !GY (**, p".01)
+ denotes significant difference from theoretical SIVmac239
value of 1 (++, p"0.01; ++++, p"0.0001).
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cell surface. The principally intracellular distribution of wildtype Env reflects its
known transport pathway.64,80 After synthesis and post-translational modification,
Env is trafficked to the cell surface and then rapidly endocytosed, with subsequent
localization to endosomes.66,68,70,77,230 In contrast, the SIVmac239∆GY Env lacked
this intracellular pattern and exhibited a more diffuse surface distribution. While
SIVmac239ΔGY R722G showed a similar cell surface distribution to
SIVmac239ΔGY, likely indicating a lack of new endocytic information,
SIVmac239ΔGY ∆QTH (YFQI or YFQL) showed an increase in the amount of
perinuclear intracellular staining (Fig. 5A).

To determine if chimeric constructs were expressed on the cell surface and
subsequently endocytosed, an “antibody feeding” experiment was performed in which
cells stably expressing the CD4-SIV gp41 tail chimeras were incubated with an antiCD4 antibody for 3 hours at 37°, washed, and permeabilized. Cells expressing the
chimera bearing the wildtype SIVmac239 cytoplasmic tail exhibited intracellular
CD4 staining, consistent with this construct being expressed on the cell surface,
endocytosed, and trafficking to an intracellular compartment, most likely endosomes
(Fig. 5B). As expected, antibody binding to the SIVmac239∆GY R722G chimera,
which does not contain a recognizable endocytosis signal, was localized
predominantly at the cell surface. Of note, because the images shown in Figure 4 are
not confocal images, the observed punctae are a combination of cell surface
microvilli and intracellular labeling. In contrast, for SIVmac239∆GY ∆QTH chimeras
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Figure 2-3: Env incorporation into virions produced in cell lines
p27 values by densitometry were normalized and the fold change
determined in the gp120:p27 ratio relative to SIVmac239. n between 7 and
28 for 293T cells and between 3 and 17 for CEMx174.
* denotes significant difference from !GY (****, p!0.0001); + denotes
significant difference from theoretical SIVmac239 value of 1 (+, p!0.05; ++,
p!0.01; ++++, p!0.0001).
(A) gp120:p27 ratio as fold change of SIVmac239; virions produced by
transfection of 293T cells. (B) gp120:p27 ratio as fold change of
SIVmac239; virions produced by infection of CEMx174 cells.
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Figure 2-4: Structure of CD4-SIV Env chimeras
Top: Human CD4 sequence is displayed in the top line, with the membrane spanning domain
underlined.
Center: CD4-SIV Env chimeric sequence bearing the CD4 ectodomain fused to a truncated SIV
envelope cytoplasmic tail. The membrane proximal tyrosine motif is shown in red.
Bottom: SIV cytoplasmic tail sequences with engineered mutations. The location of the tyrosine
motif is marked above (red).
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containing either YFQI or YFQL sequences, the anti-CD4 antibody was readily
detectable in intracellular compartments, consistent with their expression on the cell
surface and subsequent endocytosis. These data strongly suggest that the novel YxxΦ
motifs created by the ∆QTH deletion, selected in vivo, restored endocytic trafficking
functions that were lost with the ∆GY mutation.

Novel YxxΦ motifs reconstitute functional endocytosis signals and modulate Env
endocytosis
Given differences in the steady state distribution of the CD4-SIV Env
chimeras and the results of the antibody feeding experiment, we next directly
assessed the endocytic rates of these constructs. As noted, the ∆GY mutation
completely ablates endocytic function of the SIV GYxxΦ signal. To assess
quantitatively the ability of putative compensatory mutations to restore endocytic
trafficking, endocytic rates of the CD4-SIV tail chimeras stably expressed on HeLa
cells were measured using a modification of a previously described assay (Fig. 6).66
The CD4-SIV Env chimera containing the wildtype SIVmac239 tail was endocytosed
at a rate of 11.9% per minute, reflecting the robust function of the SIV GYRPV
signal. For the chimera containing the ΔGY tail, endocytosis was reduced to
approximately 2% per minute (1.8% ± 0.6%, Fig. 6B), comparable to bulk membrane
turnover and reflecting a nearly complete loss of endocytic function. For the ΔGY tail
construct, 72% ± 6% of the protein remained at the cell surface after 30 min at 37°C
in contrast to 13% ± 2% for the CD4-SIVmac239 chimera (Fig. 6A and B). For
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Figure 2-5: gp41 mutations regulate intracellular Env trafficking
Data provided by Scott Lawrence.
(A) Total anti-CD4 staining for CD4-SIV Env chimeras in permeabilized
HeLa cells. (B) Antibody feeding experiment; anti-CD4 staining for CD4SIV Env chimeras in HeLa cells incubated with anti-CD4 prior to
permeabilization. Size bar = 25 !m.
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Figure 2-6: Novel Yxx! motifs reconstitute functional
endocytosis signals and mediate Env endocytosis
Data provided by Scott Lawrence.
Endocytosis of CD4-SIV Env chimeras from the surface
was measured by quantifying CD4 expression on the
surface of transfected HeLa cells over time.
n!4 for all samples. (A) Percent of time zero anti-CD4
signal at cell surface over time for each mutant. (B) Rate
of CD4 endocytosis from the cell surface over first 5
minutes after warm up.
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constructs containing ∆GY with mutations acquired in vivo, S727P had no effect,
while R722G conferred a minimal increase in endocytosis to a rate of 3.98% per
minute (59% ± 6% remaining at the surface after 30 minutes, p=0.014). However, the
∆QTH mutations creating either the YFQI or YFQL sequences conferred a marked
gain of endocytic function to full or near wild type levels (5.74% and 12.76% per
minute, respectively) (Fig. 6B). Thus, mutations that arose in vivo in the context of 2
of 6 SIVmac239∆GY-infected macaques that progressed to AIDS restored endocytic
function lost by the ∆GY mutation to near wildtype levels.
To test whether the novel YxxΦ sequences conformed to a conventional
YxxΦ motif, alanine scanning mutagenesis was performed on CD4-SIV Env
chimeras containing ∆GY and the ∆QTH (YFQL) sequence (Fig. 7A) and endocytic
rates determined in HeLa cells stably expressing these constructs. As shown in
Figures 7B and C, Ala substitutions of the Y (position 0) or Φ (Y+3 position) residues
markedly reduced endocytosis, with minimal decreases observed for Ala substitutions
at the Y+1, +2 or +5 positions. Thus, the YFQL motif created by the ∆QTH mutation
functioned as a classical Tyr-dependent YxxΦ motif, with the major contributions
coming from the Tyr and the Φ amino acid (i.e. Leu).

Novel YxxΦ motifs depend on AP-2 to mediate endocytosis
YxxΦ motifs interact with AP-2 through insertion of bulky hydrophobic side
chains of the Y and the Y+3 amino acid into hydrophobic pockets in the AP-2 µ2
subunit.62 As such, endocytosis of YFQI and YFQL chimeras should be dependent
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Figure 2-7: Alanine scanning mutagenesis reveals that YFQL
conforms to the conventional Yxx! motif
Data provided by Scott Lawrence.
HeLa cells expressing CD4-SIV Env chimeras with indicated
alanine substitutions were incubated with an anti-CD4 antibody
4°C, then incubated at 37°C. After incubation, cells were cooled
to 4°C and anti-CD4 remaining at the cell surface was quantified.
n=3 for all samples. (A) Sequence of CD4-SIV Env chimeric
constructs with alanine substitutions. (B) Percent of initial (time
zero) anti-CD4 signal at cell surface over time for each mutant.
(C) Rate of CD4 endocytosis from the cell surface over the first 5
minutes after warm up.
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Figure 2-8: AP-2 is required for endocytosis of CD4-SIV Env chimeras
containing a Yxx! motif
Data provided by Scott Lawrence.
(A) Expression of AP-2 subunits (!-adaptin or "2) in anti-"2 siRNA
transfected or mock transfected HeLa cells. VDAC is shown as a loading
control. Blots were imaged and quantified using the LiCOR® Odyssey. (B)
Percent of AP-2 subunit depletion relative to mock siRNA transfected HeLa
cells. (C) Endocytosis of CD4-SIV Env chimeras in AP-2 depleted or nondepleted cells. Results are expressed as the rate of CD4 endocytosis from the
cell surface over the first 5 mins. n!3 for all samples.
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upon AP-2. To assess this possibility, AP-2 µ2 subunits were depleted with siRNA
and the endocytic rates of CD4-SIV Env chimeras measured (Fig. 8). Depletion of µ2
is known to destabilize the AP-2 complex and results in a decrease in AP-2 as
measured by reduced binding to an α-adaptin antibody.231 Efficient µ2 depletion was
achieved (69% ± 12%) and was associated with a reduction of AP-2 (53% ± 13%)
(Fig. 8B). Following AP-2 knockdown, the internalization rates of all chimeras
containing a YxxΦ motif were substantially reduced (Fig. 8C). Specifically,
SIVmac239 chimera internalization decreased from 12.0% to 5.3% per minute, while
endocytosis of the CD4-SIV Env chimera containing ∆GY remained at near
background levels and was essentially unaffected (2% vs. 1.5%). AP-2 depletion also
had no effect on endocytosis of CD4-SIV Env chimeras containing ∆GY and R722G
mutations (i.e. 3.9% with vs. 3.2% without depletion). In contrast, internalization of
YFQI and YFQL were each reduced by depletion of AP-2, with a greater effect seen
for YFQL (13.6% to 4.4%) than for YFQI (5.6% to 3.5%) (Fig. 8C). Collectively,
these findings confirm a role for AP-2 in endocytosis mediated by the YFQI and
YFQL sequences and further demonstrate that these mutations acquired in vivo
function as classical YxxΦ endocytosis motifs.

Novel YxxΦ motifs regulate basolateral sorting of Env in polarized cells
The tyrosine residue of the HIV-1 GYxxΦ motif noted above has also been
shown to be important for the basolateral targeting of Env in polarized MDCK
cells.88,90 Although a similar function has not been demonstrated for this motif
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(YRPV) in an SIV Env, SIVmac Envs with truncated cytoplasmic tails were shown to
be sorted to the basolateral surface less efficiently than the full-length protein, with
removal of the region containing the proximal tyrosine motif having a stronger effect
than more conservation truncations.232 For HIV-1, basolateral sorting of surface Env
also mediates polarized budding of infectious virions.89,90 We considered the
possibility that if basolateral sorting of Env and/or the polarized budding of viral
particles were important in vivo, preservation

of this function could have also

contributed to the selection of the ΔQTH mutation and the generation of new Tyrbased signals (i.e. YFQI and YFQL).

To assess basolateral sorting potential of CD4-SIV Env chimeras with
parental, SIVmac239∆GY, and SIVmac239∆GY + ∆QTH sequences, we created
MDCKII cells that stably expressed these constructs. Cells were cultured on
Transwell filters to form polarized monolayers and the expression of constructs
analyzed

by

immunofluorescence

microscopy

for

total

(i.e.

following

permeabilization) or surface CD4-SIV Env (i.e. non-permeabilized, Fig. 9)
expression. For chimeras containing either the short (Fig. 4) or full-length (long)
SIVmac239 Env tails, the majority of protein was intracellular and localized to a
perinuclear region (Fig. 9A). Cell surface expression was low but was predominantly
located on the basolateral plasma membrane. Loss of the YxxΦ motif (YRPV) by
either the ΔGY or a Y721I mutation, resulted in redistribution of constructs to both
the basolateral and apical plasma membranes. This loss of polarized expression was
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Figure 2-9: Novel Yxx! motifs rescue polarized Env trafficking lost in "GY
Data provided by Scott Lawrence.
(A) Total expression of CD4-SIV Env chimeras in polarized MDCKII cells.
(B) Surface expression of CD4-SIV Env chimeras in polarized MDCKII cells.
(C) Ratio of apical to basolateral CD4 expression of the images in (B), calculated by
measurement of intensity of CD4 staining in each membrane. n of images analyzed
is between 4 and 9 and the number of cells per image is between 10 and 29 for all
samples.
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demonstrated both for chimeras with short and full-length Env cytoplasmic tails (Fig.
9). This finding is consistent with studies of HIV-1 Env showing that the membraneproximal tyrosine (i.e. Tyr-712) is required for basolateral sorting of Env.88,89
Remarkably, in CD4-SIV Env ∆GY constructs that contained the new YxxΦ motifs
generated by the ∆QTH deletion, YFQI or YFQL, basolateral sorting was restored.
Higher cell surface expression was also observed for these mutants compared to
wildtype SIVmac239. The mechanism behind this difference has not been evaluated,
but could be due to reduced degradation, possibly through differences in lysosomal
targeting. Unlike the wildtype proximal tyrosine motif (GYRPV), YFQI and YFQL
lack the proximal glycine, and as a GYxxΦ is a preferred signal for lysosomal and
late endosomal targeting (as opposed to YxxΦ for endocytic signaling), it is possible
that the absence of this residue may have conferred endocytic rates similar to
SIVmac239 without fully recapitulating the intracellular distribution patterns of the
chimera containing the wildtype SIVmac239 protein.62,233 Together, these findings
demonstrate that the novel YFQI and YFQL sequences acquired in SIVmac239∆GYinfected progressing macaques are able to reconstitute both endocytic and basolateral
sorting functions of the parental SIVmac239 tail that were lost as a result of the ∆GY
mutation. The acquisition of these functions through the highly novel ∆QTH mutation
strongly suggests that they were selected for in vivo.

Growth of infectious molecular clones in macaque PBMCs
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In vivo in both rhesus and pigtail macaques, SIVmac239∆GY replicates to an
acute peak that is identical to that of SIVmac239, and in early studies we reported that
its in vitro replication kinetics were similar to wildtype SIV.222,223 As noted
previously, we observed that the ∆GY mutation resulted in a reduction in Env content
on virions produced in cell lines and in macaque PBMCs. Because virion Env content
has been shown to correlate directly with infectivity, we re-examined the effects of
the ∆GY mutation on viral replication in primary macaque lymphocytes as well as the
effects of mutations that occurred in SIVmac239∆GY-infected animals that
progressed to disease.109 Although SIVmac239∆GY replicated in both rhesus and pigtailed macaque PBMCs, compared to parental SIVmac239, a small but consistent
decrease in peak reverse transcriptase activity (~0.5 log) was observed in multiple
replicates of this assay (Fig. 10). This finding indicates a subtle but reproducible
attenuating effect of the ∆GY mutation that was not observed in earlier studies. We
considered whether this effect could be due to changes in dependence on CCR5 for
entry, but SIVmac239∆GY and SIVmac239 did not differ in the level of infection
seen in cells transfected with various quantities of RhM CCR5 (Fig. 11).

We next examined replication of ∆GY viruses containing mutations that were
acquired in vivo. Interestingly, viruses containing ∆GY and the ∆QTH mutations that
generated the YFQI or YFQL alone were markedly defective in replication (Fig. 10).
However, this defect was largely corrected by the addition of the R722G mutation
flanking the ∆GY mutation. While the mechanism for the R722G rescue in this
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Figure 2-10: Growth of infectious molecular clones in macaque PBMCs
n!3 for all samples. * denotes significant difference from theoretical
SIVmac239 value of 1 *, p<0.05; **, p".01; ***, p".001; ****, p"0.0001.
(A). Viral RT activity at peak infection timepoint in rhesus macaque PBMCs
as fold change of SIVmac239. (B). Viral RT activity at peak infection
timepoint in pig-tailed macaque PBMCs as fold change of SIVmac239.
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context is unclear, it is notable that in vivo the ∆QTH mutation always occurred in
association with ∆QTH mutations, suggesting a complementing effect and/or that the
R722G mutation was acquired prior to the ∆QTH mutation. Although the ∆QTH
produces deletions of two amino acids in the second exons of Rev and Tat that could
impair their functions (Fig. 1B), the R722G mutation is proximal to this reading
frame and does not affect the Rev and Tat sequences.

Mutations that arise in vivo are selected for in serial passage of SIVmac239∆GY
and derivatives in vitro
In earlier studies, we showed in competition assays in the human B/T cell
hybrid line CEMx174 cells that SIVmac239 will outcompete SIVmac239∆GY,
indicating some fitness cost to the ∆GY mutation.221,234 The slightly reduced
replication kinetics of SIVmac239∆GY compared to SIVmac239 in PBMCs are
consistent with this observation. In light of this defect, we performed serial passage of
SIVmac239, SIVmac239∆GY, SIVmac239∆GY YFQI, and SIVmac239∆GY YFQL
in CEMx174 cells, to determine if changes in SIVmac239∆GY that were observed in
progressing animals could be recapitulated in vitro. The CEMx174 cell line was
chosen for this assay because, unlike many human lymphocyte cell lines, growth in
these cells does not result in SIV cytoplasmic tail truncations even during long term
serial passaging of virus.221 SIVmac239 and SIVmac239∆GY were each serially
passaged 20 times, and PCR amplification and bulk sequencing performed on the env
gene at passage 10 and 20. No changes were observed in the cytoplasmic tail of
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parental SIVmac239 (Fig. 12A). However, at passage 10, SIVmac239∆GY Env
exhibited a mixed genotype of Ser and Pro residues at amino acid position 727, and
by passage 20 this residue was entirely Pro. The finding that an S727P mutation
occurred during serial passaging of virus in vitro as well as becoming fixed in 1 of 4
SIVmac239∆GY-infected RhM that progressed to AIDS strongly suggests that this
mutation conferred a fitness advantage and was unlikely to have been generated by
pressures from the host immune system.
We next evaluated SIVmac239∆GY YFQI and YFQL in a similar serial
passage assay. Because growth of these viruses was severely attenuated in PBMCs
(Fig. 10), we questioned whether this was a phenomenon limited to culturing in
PBMCs or whether it reflected a more generalized intrinsic defect in replication of
these mutants. Because addition of the R722G so strikingly improved replication in
PBMCs (Fig. 10), we hypothesized that this point mutation might be selected for in
serial passage in CEMx174 cells if its primary role was to restore replication fitness.
As in PBMCs, SIVmac239∆GY containing the YFQI and YFQL without the R722G
replicated slowly in CEMx174 culture; viral syncytia in CEMx174 cells were not
observed until 7 days post-infection. However, after 16 (YFQI) or 18 (YFQL)
passages, viral syncytia began to appear 3-4 days after each passage, consistent with
more accelerated kinetics of viral replication. Bulk sequencing of viral env at passage
20 revealed that R722G had appeared in both viruses and appeared to correlate with
more rapid development of syncytia (Fig. 12B). These observations recapitulate the
results of viral replication in PBMCs in which the R722G mutation restored the
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Figure 2-12: Mutations that arise in vivo are selected for in serial passage of SIVmac239!GY
and derivatives in vitro
CEMx174 cells were infected with the indicated viruses and cell freesupernatant was passaged onto
uninfected cells 20 times with bulk sequencing performed at passage 10 and 20. Mutations that
evolved during passage are shown in red. (A) Sequence of SIVmac239, and SIVmac239!GY at
passage 10 (top) and passage 20. Parental SIVmac239 shown above. (B) Sequence of SIVmac239
and SIVmac239!GY + YFQI or YFQL at passage 10 and 20. Parental SIVmac239 shown above.
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replication defect of ∆GY viruses containing only the ∆QTH mutations. The finding
that this R722G mutation was generated de novo during serial propagation in vitro
indicates that strong selection pressures was operative in vitro and in vivo to create
this specific change.

∆GY-containing mutants exhibit differences in cell surface distribution of Env in
comparison to SIVmac239
The ΔGY mutation disrupts a highly conserved YxxΦ trafficking motif in
gp41, ablating Tyr-dependent signals for both endocytosis and basolateral sorting.
However, as described above, ∆GY also results in a reduction in Env content on
virions, with an increase in steady state surface expression on infected cells. The
latter finding led us to hypothesize that the effect of this mutation could be to impair
targeting of Env to sites of budding at the plasma membrane. If Env incorporation
requires active clustering of Env at predetermined budding locations, changes in
distribution of Env on the cell surface could explain a decrease in Env on virions. We
addressed this question using the Amnis ImageStreamX, which enables multicolor
flow cytometric analysis of protein expression to be performed with direct
visualization of protein expression on individual cells, combining the analytical
power of flow cytometry with fluorescence microscopy.235 Using this technique, we
sought to examine the expression levels and distribution on SIV-infected cells (Fig.
13A). CEMx174 cells were chosen for this experiment because they are highly
permissive to SIV infection, enabling data on a large number of infected cells to be
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generated. Cells were infected with SIVmac239 or SIVmac239ΔGY at 100 ng of
p27-Gag/106 cells and cultures were monitored for the onset of infection by assessing
cytopathic effects (i.e. syncytia formation) and by fluorescence microscopy for p27Gag expression. When >50% of cells were infected, cultures were stained for Env on
the cell surface and intracellular p27-Gag using monoclonal antibodies. Flow
cytometry and image capture were performed and Env expression analyzed with
Amnis IDEAS software. Intact single cells were identified by DAPI staining and
analytical gates used to isolate p27 positive cells.

By mean fluorescent intensity (MFI), SIVmac239ΔGY infected cells had
higher levels of Env expression on the cell surface than cells infected by SIVmac239.
On average, SIVmac239ΔGY Env expression was 1.72 ± 0.19-fold greater than
SIVmac239 (Fig. 13B). Addition of R722G increased surface Env expression further,
to average 2.37 ± 0.22-fold greater than SIVmac0239, while SIVmac239ΔGY R722G
YFQL had Env levels similar to SIVmac239ΔGY (average fold increase 1.68 ± 0.14).
Images of individual cells were then analyzed for Env distribution on the cell surface.
Amnis IDEAS software was used to generate a mask that identified the plasma
membrane (rim) of cells, and the area and intensity of Env signal within this region
was measured. (Complete masking and gating strategies are described in Methods and
in Supplemental Figures 1-3). Although cells exhibited varying patterns of Env
distribution ranging from punctate to a diffuse pattern, there was a statistically
significant difference between SIVmac239 and ΔGY-containing mutants in the
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Figure 2-13: Env surface distribution on infected CEMx174 cells
(A) Representative images of SIVmac239 (left) and !GY (right) infected
CEMx174 cells at peak infection. Green, Env; red, Gag; blue, DAPI;
grayscale, brightfield. (B) Mean fluorescent intensity of Env on DAPI
+Gag+Env+ CEMx174 cells at peak infection expressed as fold change of
SIVmac239. * denotes significant difference from theoretical SIVmac239
value of 1 (**, p!.01; ***, p!0.001)(C) Pecentage of DAPI+Gag+Env+
cells with punctate Env surface distribution. * denotes significant
difference from SIVmac239 (*, p!0.05; **, p!.01)
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percentage of cells with a punctate distribution (Fig. 13C). On average, 15.8% of
SIVmac239-infected cells showed a punctate Env distribution (as defined by the
gating strategy shown in Supp. Fig. 3), in contrast to 3.5% for SIVmac239ΔGYinfected cells (p<0.05, Fig. 13C). While overlap in expression patterns was observed
between the viruses (i.e., some SIVmac239ΔGY-infected cells had punctate Env
expression, and some cells infected with SIVmac239 had diffuse Env distribution), an
overall trend was observed toward more diffuse expression by SIVmac239ΔGY. As
will be discussed, these differences may reflect a failure of the SIVmac239∆GY Env
to traffic to sites of viral budding and is also consistent with the finding of decreased
Env incorporation on SIVmac239ΔGY virions. Addition of R722G to the ∆GY
mutation, with or without YFQL, did not rescue the punctate distribution phenotype
seen with SIVmac239, as there was no change in the percentage of punctate
phenotype cells in these mutants (2.8% ± 0.6% and 3.9% ± 1.3% of SIVmac239ΔGY
R722G of SIVmac239ΔGY R722G YFQL, respectively). However, given the higher
MFI of R722G on cells (fold increase over SIVmac239 2.37 for
SIVmac239∆GY R722G vs. 1.72 for SIVmac239∆GY), it is possible that an increase
in Env on the cell surface could partially compensate for the defect imposed by the
∆GY mutation by increasing passive Env incorporation into virions. Further studies
are needed to characterize the possible microdomains of Env localization to sites of
viral budding.
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Discussion
SIVmac239ΔGY differs from its parent virus SIVmac239 by only a two
amino acid deletion in the membrane-proximal tyrosine motif of the cytoplasmic tail
of gp41. It has been previously described as having a unique attenuated phenotype in
rhesus and pig-tailed macaques, with a high acute peak in both species followed by
control to <100 copies/ml by 20 weeks post-infection in 19/21 of pig-tailed
macaques.222,223 In RhM and PTM, SIVmac239ΔGY infection is distinctive in that
even when animals develop AIDS and chronic immune activation, this occurs with
sparing of mucosal CD4+ T cells in the gut lamina propria and lack of macrophage
infection, both of which are associated with parental SIVmac239
infection.140,225,236,237 Possibly as a consequence of the preservation of CD4+ cells in
the gut lamina propria during chronic infection, SIVmac239ΔGY infected pig-tailed
macaques generate robust polyfunctional CD4+ T cell responses originating from
cells in this compartment, which may contribute to control of SIVmac239ΔGY
viremia as well as protection from pathogenic challenge.223 Due to the striking in vivo
phenotype of this virus, we sought to identify in vitro properties that could
differentiate SIVmac239ΔGY from SIVmac239 and explain their marked differences
in pathogenicity.

It is known that infectivity of primate lentiviruses is affected by virion Env
levels on virions, with viruses expressing higher per-particle Env levels being more
infectious.109 The cytoplasmic tail of gp41 has been previously implicated in
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modulating envelope incorporation into budding virions, and thus modifications to
the gp41 tail sequence could exert some effect on infectivity.61,76,91,96,102,205 The
mechanism of this process, as well as interactions of the cytoplasmic tail, the viral
matrix protein, and cellular proteins that may affect Env targeting to sites of budding,
are poorly characterized.11,98,104,205,238–240 The gp41 membrane-proximal Tyrdependent trafficking motif GYxxΦ binds the cellular adaptor complexes AP-1 and
AP-2 and, via the latter, mediates clathrin-dependent endocytosis of Env from the
surface of infected cells.64,65,71 In addition, during HIV-1 infection of polarized cells,
the tyrosine residue plays a role in mediating sorting of Env and viral budding to the
basolateral surface.90 Because of its role in Env trafficking, we hypothesized that
disruption of this signal might alter the incorporation of Env into virions and
contribute to the divergent natural history of SIVmac239 and SIVmac239ΔGY
infection in PTM.

In this Chapter, we evaluated comprehensively SIVmac239∆GY in
comparison to SIVmac239 in an attempt to identify in vitro correlates of its altered
phenotype. We assessed virion Env levels and growth in macaque primary cells as
measures of viral function. We also evaluated Env localization, endocytosis, and
sorting to basolateral membranes of polarized cells to determine how loss of the
tyrosine motif affected these characteristics. Functional defects that distinguish
SIVmac239∆GY from its parent demonstrate the role of the proximal cytoplasmic tail
motif in the SIV life cycle. In addition to direct comparisons of SIVmac239∆GY with
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SIVmac239, we used the same assays to evaluate effects of mutations acquired in
vivo in SIVmac239∆GY-infected rhesus and pig-tailed macaques that progressed to
disease. We viewed these putative compensatory mutations as potentially valuable
tools to assess the relevance of in vitro differences in SIVmac239∆GY to
SIVmac239. The ability of these mutations to compensate for the ∆GY mutation in
vivo will be addressed in Chapter 3.

Here we demonstrate that disruption of the membrane-proximal tyrosine motif
results in a reduction of Env incorporated into virions. This effect is consistent across
multiple cell types, including lymphocyte cell lines and macaque PBMCs. The
reduction in Env is associated with a loss of punctate distribution of Env on infected
cells as determined by imaging flow cytometry and a decrease in peak growth in
primary cells. Paradoxically, though not unexpectedly, ablation of this endocytosis
motif results in an increase in Env expression on the surface of infected cells. While
the increase in expression is modest, possibly due to the presence of redundant
endocytosis motifs at downstream positions in the gp41 cytoplasmic tail, it provides
critical insight into the role of this motif in the viral life cycle.66 Because HIV and
SIV virions typically bud from the plasma membrane, it could be hypothesized that
increased expression of Env on the cell surface would result in a concomitant increase
in Env on virions produced by the cell.42,241–243 However, the discordance between
cell surface Env and virion Env instead implies that to be incorporated into virions,
Env must be actively targeted to appropriate sites on the plasma membrane.
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Because the GYxxΦ signal is known to mediate protein sorting and targeting
as well as endocytosis, its role in primate lentiviruses may be relevant to the process
of Env incorporation.62,240,244 We propose a mechanism in which the membraneproximal tyrosine motif interacts with cellular proteins to be targeted from the transGolgi network to specific budding sites on the plasma membrane.66,68,70,76,95,245 As
budding is mediated by viral Gag and does not require Env, these budding sites are
likely determined by interactions of Gag and cellular proteins, with Env targeting
occurring through a separate mechanism.79 Interactions between HIV-1 matrix and
the Env tail have been implicated in Env incorporation, but these determinants have
not been mapped for SIV, and the mechanism of these interactions is poorly
understood.92,94,102,246,247 Failure of Env to target to sites where Gag assembly has
occurred in preparation for budding would result in a diffuse distribution of Env on
the cell surface, with reduced incorporation of the protein into nascent virions. The
higher Env expression on the cell surface in SIVmac239ΔGY is attributable to the
second role of the GYxxΦ as an endocytosis signal.68,70,244 This motif interacts with
AP-2 to mediate endocytosis of Env from the surface of infected cells.64,65,230
Additional downstream endocytosis motifs are present and can also function to
reduce Env expression on the cell surface, while the small but reproducible increase
in cell surface Env detectable on SIVmac239∆GY-infected cells can be explained by
ablation of the function of the membrane-proximal tyrosine motif.64,66,245
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Although neither S727P nor R722G reconstitute endocytosis motifs in gp41,
both of these mutations, especially the R722G, increase Env incorporation into
virions in the context of the ΔGY mutation, with R722G restoring Env incorporation
to levels equivalent to SIVmac239. Greater levels of Env on virions are associated
with increased infectivity, and this mutation in SIVmac239ΔGY could contribute to
its altered pathogenicity in rhesus and pig-tailed macaques.108,109 Further, these
mutations arose in multiple animals in both RhM and PTM. S727P was observed in
two rhesus macaques and was correlated with disease progression in both
animals.221,222 Interestingly, this mutation was also observed in an SIVmac239Δnef
that became pathogenic in vivo, and correlated with a gain of function in reducing
rhesus tetherin expression.190,248 R722G arose at least transiently in all rhesus and pigtailed macaque progressors, always independently of S727P, and became fixed in 2 of
6 progressing animals (both PTM).222,223 However, it is also possible that the higher
set-point viral loads in SIVmac239ΔGY progressors permitted evolution of additional
mutations that were selected for by enhancing replication fitness, and that R722G is
only a correlate, rather than a cause, of increased pathogenicity in vivo. In addition to
being identified in the six progressing animals, R722G was also seen in one pig-tailed
macaque that ultimately controlled SIVmac239ΔGY.223 This sequence analysis was
performed on plasma viremia following CD8 depletion of two SIVmac239ΔGY PTM
controllers, with R722G being identified in one of the two. Single genome sequencing
was not performed on all controllers, and thus we lack complete information on the
correlation of R722G with disease progression. While the identification of this
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mutation in one PTM controller suggests that R722G alone is not adequate to restore
a pathogenic phenotype, it does not exclude the possibility that the disease
progression is multifactorial and is determined by the kinetics of viral replication and
of host immune responses. As such, R722G may indeed be sufficient to confer a
pathogenic phenotype to SIVmac239ΔGY, but this mutation may not have arisen at
an early enough time for the virus to overcome host immune responses. Innate
immune responses such as interferon-α and upregulation of downstream interferon
stimulated genes are activated within days of infection, while the first adaptive
immune responses via specific cell-mediated immunity are on the order of
weeks.5,249,250 The window for the virus to replicate rapidly and evade these responses
may be so limited that such a compensatory mutation would need to be present at the
start of infection, rather than following several rounds of replication. In Chapter 3, we
address this question by inoculating naïve pig-tailed macaques with an SIV
containing both the ΔGY and the R722G Env mutations.

In virions produced in cell lines, novel endocytosis motifs YFQI and YFQL,
with R722G as they appeared in vivo, have a modulating effect on Env. While R722G
raises Env above wildtype levels, addition of YFQI or YFQL lowers Env levels
toward those of SIVmac239. In rhesus macaque PBMCs, the effect of S727P or
R722G alone is more modest, and addition of R722G with YFQI or YFQL does not
improve virion Env incorporation over SIVmac239ΔGY. Based on previously
published data on correlations between Env content and infectivity, viruses with
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lower Env content were predicted to be less infectious and thus attenuated in
replication.109,214,251–253 We hypothesized that mutations acquired in vivo that restore
Env content might also enhance replication of the virus in cell culture.

Despite robust replication in vivo, the decrease in Env on SIVmac239ΔGY
virions is associated with a small but repeatable decrease in replication fitness in
PBMC cultures. Compared to SIVmac239, in both rhesus and pig-tailed macaque
PBMCs, the peak of SIVmac239ΔGY replication as determined by reverse
transcriptase activity is lower than wildtype SIVmac239. Consistent with previous
reports that virion Env is correlated with infectivity, SIVmac239∆GY containing the
YFQI or YFQL in the absence of R722G showed a marked reduction in replication.
These mutations are associated with low levels of Env on virions produced in cell
lines, and we were unable to evaluate Env on PBMC-produced virions due to poor
replication in these cells. Strikingly, addition of the R722G, which raises Env levels
on virions, restored replication of SIVmac239ΔGY YFQI or YFQL to levels similar
to SIVmac239ΔGY alone. This finding supports earlier work and our initial
hypothesis that sufficient Env incorporation into virions is critical for viral replication
in primary cells and that mutations arising in vivo may compensate for the ΔGY
mutation by restoring Env content and improving infectivity.

Initially, it was hypothesized that YFQI and YFQL were detrimental to
replication due to their disruption of the tat and rev genes; the ΔQTH deletion that
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creates the YFQI and YFQL overlaps with the splice acceptor site of the second
exons of Rev and Tat. As discussed, we established that an alternative splicing pattern
is utilized by these viruses to generate largely intact proteins (Fig. 1B). The use of
this alternative splice acceptor site has been described for SIVmac239 grown in
CEMx174 cells, indicating a precedent for the virus to use this splice acceptor even
when the canonical site is available.254 However, the ΔQTH deletion ablates the
preferred splice acceptor site by removal of two residues, which alters the protein
sequence downstream of the second exon splice site and could have other effects on
Rev and Tat function. Tat enhances transcription efficiency of viral genes and is
known to be critical for efficient viral replication.120 Additionally, the second exon,
though not required for viral replication in vitro, has been specifically implicated in a
number of functions. This region has been shown to modulate the HIV-1 stimulated
innate immune response in dendritic cells and macrophages, delay apoptosis of
infected T cells, and is important for efficient replication of macrophage-tropic HIV-1
in vitro.255–257 The Rev deletion occurs in a multimerization (MM) domain that is
functionally conserved between HIV and SIV.258–262 The MM domain is critical for
nuclear localization of Rev, and in the absence of successful oligomerization of the
protein, Rev is distributed throughout the cell, even when a functional nuclear
localization signal is present.259 Rev is involved in regulation of nuclear export of
mRNA and controls expression of SIV regulatory and structural proteins, including
Env.263,264 Further, Rev is specifically involved in regulating env expression by
enhancing transport of env mRNA out of the nucleus, and by stabilizing the mRNA in
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the cytoplasm.265–268 Thus, it is reasonable, to hypothesize that defects in replication
in viruses with mutations in rev and tat, particularly in functional regions, could be
due in part to loss of function of these proteins. This does not directly explain,
however, the gain of function observed with the addition of R722G, which does not
overlap with rev and tat exons. One possibility is that there is a decrease in Rev
protein function, and therefore a decrease in overall cellular Env levels, that is
compensated by the addition of R722G. The introduction of R722G, YFQI, and
YFQL to an SIVmac239 without ΔGY could be used to determine the effect of these
mutations on an otherwise fully competent virus. Measuring mRNA transcripts or
protein expression of rev, tat, and env in these various mutants may provide
additional insight as to the mechanism by which R722G rescues the replication
defects imposed by YFQI and YFQL. While it is clear than addition of R722G
increases virion Env content and confers a replication advantage to SIVmac239ΔGY
YFQI and YFQL viruses in PBMCs, whether there is an additional effect unrelated to
Env has not yet been explored.

Despite being associated with poor replication in vitro, YFQI and YFQL were
selected for in two different SIVmac239ΔGY infected rhesus macaques that
progressed to disease, and in vivo the virus appears to tolerate and even prefer these
deletions provided they are in the presence of R722G. This finding indicates that they
are likely to impart a gain of function for SIVmac239ΔGY that is relevant in vivo,
thus compensating for the loss of the proximal tyrosine motif. The mechanism
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underlying SIVmac239ΔGY’s altered pathogenesis is not yet fully characterized, but
results in impaired mucosal infection, as evidenced by preservation of CD4+ T cells in
gut, and severely reduced or absent infection of macrophages and microglia
cells.222,223 One possible explanation for this phenotype is that SIVmac239∆GY is
specifically impaired in its ability to spread cell-to-cell through a virological
synapse.113 Virological synapses formed by retroviruses have been imaged in vivo,
and synapse formation by HIV-1 has been demonstrated in vitro.269–271 Formation of
the synapse is mediated by Env, and there is substantial evidence that Env must be
targeted to particular locations on the originating cell for efficient cell-to-cell
spread.89,271–274 Further, recruitment of Env to sites of viral assembly has been shown
to be dependent on the cytoplasmic tail.275 Inability to properly direct Env to these
sites could result in lowered budding efficiency or failure to form a synapse at the
appropriate pole of the cell.88,90,276,277 If SIVmac239∆GY budding occurs more
diffusely, the virus may rely more heavily on cell-free spread as its primary mode of
transmission. This process is thought to be less efficient than cell-to-cell spread, and
renders the virus more exposed to targeting by antibodies.278–280 This reduced
efficiency is reflected by greater receptor dependence; cell-to-cell spread appears to
tolerate lower CD4 expression than cell-free.114 As macrophages express a lower
density of CD4 than CD4+ T cells, SIVmac239∆GY may be unable to infect them due
to a greater dependence on cell-free spread for transmission.114,124,281 Unlike other
attenuated SIVs such as SIVmac239∆nef, SIVmac239∆GY achieves an acute peak in
vivo identical to that of its parent virus, which suggests that it has not lost the ability
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to replicate well in animals.187,197,222,223 Instead, SIVmac239∆GY appears to be
exquisitely sensitive to host immune responses that arise sometime after two weeks
post-infection, an attribute that may be partially explained by impaired cell-to-cell
spread and the preservation of CD4+ T cells in the GI compartment.282

The novel SIVmac239 variant SIVmac239∆GY provides insight into new
roles for the proximal tyrosine motif in regulating Env trafficking, including cell
surface distribution and incorporation into virions. The effects of these alterations on
viral growth, infectivity, and pathogenesis in vivo imply that this motif is critical to
aspects of the viral life cycle and that its disruption represents a significant
impairment to function in the host. In this study, we identified multiple attributes that
distinguish SIVmac239∆GY from its parent virus, including reduced virion Env
content, impaired endocytic, trafficking, and basolateral targeting function, and
attenuated growth in multiple cell types. A key finding is that SIVmac239∆GY
exhibits defects in mediating a clustered Env phenotype on infected cells, which
could explain poor Env incorporation into virions and have implications for formation
of virological synapses that mediate cell-to-cell spread. Together, the differences in
properties measured by in vitro assays could largely explain the susceptibility of
SIVmac239∆GY to immune control by the host. This phenomenon appears to be
related to CD8+ cell mediated immunity and also confers protection from an
expanded array of pathogenic challenge viruses. The defects in these in vitro
functions were partially restored by mutations that appear to recapitulate the motif
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ablated in SIVmac239∆GY and which correlate with progression to AIDS in
SIVmac239∆GY-infected macaques. Understanding the effect of this signal on in
vitro properties is important to elucidate the mechanism by which SIVmac239∆GY is
controlled by host immune responses, and may direct rational design of immunogens
in future vaccine efforts. Putative compensatory mutations that restore function in in
vitro assays and which correlate with disease progression in vivo inform us on what
virologic attributes are important for pathogenesis in a host. In Chapter 3, we will
address questions regarding the compensatory function of these mutations by
inoculating naïve macaques with a modified SIVmac239∆GY that also contains
mutations that restore Env function in vitro. We will use these novel viruses to
determine whether such mutations are sufficient to restore an SIVmac239 natural
history to SIVmac239∆GY. In vivo assessment of novel mutant viruses will aid in
mapping determinants of pathogenicity in the SIVmac239 cytoplasmic tail.
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Supplemental Figure 2-1: Imaging flow cytometry channels and masking strategy
(A) Channel definitions for imaging flow cytometry on ImagestreamX. Left grayscale:
brightfield, channel 1; Green: channel 2, Envelope; Blue: channel 7, DAPI; Grayscale:
brightfield, channel 9; Red: channel 11, Gag. Images shown are a single !GY-infected
CEMx174 cell. (B) Masking strategy for imaging flow cytometry. Masks displayed in
each column are as labeled. Cells were fitted with a plasma membrane mask using the
brightfield channel (channel 1) as defined: An object mask dilated by 0.33µm was used
to define the entire cell (“whole cell”). Next, an object mask eroded by 2.97 µm was
used to define the cytoplasm of the cell (“cytoplasm”). The plasma membrane (PM)
mask was defined as “whole cell and not cytoplasm” (right panel). Within this mask, the
median pixel intensity feature of channel 2 was used to measure the median intensity of
Env signal within the plasma membrane. The area intensity feature was applied to
measure the total area within the plasma membrane mask that was positive for Env
signal. Env signal positivity was defined as Env signal above a pixel intensity threshold
of 67.
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Supplemental Figure 2-2: Imaging flow cytometry gating strategy
Gating strategy for evaluation of Env distribution on infected CEMx174 cells.
Top panel, rows 1-2: gating strategy for identification of DAPI+Gag+Env+ single,
focused cells. Bottom panel: Env distribution gating with phenotypic gates identified.
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Supplemental Figure 2-3: Imaging flow cytometry phenotypic gates for
DAPI+Gag+Env+ cells
A repesentative image of phenotype from within each gate is displayed
(insets). The corresponding location of the displayed cell on the scatterplot is
marked by a green cross. Top, punctate phenotype; middle, partial rim
phenotype; bottom, diffuse phenotype.
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CHAPTER 3

Mutations in the Env Cytoplasmic Tail Partially Restore Pathogenicity of an
SIVmac239 Variant Lacking a Tyr-Dependent Trafficking Signal
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Abstract
SIVmac239 infection of Asian macaques recapitulates key features of HIV-1
infection of humans, including high peak viral loads, acute depletion of CD4+ T cells
in GI lamina propria, and gradual decline of CD4+ T cells in peripheral blood.
SIVmac239∆GY is an SIVmac239 derivative with a deletion of residues 720 and 721
of the membrane-proximal tyrosine dependent trafficking motif in the envelope (Env)
cytoplasmic tail domain. This virus has been evaluated in rhesus (RhM) and pigtailed (PTM) macaques and despite replicating to a high acute peak comparable to
SIVmac239, it lacks characteristic pathogenic features of its parent virus. RhM
infected with SIVmac239∆GY develop AIDS, but do not exhibit depletion of CD4+ T
cells in gastrointestinal lamina propria, microbial translocation, or macrophage
infection. PTM infected with SIVmac239∆GY also develop high peak viremia, but a
majority (19/21) of infected animals rapidly control plasma virus to <102 RNA
copies/ml, exhibit only a mild and transient decrease in gut CD4+ T cells, and remain
healthy. Two PTM had high set-points and died with similar phenotypes as
SIVmac239∆GY-infected RhM. In all progressing animals, additional mutations in
the cytoplasmic tail of Env were observed, which we hypothesized could be
compensating for alterations in pathogenesis induced by ∆GY. We selected two of
these mutations for further study, an R722G identified in all progressors, and a ∆QTH
(residues 734-736) that produced novel tyrosine motifs, either YFQI or YFQL. To
determine whether these mutations were sufficient to restore a pathogenic phenotype
to SIVmac239∆GY, we inoculated naïve PTM with SIVmac239∆GY R722G or
	
  

91	
  

SIVmac239∆GY R722G + YFQL and monitored plasma virus, macrophage infection,
and CD4+ T cells in peripheral blood and GI lamina propria. We also sequenced
plasma virus at multiple timepoints to evaluate the evolution of any additional
mutations.
All animals developed high peak viremia but diverged into two distinct
phenotypes not determined by their inoculum. Progressors (3/6) had high set-points
and declining peripheral CD4+ T cells, and two of these animals died with AIDS at 36
and 37 weeks post-infection. Controllers (3/6) developed very low or intermediate
set-points and remained healthy. In all animals, but progressors more than controllers,
there were trends toward more severe and sustained depletion of gut CD4+ T cells
than historical SIVmac239∆GY controls. At terminal timepoints, single genome
amplification (SGA) of plasma virus showed that 2 of 2 SIVmac239∆GY R722Ginfected progressors developed additional Env mutations that reconstituted
endocytosis motifs, while the SIVmac239∆GY R722G + YFQL-infected progressor
had few additional mutations in the cytoplasmic tail. The functional significance of
novel mutations in in vitro assays is under investigation. This study highlights the
critical importance of the membrane-proximal tyrosine motif to SIVmac239
pathogenesis. Despite the addition of partially compensatory mutations to the
inoculum, ∆GY renders SIVmac239 unable to fully escape host immune responses.
Additional knowledge of the mechanistic role of the GYxxΦ motif through in vitro
studies may allow improved design of compensatory mutants that restore its function
in animals and provide insight to viral determinants of pathogenicity. Understanding
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immune responses that control SIVmac239∆GY in PTM could also direct
immunogen design for future vaccine efforts.

Introduction
Human immunodeficiency virus (HIV) infection of humans and simian
immunodeficiency virus (SIV) infection in Asian macaque models have similar viral
kinetics and induce a number of characteristic pathologic effects.153 While using the
well-characterized SIV infectious molecular clone (IMC) SIVmac239 in rhesus
(RhM) and pig-tailed (PTM) macaque models of HIV infection, plasma viremia peaks
at roughly two weeks post-infection with plasma viral loads typically between 106
and 108 viral RNA copies/ml.148,159,164,283 With the onset of antiviral immune
responses, viremia decreases to a set-point viral load between 104 and 106 copies/ml,
which is maintained for several months with progression to AIDS usually occurring
within one year post-infection.148,159,160,284 Early events in SIVmac239 infection
include rapid and profound depletion of CD4+ CCR5+ T cells in gastrointestinal (GI)
lamina propria, compromise of GI epithelial barrier integrity with translocation of
microbial products from the gut lumen into systemic circulation, and infection of
macrophages.139,140,142,148,149,224,225,236,284–287 The presence of microbial products in
tissue and blood contributes to a state of chronic immune activation in infected hosts,
with increased proliferation and activation of T cells observed, as well as
upregulation of pro-inflammatory cytokines such as the interleukins IL-1β, IL-6, IL18, and tumor necrosis factor alpha (TNF-α).8,142,145,217,288 As disease progresses, T
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central memory (TCM) cells can no longer maintain a functional population of CD4+ T
effector cells, and as it is gradually depleted, the host becomes susceptible to
opportunistic infections and neoplasms characteristic of immunodeficiency.289 In
macaques, this simian immunodeficiency syndrome is highly reminiscent of AIDS in
humans, characterized by a blood CD4+ T cell count of <200 cells/µl, a blood CD4+ T
cell percentage of <15%, or an AIDS-defining complication such as pneumocystis
pneumonia.290

Our laboratory has previously described an SIVmac239 mutant with a two
amino acid deletion in the envelope (Env) cytoplasmic tail domain.221–223 Deletion of
glycine-720 and tyrosine-721 ablates key residues of the highly conserved membraneproximal tyrosine motif (i.e. YxxΦ) and the virus, SIVmac239ΔGY, has been studied
in both RhM (n=10) and PTM (n=21).221–223 This deletion is stable and has not been
observed to revert to wildtype sequence in vivo when studied for periods of 1-2 years
in RhM and >2 years in PTM.221–223 In both species, peak plasma viremia of
SIVmac239ΔGY is equivalent to that of parental SIVmac239, though in RhM it is
delayed by ~7 days.222 Moreover, in SIVmac239ΔGY infection, GI lamina propria
CD4+ T cells are largely spared, with only mild and transient depletion, and are
reconstituted to pre-infection levels by week 30 post-infection in both RhM and PTM.
This is in stark contrast to SIVmac239 infection, where severe CD4+ T cell depletion
occurs early and is never reconstituted even with antiretroviral therapies.291 In
addition, while infected macrophages are abundantly detectable in SIVmac239	
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infected RhM and PTM, only rare infected macrophages are detectable in
SIVmac239ΔGY-infected animals in early and chronic infection. While RhM and
PTM exhibit similar peak viremia, the set-point viral load in PTM is markedly lower;
mean 45 RNA copies/ml, compared to a mean of 3.9 x 104 for RhM.222,223
Specifically, 15/19 animals controlled viremia to below the limit of detection (<15
RNA copies/ml).223 Long term, 90% (19/21) of PTM remained healthy, with low setpoints, while all four RhM followed into the chronic phase did eventually develop
AIDS, including small declines in peripheral CD4+ T cell counts late in infection and
AIDS-defining illnesses (Table 1).222,223

In progressing animals (4/4 RhM, 2/21 PTM), additional mutations arose in
the Env cytoplasmic tail and were maintained in a predominance of viruses isolated
from animals late in infection.222,223 Importantly, by SGA of plasma virus, the ∆GY
mutation was stable in all amplicons in the 6 progressing animals throughout 95
weeks of infection. An additional mutation was found immediately flanking the ∆GY
mutation (R722G), observed in at least some amplicons in 6/6 animals. In two RhM,
a remarkable deletion (∆QTH) of amino acids 734-736 created two novel tyrosine
motifs, either YFQI or YFQL, depending on the reading from of the 9 nucleotide
deletion. While the R722G was seen with or without ∆QTH, the ∆QTH mutation was
seen only in the context of the R722G mutation. An S727P point mutation was also
observed in 1/4 RhM. S727P had been noted in an SIVmac239∆GY-infected RhM
progressor in a small pilot study of three animals.221 S727P has been characterized in
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vivo in RhM and is associated with partial restoration of gut targeting and acute
depletion of GI lamina propria CD4+ T cells.292 However, S727P did not fully
reconstitute a pathogenic phenotype as seen in SIVmac239 infection, nor did it permit
robust infection of macrophages.292

In Chapter 2, SIVmac239∆GY mutants (Ch. 2, Fig. 1) were evaluated in a
variety of in vitro assays to determine if these changes restored to SIVmac239∆GY
any of the properties that were lost from parental SIVmac239. As we demonstrated,
∆GY reduced the Env content of virions produced in rhesus macaque PBMCs and
slightly attenuated growth when compared to SIVmac239. The R722G mutation
alone restores Env content to that of SIVmac239, with more modest increases seen
with S727P or R722G + ∆QTH (YFQI or YFQL). Alone, the ∆QTH mutation
(producing either the YFQI or the YFQL sequence) exhibited a markedly impaired
replicative capacity that was largely restored when the R722G mutation was added. In
CEMx174 cells infected with HEK-293T-produced virus, this decrease in virion Env
content occurs in spite of equal or higher levels of Env present on the surface of
infected cells. Together with the observation that a higher percentage of SIVmac239infected cells have punctate Env surface distribution, while SIVmac239∆GY Env is
diffusely distributed, this implies a failure of Env to target to sites of
budding.275,293,294 Defects in Env targeting and incorporation into virions could affect
formation of the virological synapse, provide a possible explanation for the observed
in vivo properties, including decreased mucosal transmission, reduced infection of
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CD4+ T cells in GI mucosa, and impaired infection of
macrophages.69,110,117,240,251,280,295

In this Chapter, we evaluated the ability of two novel mutations characterized
in vitro to restore pathogenicity to SIVmac239∆GY. We constructed IMCs containing
∆GY with R722G alone or with ∆QTH (generating the YFQL mutation) and infected
naive PTM. The R722G mutation was selected because it appeared in all progressing
animals regardless of species, and became fixed in 2/2 progressing PTM.222,223 ∆QTH
(YFQL) was selected on the basis of its documented ability to restore endocytic and
basolateral sorting functions at levels that were comparable to wildtype SIVmac239
(Ch. 2, Fig. 6 & 9). The aim of this study was to determine which aspects of the
SIVmac239 in vivo phenotype are attributable to the endocytosis and basolateral
sorting functions of the membrane-proximal tyrosine motif that are restored by
R722G and ∆QTH, and how this conserved region of Env contributes to SIV
pathogenesis.

Methods
Ethics statement
The Tulane University Institutional Animal Care and Use Committees approved all
experiments using pig-tailed macaques (protocol 3617). The Tulane National Primate
Research Center (TNPRC) facility is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International and follows
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recommendations of the Guide for the Care and Use of Laboratory Animals.296 The
NIH Office of Laboratory Animal Welfare assurance number for TNPRC is A449901. All clinical procedures were performed under the direction of a laboratory animal
veterinarian. Macaques were anesthetized for phlebotomy using 10 mg/kg ketamine.
Laboratory animal veterinarians performed all surgeries including jejunal resections
and lymph node biopsies. Prior to general anesthesia, preanesthetics acepromazine
and glycopyrolate, were administered. General anesthesia was induced with 10 mg/kg
ketamine hydrochloride or 8 mg/kg tiletimine-zolazepam. Animals were intubated
and maintained on an isoflurane oxygen mixture. Analgesia intraoperatively and
postoperatively was achieved with buprenorphine. All possible measures were taken
to minimize discomfort of macaques during this study. Animals were monitored daily
post-surgery for signs of illness and medical intervention was undertaken as needed.
Euthanasia was performed in accordance with the recommendations of the panel on
Euthanasia of the American Veterinary Medical Association. Tulane University
complies with the NIH policies on animal welfare, the Animal Welfare Act, and all
other applicable federal, state, and local laws.

Animals, viral inoculations, and sample collection
(Pyone Aye, Andrew Lackner, TNPRC)
A total of 6 male pig-tailed macaques were used in this study. All macaques were
housed and maintained at TNPRC. Animals were inoculated intravenously (IV) with
100 50% tissue culture infective dose (TCID50) of SIVmac239ΔGY R722G (n=3) or
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100 TCID50 of SIVmac239ΔGY R722G + YFQL. 12 pig-tailed macaques housed at
TNPRC were used as historical controls and had been inoculated with 100 TCID50
SIVmac239ΔGY IV (n=8) or 100 TCID50 SIVmac239 IV (n=4) as described in a
previous study.223 Viruses were produced in 293T cells transfected with plasmids
containing full-length proviral DNA. Viruses were quantified by determining TCID50
on rhesus macaque peripheral blood mononuclear cells (PBMCs). Prior to use, all
animals tested negative for antibodies to SIV, simian T cell leukemia virus (STLV),
and type D retrovirus, and were negative by PCR for type D retrovirus. Prior to all
procedures, macaques were anesthetized by an intramuscular (IM) injection of 10
mg/kg ketamine hydrochloride. Blood samples and small intestinal biopsies
(duodenal pinch biopsy via endoscopy and jejunal resectional biopsy samples) were
collected under anesthesia (ketamine hydrochloride or isoflurane) at various times
from each animal as described in relevant figures. Two macaques died during the
course of the study; the remaining 4 animals were euthanized following final sample
collection. Complete necropsies were performed on all deceased and euthanized
animals. All animals were maintained at TNPRC in accordance with standards of the
Association for Assessment and Accreditation of Laboratory Animal Care and the
Guide for the Care and Use of Laboratory Animals prepared by the National Research
Council. The TNPRC Institutional Animal Care and Use Committees approved all
studies.

Quantitation of viral load in plasma
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(Yuan Li, Mike Piatak, Jeff Lifson, NCI)
Plasma viral loads at each timepoint were measured using a reverse transcriptionPCR (RT-PCR) assay with a limit of detection of 15 SIV RNA copies/ml.297

Lymphocyte isolation from intestinal tissues
(Faith Schiro, Pyone Aye, TNPRC)
Cells were collected from pig-tailed macaques either by endoscopic pinch biopsies of
the small intestine or by 2-cm surgical resections of jejunum at multiple time points.
Biopsy and intestinal cell isolation procedures have been previously described.284,298
Briefly, intestinal cells were isolated by EDTA-collagenase double digestion followed
by Percoll density gradient centrifugation.
T cell immunophenotyping and activation/proliferation
(Workineh Torben, Bapi Pahar, TNPRC)
T cell immunophenotyping was performed on isolated lamina propria lymphocytes
(LPLs) and anticoagulated whole blood. Immunophenotyping of LPLs was performed
using antibodies against CD3 (SP34), CD4 (L200), and CD8 (SK1 or SK2) (BD
Biosciences, San Jose, CA). Immunophenotyping of whole blood was performed
using antibodies against CD3 (SP34), CD8 (SK1 or SK2), CD4 (L200), CD95 (DX2),
and CD28 (28.2) (BD Biosciences; except CD28 [28.2], Beckman Coulter). Cells
were stained for 30 min at room temperature in the dark. CD4+ and CD8+
lymphocytes from lamina propria and peripheral blood were analyzed for activation
and proliferation by measuring the expression of HLA-DR and Ki67, using Anti	
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HLA-DR (G46-6) and Anti-Ki67 (B56) respectively; both the activation and
proliferation antibodies were from BD Biosciences. For Ki67 staining, cells were
permeabilized (BD cytofix/cytoperm solution) for 20 min at 4oC, and then stained
with Ki67 for 30 min at room temperature in the dark. Lymphocytes were analyzed
for percent positive or fraction of baseline for HLA-DR and Ki67 expression at
various time points and compared to historical controls from SIVmac239 or
SIVmac239ΔGY-infected controller pig-tailed macaques. Samples were analyzed
using a FACS LSRII or a FACS Aria flow cytometer (BD Biosciences). Flow
cytometry data were analyzed using FlowJo software (TreeStar, Inc., Ashland, OR).
Peripheral blood or gut LPLs were analyzed by gating of side-scatter and forwardscatter, lymphocytes, CD3+ cells, CD4+ cells, and, if used, CD28+ CD95+, CD28+
CD95-, and CD28- CD95+ cells. Absolute cell counts from whole blood were
measured by multiplying complete blood count (CBC) values by the percentages of
each cell subset population as determined by flow cytometry.

In situ hybridization (ISH) and quantitation of SIV positive cells in tissue
(Robert Blair, TNPRC)
Tissue samples were fixed in Z-Fix (Anatech, Battle Creek, MI) and embedded in
paraffin, and 5-µm-thick sections were cut and adhered to charged glass slides. SIV
RNA in situ hybridization (ISH) was then performed, as described previously.299
Quantification of SIV RNA ISH-positive cells was performed on jejunal sections at
multiple timepoints and compared to SIVmac239 or SIVmac239ΔGY-infected
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historical time-matched control samples. Images were collected using liquid crystal
tunable filter multispectral imaging (Nuance multi- spectral imaging system; CRI,
Inc., Woburn,MA) . All slides were scanned at medium power (10x) to identify if ISH
positive cells were present. Slides containing infected cells were then evaluated for
the number of infected cells/mm2, intensity (I) of the staining, and the presence of a
reticular staining pattern in lymphoid follicles. The number of infected cells/mm2
was determined by counting the number of infected cells in 10 random, contiguous,
40x fields (total area = 4 mm2), starting in the most densely infected area. Slides were
also scored based on the intensity of staining of the infected cells with 1+= light, 2+=
moderate, and 3+ = marked.

Confocal microscopy
(Robert Blair, Xavier Alvarez-Hernandez, TNPRC)
Double- and triple-label confocal microscopy was performed for colocalization of
SIV RNA with cell type-specific markers to identify the immunophenotype of
infected cells, as previously described.300 Immunofluorescent labeling of T cells
(rabbit polyclonal anti-CD3 [Dako]) or macrophages (mouse IgG1 monoclonal antiCD68 [Dako] or CD163 [Serotec]) was performed after ISH, as previously
described.300 Following incubation with the primary antibodies (anti-CD3, anti-CD68,
anti-CD163) and subsequent washes, secondary antibodies were applied (Alexa Fluor
488- or 647-conjugated goat anti-rabbit or goat anti-mouse IgG1 [Invitrogen,
Carlsbad, CA]). Confocal microscopy was performed using the sequential mode to
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independently capture fluorescence from the different fluorochromes (Leica
Microsystems, Exton, PA). NIH Image v1.62 and Adobe Photoshop v7 software were
used for color correction: Alexa 488 (green), Alexa 568 (red), Alexa 647 (blue), and
differential interference contrast (DIC) (gray scale). In selected animals and tissues,
the numbers of infected cells by phenotype were quantitated as described
previously.222

Single genome amplification (SGA)
(Samra Elser, Carolyn Reid, Brandon Keele, NCI)
SGA and direct sequencing was performed on plasma samples from all six animals at
week 2, week 10, and at additional timepoints for individual animals. The full env
gene was sequenced using a limiting-dilution PCR to ensure that only one amplifiable
molecule was present in each reaction mixture, as described previously.158,222,223
Sequence alignments were generated with Clustal W and used to create alignments
shown as highlighter plots Unrooted neighbor-joining trees were constructed in
Clustal W and excluded gaps and corrected for multiple substitutions. APOBEC
signature mutations were identified with Hyper-Mut (www.hiv.lanl.gov).

Statistical analysis
All statistical analyses were performed with GraphPad Prism v6.0g (GraphPad
Software, Inc., La Jolla, CA). Pairwise comparisons were conducted using KruskalWallis tests as samples sizes were insufficient to assess normality. The Holm-Sidak
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test was used to adjust p-values for multiple comparisons. Where applicable, results
are expressed as mean ± standard error of mean.

Nucleotide sequence accession numbers. All sequences in this study were deposited
in GenBank.

Results
Viral dynamics of SIVmac239ΔGY R722G±YFQL in pig-tailed macaques
Pig-tailed macaques were inoculated intravenously (IV) with 100TCID50
SIVmac239ΔGY R722G (n=3) or SIVmac239ΔGY R722G + YFQL (n=3) (Fig. 1).
Plasma viral loads for individual SIVmac239ΔGY R722G±YFQL-infected animals
are shown in Figure 2. KV51, KV73, and KV75 were inoculated with
SIVmac239ΔGY R722G, while KV52, KV74, and KV76 received SIVmac239ΔGY
R722G + YFQL. All SIVmac239ΔGY R722G±YFQL-infected animals developed
high peak plasma viral loads (mean 4.83 x 106 ± 1.44 106 RNA copies/ml, Fig.
3A&B) that were not significantly different from those of SIVmac239 and
SIVmac239ΔGY-infected historical controls (Fig. 3B). During chronic phase, animals
diverged into two phenotypic groups. Progressors (two SIVmac239ΔGY R722G and
one SIVmac239ΔGY R722G + YFQL) developed high set-points (defined as mean
plasma viral load at ≥week 20 post-infection), while controllers (one
SIVmac239ΔGY R722G and one SIVmac239ΔGY R722G + YFQL) developed very
low to intermediate set-point viral loads. Mean plasma viremia over time, grouped by
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SIVmac239
RhM & PTM

SIVmac239!GY
RhM
progressors
(4/4)

SIVmac239!GY
PTM controllers
(19/21)

SIVmac239!GY
PTM
progressors
(2/21)

Acute peak
viremia

High

High

High

High

(106-108 RNA copies/ml)

(107-108 RNA copies/ml)

(106-107 RNA copies/ml)

(106-107 RNA copies/ml)

Set-point
viremia

High

Intermediate

Low

Intermediate

(106-108 RNA copies/ml)

(104-105 RNA copies/ml)

(<100 RNA copies/ml)

(103-105 RNA copies/ml)

CD4+ T cells
in GI lamina
propria

Rapid and
sustained depletion

Mild and transient
depletion

Mild and transient
depletion

Mild and transient
depletion

CD4+ T cells
in peripheral
blood

Gradual decline

Stable, small
decline late

Stable near
baseline level

Stable, small
decline late

Macrophage
infection

Present

Absent

Absent

Absent

CNS disease

Present

Absent

Absent

Absent

AIDS

Yes

Yes

No

Yes

Table 3-1: Features of SIVmac239 and SIVmac239!GY infection in macaques
Infection phenotypes of SIVmac239 (left column) or SIVmac239!GY (right three columns)
are shown for progressor rhesus and progressor or controller pig-tailed macaques.
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phenotype (progressor or controller), is shown in Figure 3A. Set-point viral loads for
progressors (3/6) were significantly higher, while controller set-point viremia was not
significantly higher than for historical SIVmac239ΔGY-infected controllers (Fig.
3B).223 Two progressors, KV51 and KV73, both infected with SIVmac239ΔGY
R722G, died at week 36 and 37 post-infection (Fig. 2). At necropsy, both animals had
lesions consistent with simian AIDS, with death due to pulmonary or aortic
thrombi.159,284

Dynamics of CD4+ T cells in peripheral blood during chronic infection
During infection of macaques with SIVmac239, CD4+ T cells gradually
decline as a percentage of CD3+ lymphocytes in the peripheral blood (Fig. 4A). In
contrast to SIVmac239, SIVmac239ΔGY controllers maintain a stable population of
CD4+ lymphocytes throughout infection. While neither SIVmac239ΔGY
R722G±YFQL progressors nor controllers exhibited loss of CD4+ T cells in blood
comparable to SIVmac239, progressors trended toward lower percentages of CD4+
cells in blood than controllers or than SIVmac239ΔGY-infected PTM (Fig. 4A).
CD4+ T cells counts in SIVmac239ΔGY R722G±YFQL controllers were
indistinguishable from SIVmac239ΔGY, while progressors showed a slight decrease
at greater than 20 weeks post-infection. Note: 2/3 progressors died between weeks 35
and 40 post-infection and thus longer term CD4+ T cell dynamics are based on a
single surviving progressor. Thus, although R722G±YFQL did not produce CD4+ T
cell depletion similar to that observed in SIVmac239 infection, there is some
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Figure 3-1: SIVmac239 mutants for infection of naive pig-tailed macaques
Six naive pig-tailed macaques were inoculated intravenously with 100TCID50 of
one of two infectious molecular clones: SIVmac239!GY + R722G (n=3) or
SIVmac239!GY + R722G + !QTH (YFQL) (n=3)
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Figure 3-2: Plasma viral loads of SIVmac239!GY R722G ±YFQLinfected pig-tailed macaques
Plasma viral loads of individual PTM infected with SIVmac239!GY R722G
(left column) or SIVmac239!GY R722G + YFQL (right column).
SIVmac239!GY R722G-infected animals are KV51, KV73, and KV75.
SIVmac239!GY R722G + YFQL-infected animals are KV52, KV74, and
KV76.
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evidence that there is greater loss of peripheral CD4+ T cell than in
SIVmac239ΔGY infection.

SIVmac239∆GY R722G±YFQL progressors exhibit increased infection and
depletion of gut CD4+ T cells compared to controllers or SIVmac239∆GY
SIVmac239 infection is known to cause rapid and sustained depletion of
CD4+ lymphocytes in the GI tract lamina propria.140,237 In contrast, our prior studies
have shown that SIVmac239∆GY-infected pig-tailed macaques experience only mild
decreases in CD4+ lamina propria lymphocytes (LPL) and that these cell numbers
cover and are maintained at near-pre-infection levels throughout infection, even in
animals that progress to AIDS.223 Due to the divergent phenotype between
SIVmac239 and SIVmac239∆GY, we examined CD4+ T cell dynamics in gut LPL to
determine whether addition of YFQL and/or R722G allowed the virus to infect and
deplete cells in this compartment. Shown are CD4+ T cells in gastrointestinal lamina
propria of SIVmac239∆GY R722G±YFQL progressors or controllers as a percentage
of CD3+ lymphocytes (Fig. 4B) and as fold change from pre-infection baseline
samples (Fig. 4C), with data from historical ∆SIVmac239GY-infected controllers for
comparison. As previously described, SIVmac239∆GY-infected PTM exhibited a
mild reduction (average cell count 53% of baseline) in gut CD4+ cells (Fig. 4B&C).
The kinetics of this change were delayed compared to SIVmac239, with peak
depletion occurring at week 4 post-infection, while SIVmac239 depletes CD4+ LPL
by week 2 post-infection.139,140,223,224 CD4+ LPL in SIVmac239ΔGY-infected animals
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Figure 3-3: Mean plasma viral loads, peak viremia, and set-point
(A) Plasma viral loads of SIVmac239!GY R722G ±YFQL progressors and
controllers. SIVmac239 and SIVmac239!GY historical data is graphed for
comparison. (B) Mean peak (left), and mean set-point (right) plasma virus. Peak
viremia is reached at 2 weeks postinfection. Set-point is defined as viral load at !week
20 postinfection. * denotes significant difference from SIVmac239!GY (*, p<0.05)
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recovered to pre-infection levels by week 34 post-infection (average percentage of
baseline LPL CD4+ cells 96% at week 34, Fig. 4C).

Progressor SIVmac239ΔGY R722G±YFQL-infected PTM exhibited a
reduction to 28% of baseline at week 2 post-infection, while controllers manifested a
delayed and milder depletion (maximal depletion, 41% of baseline, week 4 postinfection) (Fig. 4B). By week 34 post-infection, SIVmac239ΔGY R722G±YFQL
controllers recovered CD4+ gut LPLs to average 108% of pre-infection levels, similar
to historical SIVmac239ΔGY-infected PTM, which recovered to an average 96% of
baseline (Fig. 4C). SIVmac239ΔGY R722G±YFQL progressors did not recover
CD4+ T cells in gut to pre-infection baseline, but remained at average 44% (week 34)
of pre-infection count (Fig. 4C). Thus there was a trend of more rapid and severe
reduction in CD4+ gut LPL in SIVmac239ΔGY R722G±YFQL infection over
SIVmac239ΔGY.

Increased immune activation in SIVmac239∆GY R722G±YFQL progressors
Due to differences in CD4+ cell dynamics between SIVmac239ΔGY
controllers and SIVmac239ΔGY R722G±YFQL-infected animals, we hypothesized
that there might be differences in proliferation of CD4+ or CD8+ T cells. Expression
of the proliferation marker Ki67 is used as a marker for immune activation.249,301,302
We measured intracellular Ki67 expression by flow cytometry and examined the
percentage of Ki67+ CD4+ or CD8+ lymphocytes. SIVmac239ΔGY controllers show
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Figure 3-4: CD4+ T lymphocytes in peripheral blood and small intestine
(A) Percent CD4+ of CD3+ T lymphocytes in peripheral blood of SIVmac239!GY R722G
±YFQL progressors and controllers. SIVmac239 and SIVmac239!GY historical data are shown
for comparison. (B) Percent CD4+ of CD3+ T lymphocytes in small intestine of SIVmac239!GY
R722G ±YFQL progressors and controllers. SIVmac239 and SIVmac239!GY historical data are
shown for comparison. (C) Fold change from baseline of CD4+ T lymphocytes in
SIVmac239!GY R722G ±YFQL progressors and controllers. SIVmac239!GY historical data are
shown for comparison.
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only a small increase over baseline in percentage of Ki67+ CD4+ cells in blood and
gut at week 2 post-infection (Fig. 5A), which returns to baseline and remains stable
over subsequent timepoints. SIVmac239ΔGY R722G±YFQL progressors and
controllers show substantial increases in Ki67+ CD4+ cells in blood and GI LPL over
baseline, with a slight delay from SIVmac239ΔGY. For SIVmac239ΔGY
R722G±YFQL-infected animals, the increase in proliferation occurs at week 4 postinfection, in comparison to week 2 for SIVmac239ΔGY (Fig. 5A&C). Comparative
data of Ki67 expression is not available for SIVmac239-infected PTM, but a prior
study showed that Ki67+ CD4+ cells in blood declined during acute (2 week) infection,
similar to other CD4+ T cell populations, then rebounded to high levels (30-40% of
CD4+ cells) after 2 weeks post-infection.148

Although SIVmac239ΔGY animals have an increase in Ki67+ CD8+ cells at
week 2 that is of greater magnitude in GI LPL than blood, this returns to baseline by
week 10. In contrast, both SIVmac239ΔGY±YFQL-infected progressors and
controllers continue to show increases in Ki67+ CD8+ cells in both compartments
through chronic infection, though this is again more evident in blood (Fig. 5B&D).
There were trends toward a greater magnitude during early infection and persistence
of immune activation in SIVmac239ΔGY±YFQL-infected progressors than in
SIVmac239ΔGY±YFQL-infected controllers. Thus, although there was considerable
variation, progressing animals exhibited a subtle trend towards increased Ki67
expression over time.
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Figure 3-5: Percent Ki67+ of CD4+ and CD8+ T lymphocytes in peripheral
blood and small intestine.
Percentage of Ki67+CD3+CD4+ or Ki67+CD3+CD8+cells in peripheral blood or GI
lamina propria lymphocytes (GI LPL) from SIVmac239!GY R722G ±!QTHinfected PTM was determined at pre-infection baseline and for multiple timepoints
during infection. Mean ± SEM is graphed for each group. SIVmac239!GY
historical data is shown for comparison. (A) Percent Ki67+ of CD4+CD3+ T
lymphocytes in peripheral blood. (B) Percent Ki67+ of CD8+CD3+ T lymphocytes
in peripheral blood. (C) Percent Ki67+ of CD4+CD3+ T lymphocytes in GI LPL.
(D) Percent Ki67+ of CD8+CD3+ T lymphocytes in GI LPL.
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Characterization and quantitation of SIVmac239∆GY R722G±YFQL infected
cells in tissue via in situ hybridixation
To assess the ability of SIVmac239ΔGY R722G±YFQL to infect cells in
various tissue compartments, peripheral lymph node and small intestinal (jejunal)
biopsies were obtained at multiple timepoints during early and late infection. Jejunal
biopsies were available from for SIVmac239ΔGY- and SIVmac239ΔGY
R722G±YFQL-infected animals at week 2 post-infection. In situ hybridization of gut
biopsies at two weeks post-infection showed a higher frequency of infected cells in
SIVmac239ΔGY R722G±YFQL (Fig. 6B) compared to SIVmac239ΔGY-infected
animals (Fig. 6A), although this did not reach statistical significance (Fig. 6C).
Terminal jejunal biopsies were obtained at varied times post-infection between
groups due to differences in disease progression between viruses. SIVmac239infected animals showed high levels of infected cells at necropsy in jejunum (mean
10.06 infected cells/mm2) while SIVmac239ΔGY-infected animals had 0 positive
cells identified (Fig. 6C). SIVmac239ΔGY R722G±YFQL-infected animals had
small numbers of infected cells in jejunum at necropsy (average 0.33 infected
cells/mm2) (Fig. 6C).

Lymph node samples from week 2 post-infection were available from all
groups. At week 2, SIVmac239-infected animals had the highest average infected
cells per mm2, 7.42 versus 1.45 for SIVmac239ΔGY-infected and 4.17 for
SIVmac239ΔGY R722G±YFQL-infected (Fig. 7A). Lymph node biopsies were also
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Figure 3-6: SIV RNA in situ hybridization (ISH) of jejunal biopsy
Select SIV+ cells are indicated by arrows. Bar = 200 µm (A) SIVmac239!GYinfected animal jejunal biopsy, week 2 (historical sample processed for comparison,
animal GG10). (B) SIVmac239!GY R722G ±YFQL-infected jejunal biopsy, week 2
(shown, SIVmac239!GY R722G-infected animal KV51). (C) Quantification of
infected cells per mm2 at week 2 and terminal timepoints for SIVmac239!GY R722G
±YFQL. SIVmac239 (terminal only) and SIVmac239!GY (week 2 and terminal)
historical samples were processed by the same methods for comparison.
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Figure 3-7: SIV RNA in situ hybridization of peripheral lymph nodes
Infected cells by in situ hybridization (SIV RNA positive cells counted per mm2 of tissue) in
peripheral lymph node (LN) for SIVmac239!GY R722G ±YFQL. SIVmac239 and
SIVmac239!GY historical samples were processed and quantified by the same methods for
comparison.(A) Infected cells quantified from peripheral lymph node biopsy at week 2 postinfection. (B) Infected cells quantified from peripheral lymph node biopsy at necropsy.
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obtained at necropsy for SIVmac239, SIVmac239ΔGY, and SIVmac239ΔGY
R722G±YFQL-infected animals. SIVmac239 infected animals showed high levels of
infected cells at necropsy (mean 10.25 infected cells/mm2) while SIVmac239ΔGYinfected animals had 0 positive cells identified, similar to the results observed in
jejunal biopsies (Fig. 7B). SIVmac239ΔGY R722G±YFQL animals had small
numbers
Of infected cells in lymph node at necropsy (average 0.25 infected cells/mm2, Fig.
7B).
A distinctive feature of SIVmac239∆GY infection is greatly decreased to
absent macrophage infection, even in areas of tissue where SIV infected CD3+ T cells
are identified.222,223 Consistent with previous results, confocal microscopy of jejunal
biopsies from one SIVmac239∆GY-infected macaque at week 2 post-infection and
necropsy had no identifiable infected macrophages, although numerous CD68+
CD163+ macrophages were present (Fig. 8A). In week 2 post-infection and necropsy
tissue samples from SIVmac239ΔGY R722G±YFQL progressors, low but detectable
numbers of infected macrophages were observed, although levels were not
comparable to SIVmac239 (Fig. 8B&C). Two SIVmac239 animals were sampled at
the terminal timepoint and multiple infected macrophages were observed, as well as
uninfected macrophages and infected CD3+ T cells (Fig. 8D&E).

Envelope cytoplasmic tail undergoes further sequence evolution during long
term infection with SIVmac239∆GY R722G±YFQL
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Sequence evolution of env during infection with mutant viruses is of great
interest, as selection for additional mutations within this gene can provide information
as to motifs that are important for pathogenesis.190,207,209,248,292,303,304 Particularly,
mutations that arise in multiple animals and become fixed over the course of infection
likely indicate that acquisition of these changes was advantageous to the virus.187,305

Viral RNA was isolated from plasma samples at week 2, week 10, and long
term (>week 22) timepoints from all animals with sufficiently high viral loads (i.e., 5
of 6 animals). Single genome amplification (SGA) was performed on each sample
and env genes were sequenced. Of note, engineered mutations in the inoculum (∆GY,
R722G, YFQL) were maintained in all amplicons throughout infection. At week two
post-infection, no consensus or fixed mutations were apparent in env when its
sequence was compared to the inoculum from each animal, indicating that
SIVmac239ΔGY R722G ± YFQL was able to replicate to high viral peaks (average
4.83±1.44 x 106 RNA copies/ml) in each animal without the addition of new changes
(Fig. 9). At week 10 post-infection, mutations began to arise in multiple amplicons,
including the previously identified V67M in the C-terminus of gp120. In one
progressing animal (KV73, infected with SIVmac239∆GY R722G), a ∆QTH
mutation in 1/22 amplicons was identified at week 10 (Fig. 11). The nucleotide
deletion was such that a YFQI (identical to that seen previously in a
SIVmac239∆GY-infected RhM progressor) was created. This deletion was different
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from that engineered into the inoculum for the SIVmac239∆GY R722G +YFQL
animals, ruling out the possibility that this single sequence was a contaminant.

V67M, previously characterized as one of three gp120 mutations that confer
macrophage tropism to SIVmac316, was observed in all animals by week 20 or
later.287 We have also observed this mutation arising in SIVmac239ΔGY-infected
RhM and PTM progressor animals.222,223 Additionally, multiple animals developed
the R751G mutation that has been described as a correction for suboptimal nucleotide
sequence in SIVmac239.190,306 Interestingly, while 4/5 animals developed the R751G
in a predominance of amplicons, the one surviving progressor began to lose this
mutation late in infection and it was nearly absent by week 40 post-infection;
however, a flanking E750G arose instead in this animal. E750G and R751G were not
mutually exclusive, however; 3/5 animals (2/3 progressors) manifested both changes.
Multiple other Env mutations observed in a majority of amplicons in at least two
SIVmac239ΔGY R722G±YFQL-infected animals are shown in Figure 10.

Of the three progressors, two (KV51 and KV73) received SIVmac239∆GY
R722G, and one (KV74) received SIVmac239∆GY R722G + YFQL). Both
SIVmac239ΔGY R722G animals died between week 36 and 37 post-infection.
Interestingly, the ∆QTH mutation was observed in each of these animals. In KV51, it
first appeared at week 18 in 26/29 amplicons, and evolved to consensus in 26/26
amplicons at week 34, the last timepoint sampled. The ∆QTH deletion in this animal
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Figure 3-8: In situ hybridization & confocal microscopy of infected macrophages
Images are taken with a 40x objective. CD68+ macrophages (green), CD3+ T cells (blue),
SIV RNA (red), and DNA (white). Select SIV+ cells are indicated by arrows. Bar = 20
µm. (A) Jejunum from SIVmac239!GY-infected GG10 at week 2 post-infection. (B)
Jejunum from SIVmac239!GY R722G-infected KV51 at week 2 post-infection. (C)
Lymph node from SIVmac239!GY R722G + YFQL-infected KV76 at week 2 postinfection. (D) Lymph node of SIVmac239-infected IK37 at terminal timepoint. (E)
Jejunum of SIVmac239-infected IK37 at terminal timepoint.
Insets show higher magnification of CD68+ cells demonstrating intranuclear staining of
SIV RNA (B-E) or lack thereof (A).
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initially created a YFQI mutation, but in 7 of 19 amplicons at week 18, a point
mutation also occurred that altered the amino acid sequence to YFQL. By week 34,
all 26 amplicons contained the ∆QTH corresponding to a YFQL sequence, suggesting
that a leucine in the Y+3 position was preferred. In KV73, as noted above, in 1/22
amplicons at week 10 (Fig. 11) a ∆QTH was observed that generated the YFQI
sequence, although this sequence was lost at later timepoints. A cluster of additional
mutations emerged just downstream from the site of the ΔQTH (Fig. 11). These
changes were T735I, Q739R, and P744L, and after the initial appearance of the
P744L mutation in 21 of 22 amplicons at week 18, all three mutations became nearly
fixed, occurring in 20/21 amplicons at the terminal sample (week 34). The P744L is
especially interesting, as it is adjacent to the leucine residue at position 743 and could
represent formation of a dileucine motif, possibly forming a new endocytosis
signal.64,95,244,245 It is also notable that T735I, Q739R, and P744L, like the ∆QTH,
overlap with exon 2 of rev and tat (Fig. 12).95,244,307 The rev reading frame is
maintained, though a point mutation is introduced at residue 31 (G31S) (Fig. 12A).
Remarkably, the Tat protein is predicted to have multiple point mutations arising
from these 3 changes, including a truncation due to residue Q96 changing to a stop
codon as a result of the P744L mutation in Env (Fig. 12B). The ability of this novel
dileucine to mediate endocytic and basolateral sorting function, as was shown for
YxxΦ motifs created by ∆QTH, is currently under investigation using in vitro assays
as described in Chapter 2. Collectively, the SGA findings highlight that, despite the
presence of R722G and ∆QTH, there remains pressure for the virus to evolve
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Figure 3-9: Highlighter plots of env sequences from SIVmac239!GY R722G ± YFQLinfected PTM at acute peak viremia
Single genome amplification was performed at week 2 post-infection and highlighter plots of
Env sequences were generated for each animal. SIVmac239 is included as the reference
sequence in all plots. Engineered Env deletions (!GY, "QTH, denoted by gray bars in all
sequences) and the point mutation R722G (denoted by yellow bar in all sequencs) Mutations
that evolved in vivo in each animal are indicated by green, blue, yellow, or purple bars and are
distributed randomly throughout sequences.
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Figure 3-10: Predominant Env mutations identified in !GY R722G ± "QTH
infected pig-tailed macaques.
Mutations shown appeared in at least two SIVmac239!GY R722G ± "QTH
infected pig-tailed macaques and were present in a majority of amplicons at the
final timepoint sampled.
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Figure 3-11: gp41 cytoplasmic tail mutations in SIVmac239!GY R722G- infected
progressors at terminal timepoint
(A) Viral load graphs for SIVmac239!GY R722G- infected progressors. Death is indicated by a
red cross. Green arrows indicate timepoints when single genome amplification (SGA) was
performed on plasma samples. (B) gp41 cytoplasmic tail mutations observed in SIVmac239!GY
R722G- infected progressors at various timepoints. The number of amplicons sequenced at each
timepoint and the number containing the indicated mutation are listed. (C) Location within the
gp41 cytoplasmic tail of mutations in each animal that appear to reconstitute known or predicted
endocytosis motifs.
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Figure 3-12: Rev and Tat sequences from SIVmac239!GY + R722G ±YFQL progressors
SIVmac239, SIVmac239!GY, and SIVmac239!GY + !QTH (YFQI or YFQL) Rev and Tat are
!"
shown for comparison. Mutations in the inoculum for each animal (in addition to !GY) are shown
beside animal IDs.

	
  

126	
  

additional mutations in gp41 that may compensate additionally for the ∆GY mutation
and contribute to pathogenicity.

Discussion
This study evaluated, using a pig-tailed macaque model, the effects of selected
mutations acquired in vivo during long term SIVmac239ΔGY infection. R722G and
ΔQTH (residues 734-736 of Env) were engineered into an SIVmac239ΔGY IMC
with the goal of determining whether the addition of these mutations would be
sufficient to produce SIVmac239-like pathology in naïve PTM. The evolution of the
R722G mutation became fixed in both SIVmac239ΔGY-infected animals pig-tailed
macaques that exhibited a progressor phenotype.222,223 It was also identified in at least
some amplicons in all four rhesus macaques inoculated with SIVmac239ΔGY. The
ΔQTH mutation, which, as we demonstrated in Chapter 2, recreates an endocytosis
signal, had appeared in two of four RhM progressors, and only in amplicons in which
the R722G mutation was already present.222 This remarkable deletion of nine
nucleotides spans three reading frames (env, rev, and tat) and results in an Env
sequence, YFQL, that conforms to a YxxΦ trafficking motif (Chapter 2).
SIVmac239ΔGY R722G and SIVmac239ΔGY R722G + YFQL were chosen for
testing in vivo because the former was associated with disease progression in 2/2
PTM, and the latter contained both components of the trafficking signal (glycine and
YxxΦ, although not adjacent as in SIVmac239) ablated by the ΔGY mutation.62,64,66,72
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As with SIVmac239 and SIVmac239ΔGY, the engineered viruses replicated
to high acute peaks at 14 days post-infection in all six animals. In contrast to
SIVmac239ΔGY, 3 of 6 animals (KV51, KV73, and KV74) were identified as
progressors, with high set-point viral loads, and two additional animals (KV52 and
KV76) developed low to intermediate set-points. Only one animal (KV75), inoculated
with SIVmac239∆GY R722G, controlled viremia to <15 RNA copies/ml as is seen in
typical SIVmac239ΔGY infection of PTM.223 Two progressors (KV51 and KV73,
both infected with SIVmac239ΔGY R722G) died at week 36 and 37 post-infection,
respectively, and arteriopathies (pulmonary and aortic thrombi) were identified at
necropsy, consistent with previous necropsy findings in the two SIVmac239ΔGYinfected PTM that progressed to AIDS.223 The third progressor was infected with
SIVmac239ΔGY R722G + YFQL. Two animals with intermediate set points (KV52
and KV76), designated as controllers in our analysis, were infected with
SIVmac239ΔGY R722G + YFQL, while KV75, which controlled viremia to below
the limit of detection, was infected with SIVmac239ΔGY R722G. Findings for CD4+
T cell dynamics in gut, discussed further below, showed a greater decrease in
progressors, although not to levels typically seen in SIVmac239 infection. Thus,
although our sample size was small, it appears that the introduction of putative
compensatory changes into the SIVmac239∆GY background did not fully
reconstitute the pathogenic phenotype of SIVmac239. However, 3 of 6 animals
developed high viremia and two died with AIDS-related complications, indicating
some increase in pathogenicity over SIVmac239∆GY. We did not observe a clear
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gain of function in vivo for SIVmac239ΔGY R722G + YFQL over SIVmac239ΔGY
R722G alone. However, further sequence evolution in the two SIVmac239ΔGY
R722G progressing animals (one developing the previously described ∆QTH
mutation, the other developing point mutations T735I, Q739R, and P744L), may
represent additional compensation for the ΔGY mutation and are discussed further
below.

Historical SIVmac239ΔGY RhM and PTM progressors have exhibited a
unique disease course that induces immune pathology but lacks many of the features
of SIVmac239. Hallmarks of SIVmac239 pathology include high peak and set-point
viremia, infection of macrophages at the 14-21 day timepoints, massive infection and
irreversible depletion of CD4+ T cells in gut lamina propria, gradual decline of
peripheral blood CD4+ cells, and systemic immune activation.142,148,159,170,225,284,309,310
SIVmac239ΔGY-infected progressors maintain intermediate or high set-point
viremia.222 In contrast to SIVmac239, SIVmac239ΔGY-infected progressors and
controllers have very rare to no infected macrophages identifiable by confocal
microscopy, both at peak and late in infection. This is not thought to be due to less
robust infection in general, as uninfected macrophages were frequently observed in
areas of tissue with an abundance of SIV RNA+ CD3+ T cells.223,292 Relatively high
plasma viremia in SIVmac239ΔGY progressors is evidence of ongoing infection and
replication, so lack of macrophage infection is unlikely to represent low levels of
productively infected cells overall.223 Finally, SIVmac239ΔGY disease is
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distinguished from SIVmac239 by preservation of CD4+ gastrointestinal lamina
propria lymphocytes (GI LPL). This population of cells is a site of massive viral
infection acutely, and is typically depleted by 2 weeks post-infection with
SIVmac239.140,224 Subsequent to this timepoint, CD4+ GI LPL are rarely identified in
SIVmac239 infected animals, and SIV+ cells of this immunophenotype are even more
rare due to their relative depletion in the lamina propria compartment.140 In contrast,
while infection of CD4+ GI LPL is observed in SIVmac239ΔGY progressors, only a
small decrease is seen during early infection, and by week 34 post-infection, a return
to baseline percentage is observed in a majority of animals.223 Translocation of
bacterial products (LPS) from the gut lumen and soluble CD14 (sCD14) are similarly
unchanged in SIVmac239ΔGY controllers and progressors, while they are increased
in SIVmac239 infection.142,148,222,223 As microbial translocation is thought to be a
major contributor to immune stimulation and chronic immune activation that is
implicated in development of AIDS, SIVmac239ΔGY progressors are an important
cohort for evaluation of other factors that result in chronic immune pathology and
underlie disease progression.8,142,145,148,311,312

Despite a majority of SIVmac239ΔGY R722G±YFQL-infected animals
failing to control viremia below the limit of detection, characteristic pathologic
features of SIVmac239 infection were not evident in these animals. Instead, the two
progressors that died (both infected with SIVmac239ΔGY R722G) exhibited a
disease course that is typical of historical SIVmac239ΔGY-infected progressors;
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immune activation, thrombocytopenia, and arteriopathies, in the absence of
characteristics of simian AIDS such as macrophage infection, gut CD4+ T cell
depletion, and central nervous system (CNS) disease.140,159,223,224,236,237,313–316 Neither
of the SIVmac239ΔGY R722G-infected animals that died (nor the third progressor,
which was alive at termination of the study) had significantly increased levels of
macrophage infection; quantitative data on CNS infection is not yet available. While
depletion of gut CD4+ LPL was more severe and prolonged than in SIVmac239ΔGYinfected animals, it did not approach the potency of SIVmac239 at infecting these
cells.139,140,222–224 Further, only intermediate levels of infected cells were counted in
lymph node tissue samples at week 2 and at terminal timepoints compared to
SIVmac239 (high) and SIVmac239ΔGY (0-rare), consistent with the intermediate
set-point viremia in these animals.

Based on these findings, it is likely that while addition of R722G and YFQL
confers some advantage to SIVmac239ΔGY, these mutations alone are not sufficient
to fully compensate for ablation of the membrane-proximal tyrosine motif and to
reconstitute the pathogenicity of parental SIVmac239. This conclusion is underscored
by single genome amplification (SGA) sequencing performed on viremic animals late
(>30 weeks) post-infection. Two controllers and one progressor infected with
SIVmac239ΔGY R722G + YFQL developed few mutations in a majority of
amplicons, including V67M (seen in SIVmac239ΔGY progressors and associated
with macrophage tropism in SIVmac316) and R751G, an optimization mutation well
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characterized in SIVmac239.190,287,306,317 In contrast, SIVmac239ΔGY R722Ginfected progressors showed additional attempts to form endocytosis motifs, with one
animal developing the previously characterized ΔQTH (creating a YFQL sequence)
and the other sampling ΔQTH early in infection but having a predominance of three
mutations at death: T735I, Q739R, and P744L. The development of a leucine at
position 744 is especially interesting, as residue 743 in SIVmac239 is also a leucine.63
Dileucine motifs in general are known to mediate endocytosis of transmembrane
proteins in eukaryotic cells.62,72,85,228,233,238,318,319 The C-terminal dileucine motif of
HIV-1 (conserved in SIVmac239) is an AP-2 dependent endocytosis signal that has
functional redundancy with the membrane-proximal tyrosine motif.64 In HIV-1, the
terminal dileucine is also a mediator of association with AP-1, which is thought to be
an important adapter protein for basolateral sorting function.245 The evolution of this
dileucine may indicate selection for endocytic and/or basolateral sorting function by
development of a novel sequence.

The presence of these additional mutations in the cytoplasmic tail provides
evidence that R722G alone is not sufficient to restore all functions of the membraneproximal tyrosine motif to SIVmac239ΔGY. However, there is evidence that a
endocytosis and basolateral sorting motif in the membrane-proximal region is
associated with development of disease, as both SIVmac239ΔGY R722G-infected
animals that died with high viral loads developed the ΔQTH that creates a confirmed
functional endocytosis motif. While ΔQTH occurred only transiently and in a single
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sequence for KV73, the P744L mutation in this animal may represent an alternative
method to recreate these functions. Although the presence of ΔQTH seems slightly
deleterious or at least not beneficial early in disease, there appears to be pressure for
the virus to reconstitute endocytosis motifs during chronic infection, as this occurred
independently in two different animals. The ΔQTH (KV51) is a confirmed
endocytosis signal, and P744L (KV73) conforms to the described dileucine
endocytosis motif, though we have not yet determined whether this sequence is
capable of mediating endocytosis and/or basolateral sorting functions.62,64,72,319

Despite this selection, it appears that SIVmac239ΔGY R722G + YFQL is less
effective than the wildtype GYRPV sequence at performing the functions of the
GYxxΦ motif, as none of the animals inoculated with SIVmac239ΔGY R722G +
YFQL developed fatal disease. This could be due to decreased efficiency in directing
Env targeting compared to wildtype Env, or to an as yet unknown function of this
motif in the host. Additional functions of the membrane-proximal tyrosine motif are
suggested by the finding in Chapter 2 that R722G with or without YFQL did not
reconstitute wildtype distribution of Env on the surface of CEMx174 cells, despite
restoring endocytosis and basolateral sorting. Mechanistic studies of Env constructs
containing ΔGY and the P744L are underway to establish whether this motif is also a
functional endocytosis and basolateral sorting signal as was determined for YFQL. If
so, there will be significant evidence that these functions are important for
development of disease in animals. However, the mechanism by which the
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membrane-proximal tyrosine motif contributes to macrophage infection and targeting
of mucosal CD4+ T cells in the host has not been fully elucidated, as this is not
restored even by addition of mutations that confer the functions of virion Env
incorporation, endocytosis, and basolateral sorting.

A highly unusual finding is that the P744L also results in introduction of a
stop codon that truncates the Tat protein at residue 96, as the Tat second exon has
been demonstrated to be important for chronic replication of SIV in animals. When
macaques were infected with an SIVmac239 variant with a stop codon at the end of
the tat first exon, multiple animals reverted to an open reading frame to restore the
second exon.307 We are currently investigating the splicing pattern used by this
mutant to determine if a truncated protein was truly predominant in vivo. Interestingly,
all three progressors also had mutations in known CD8+ T cell epitopes in Tat, likely
indicating pressure on the virus to evolve to escape these responses.308 This
observation provides further evidence that cell-mediated immunity, via CD8+ and
possibly CD4+ CTLs, is important in control of SIVmac239∆GY and may be a
critical mechanism of protection from pathogenic challenge.

Microbial translocation due to loss of gastrointestinal epithelial barrier
function has been established as a major contributor to the chronic immune activation
that underlies AIDS progression.142,143,320 At least one study found that depletion of
CD4+ T cells in GALT was necessary, but not sufficient, to induce AIDS in rhesus
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macaques.321 This is in contrast to our findings in initial studies of SIVmac239ΔGY,
in which animals with partial or complete restoration of CD4+ T cells in GALT after
the acute phase nevertheless developed disease.222,292 These findings imply that
chronic immune activation in SIV infection is a result of other factors besides
sustained gastrointestinal epithelial dysfunction. Transcriptomic studies of pathogenic
and nonpathogenic hosts of SIV have identified strong type I interferon responses in
multiple tissues of both groups, but a failure to downregulate these responses postacutely in pathogenic hosts.220,322 It is possible that the mild decrease in GALT CD4+
T cells in SIVmac239ΔGY-infected controllers does not induce sufficient
proliferation and inflammatory responses to result in chronic immune activation.
Further, the trend of greater depletion and increased proliferation in SIVmac239ΔGY
R722G±YFQL progressors may contribute to an inflammatory environment in GALT
and to systemic immune activation.

In SIVmac239ΔGY infection, GALT CD4+ T cells are ultimately
reconstituted, and the preservation of these cells permits the development of cytokine
responses that would be absent in SIVmac239 infection and may also help mediate
control of acute inflammation.223 T regulatory cells (Treg) are CD4+CCR5+ T cells that
modulate the immune response by reducing activation of other T cells.135,323 It has
been proposed that loss of Tregs could contribute to chronic immune activation by
elimination of signals that normally downregulate inflammation.324 Preservation of
these and other CD4+ T cells in SIVmac239ΔGY infection could help modulate
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inflammatory responses in the gut, minimizing gut damage and aiding in prevention
of disease progression. Increased severity of depletion in SIVmac239ΔGY
R722G±YFQL infection may be sufficient to dysregulate inflammation and
contribute to development of disease. Markers of microbial translocation (LPS,
sCD14) were not evaluated in this study, but should be considered for future studies
to determine if gut damage occurs with SIVmac239ΔGY R722G±YFQL. Although
increased microbial translocation is not necessary for disease progression in the
SIVmac239ΔGY model, its presence would indicate a gain of function for
SIVmac239ΔGY R722G±YFQL over SIVmac239ΔGY. An alternative explanation is
that SIVmac239ΔGY infection preserves CD4+ cells that contribute actively to
control of viral replication, whether through providing help to CD8+ T cells or by
acting as cytotoxic T lymphocytes (CTLs) themselves.134,325–327 There is evidence for
HIV-specific CD4+ CTLs, and the preservation of this population in SIVmac239ΔGY
might be important for contributing to control of viremia.282

An open question is why ΔQTH or another putative endocytosis signal was
selected for during chronic infection, when its presence in the inoculum did not
provide a clear gain of function. Our in vitro results showing decreased replication in
PBMCs and lower Env on virions, both improved by addition of R722G, indicate an
inherent fitness defect resulting from the ΔQTH that is independent of the effect of
the host immune system. ΔQTH overlaps with the rev and tat reading frames, it could
be speculated that decreased fitness in cell culture is related to mutations in these
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proteins. Rev is important for env transcription, and mutations in this protein could
lower cellular Env levels.259,264 As R722G increases Env on virions by an
undetermined mechanism, it may be that R722G can compensate for a Rev defect by
raising cellular Env. This hypothesis is currently under investigation. Potentially, the
presence of YFQL may be irrelevant acutely, becoming advantageous only later in
infection, when the ability to evade adaptive immune responses is a greater
determinant of propagation than replication fitness alone.

A possible mechanism for this phenomenon is the relative contribution to
spreading infection of cell-free versus cell-to-cell spread. Early in infection, large
amounts of virus are present in plasma, and combined with an abundance of target
cells, cell-free spread is likely sufficient to achieve high peak viremia.280 This is
especially true as cells that mediate innate immunity, such as plasmacytoid dendritic
cells, predominantly exist in lymphoid tissue compartments rather than peripheral
circulation.328 Env incorporation into virions mediated by the membrane-proximal
tyrosine motif may be the dominant predictor of acute viral replication, and thus
SIVmac239ΔGY R722G and SIVmac239ΔGY R722G + YFQL can perform equally
well. Following induction of adaptive immune responses, including development of
antibodies against circulating virus, cell-to-cell spread that allows for clandestine
propagation of virus without exposure to antibody may become more
significant.278,284 Cell-to-cell spread of virus occurs by formation of a virological
synapse, a link between the infected donor cell and a naïve target cell.112,116,279 In
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HIV-1, interaction between Env on the infected cell and CD4 on the surface of the
recipient cell is the primary mediator of synapse formation.110,271,329 As such, defects
in Env trafficking could substantially affect the efficiency of cell-to-cell spread and
render the virus more dependent on cell-free modes of transmission.89,115,271,273 In
addition to exposing the virus to selection pressure that could require compromise of
fitness to evade immune responses raised by the host, cell-free spread has other
disadvantages. Cells producing low levels of viral gene products may be able to
compensate for this by concentrating viral transfer to a single area of the
membrane.110 The membrane-proximal tyrosine motif may be important in trafficking
Env to virological synapses and R722G may not confer targeting functions to
SIVmac239ΔGY despite restoring Env content on virions. Therefore, if YFQL
confers endocytic and targeting functions to SIVmac239ΔGY independent of virion
Env, viral sequences with this or other sequences with similar functions may be
selected for only later in the context of ΔGY and R722G. This model would explain
the similar acute peak of the SIVmac239ΔGY R722G + YFQL compared to
SIVmac239ΔGY R722G, and the later selection for ΔQTH and P744L in
SIVmac239ΔGY R722G-infected progressors.

Evaluation of SIVmac239ΔGY R722G in larger numbers of animals may
provide greater insight into selection of sequence motifs in gp41 during chronic
infection. The progressor versus controller phenotype could be more fully evaluated if
PTMs were MHC typed prior to infection and alleles associated with long term
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nonprogressor status excluded.171,173,330,331 However, continued controversy over the
role of MHC in control of SIV in PTM may make selection of susceptible individuals
more difficult. Inocula that include additional putative compensatory mutations, such
as V67M, E750G, and/or R751G could also be considered for testing to determine
whether the presence of these mutations during acute infection assists in restoring
macrophage infection and CD4+ GI LPL depletion. As V67M is one of the mapped
determinants of in vitro macrophage infection in SIVmac316, perhaps it is also
critical to SIVmac239ΔGY, although it is dispensable for macrophage infection by
SIVmac239 in vivo.225,287 This study further emphasizes the critical function of the
membrane-proximal tyrosine motif in SIVmac239 pathogenesis and indicates that
addition to SIVmac239ΔGY of combinations of mutations that independently mediate
the functions of this motif in in vitro assays are nevertheless not sufficient to
reestablish a wildtype natural history in pig-tailed macaques.
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CHAPTER 4

Conclusions and Future Directions
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Overview
The HIV envelope (Env) protein is a vital contributor to the viral life cycle as
the mediator of entry into permissive cells and as a shield for conserved epitopes
against the host immune system. Lentiviruses consistently have envelope
transmembrane (gp41) domains with particularly long cytoplasmic tails that extend
into the virion core.293 Within gp41, all primate lentiviruses have a conserved GYxxΦ
sequence.63 Strict conservation in a typically sequence-diverse protein implies
functional importance of this domain, and indeed the Env cytoplasmic tail has been
implicated in myriad aspects of HIV and SIV virology, including incorporation of
envelope into virions (thus affecting infectivity), recycling of Env from the surface of
infected cells, and polarized budding of HIV from lymphocytes.63,66,70,71,89,90,108,245
Despite extensive investigation, the mechanisms by which this domain confers such
functions have yet to be fully characterized. We have previously performed in vivo
studies of the SIVmac239 mutant SIVmac239ΔGY, which has two critical amino
acids deleted from the membrane-proximal tyrosine motif. In both rhesus and pigtailed macaques, SIVmac239ΔGY replicates to a high acute peak, but is defective in
its ability to infect macrophages and to efficiently infect and deplete CD4+ T cells in
the gut lamina propria.222,223 In rhesus macaques, animals progress to AIDS while
maintaining CD4+ T cells in gut, and this progression is correlated with additional
mutations in the Env cytoplasmic tail. In pig-tailed macaques, SIVmac239ΔGY is
controlled by host immune responses to <100 copies per ml in 90% of animals,
though two animals progressed to AIDS with similar pathologic findings as rhesus
	
  

141	
  

macaques.223 SIVmac239ΔGY-infected pig-tailed macaques develop robust
polyfunctional T cell responses from the preserved gut CD4+ cells, are protected from
homologous challenge, and can control heterologous SIV and SHIV challenges (A.
Lackner & J. Hoxie, unpublished data).

In Chapter 2, we evaluated differences between SIVmac239ΔGY and its
parent virus, the pathogenic infectious molecular clone (IMC) SIVmac239, in a
number of in vitro assays to determine the effect of ablating this motif on viral fitness
and Env protein function. SIVmac239ΔGY was found to have decreased Env on
virions, defects in endocytosis and basolateral targeting, and altered distribution of
intracellular and surface Env. Small defects in replication in macaque PBMCs were
also observed. Mutations that arose in vivo in progressing animals restored function to
SIVmac239ΔGY to variable degrees, with some improving replication or virion Env
content and others reconstituting functional trafficking signals for endocytosis and
basolateral sorting, which, like the wildtype tyrosine motif, were dependent on the
adaptor protein complex AP-2 for endocytic function.65,66,71,245

In Chapter 3, we sought to determine if mutations that arose in
SIVmac239∆GY-infected animals that progressed to disease could reconstitute the
pathogenic phenotype of SIVmac239. We inoculated naïve pig-tailed macaques with
two novel IMCs containing ΔGY and one or more putative compensatory mutations
in an SIVmac239 background. One group of three animals received SIVmac239ΔGY
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with R722G, a point mutation that restores Env on virions but does not form a
trafficking motif; the second group of three received SIVmac239ΔGY R722G +
ΔQTH (YFQL), resulting in the addition of a novel YxxΦ domain to the proximal
cytoplasmic tail. In Chapter 2, we showed that YFQL could mediate both endocytosis
and basolateral sorting function. Like SIVmac239 and SIVmac239ΔGY, novel
viruses achieved high acute peak viremia. In general, animals infected with
SIVmac239ΔGY R722G±YFQL exhibited increased acute depletion and reduced
recovery of gut CD4+ cells compared to SIVmac239ΔGY. Animals then diverged into
two phenotypes. Progressors were characterized by high set-point viremia, more
severe and sustained depletion of gut CD4+ T cells, trends toward increased immune
activation in blood and gut, and development of AIDS in 2/3 animals. Controllers had
undetectable to intermediate set-points, maintained CD4+ cells in blood and recovered
gut CD4+ cells to baseline levels, and did not develop AIDS. Unlike SIVmac239ΔGY
PTM controllers, progressors maintained high viremia for the duration of the study,
and two of three died within 35 weeks with arteriopathies and lymphadenopathy that
are typical AIDS-related complications in this species.153,170,220,310 Although no
controllers developed disease, and one controlled viremia to below the limit of
detection similar to SIVmac239ΔGY-infected PTM, the two remaining animals
(KV52 and KV76, infected with SIVmac239ΔGY R722G + YFQL) had intermediate
levels of viremia that were greater than typically seen with SIVmac239ΔGY. Rare
infected macrophages could be identified but were markedly reduced compared to
macrophage infection typically seen in SIVmac239 infection.
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Two of three progressors were infected with SIVmac239ΔGY R722G and
developed additional mutations in the Env cytoplasmic tail that recapitulated
observations in previous studies, i.e. further attempts to reconstitute trafficking motifs.
However, as none of the animals infected with SIVmac239ΔGY R722G + YFQL
developed AIDS, and two were controllers, it appeared that addition of the
endocytosis motif was not advantageous to the virus early in infection. A possible
explanation for this finding is that the components of the GYxxΦ domain function
somewhat independently. While Env incorporation into virions, perhaps mediated by
the glycine, may be important for the virus at all stages of infection, trafficking
functions of the YxxΦ sequence may be more relevant in the presence of the adaptive
immune response.

Mapping of Functions of the gp41 Membrane-Proximal Tyrosine Motif
As discussed, despite differing from the parent virus SIVmac239 by only a
two amino acid deletion in the cytoplasmic tail of gp41, SIVmac239ΔGY is
distinguished by a number of in vitro traits that are restored to varying degrees by the
addition of gp41 mutations identified in SIVmac239ΔGY-infected progressor animals
from previous studies. A notable effect of ΔGY is the decrease in virion Env content
compared to wildtype. This observation has been consistent across multiple cell types
and is improved by addition of the point mutations S727P or R722G, but not by the
ΔQTH that creates novel YxxΦ sequences. In contrast, intracellular localization to
perinuclear regions and endocytic and basolateral sorting function are restored to
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near-wildtype levels by addition of ΔQTH, but not by S727P or R722G. These
findings suggest that although there may be overlap, virion Env incorporation and
intracellular trafficking are primarily controlled by separate residues within the
GYxxΦ motif. In previous studies, both the glycine and the tyrosine have been shown
to contribute to endocytosis for SIV Env,66 though in the present study addition of a
YxxΦ domain in the form of YFQL without a preceding glycine allowed endocytosis
rates comparable to SIVmac239. Additionally, while earlier work has examined the
effect of deletions in the Env cytoplasmic tail on Env incorporation into virions, this
has been only in the context of tail truncations or ablation of the tyrosine
residue.96,108,332 Earlier findings that these mutations increase Env on virions are
consistent with the hypothesis that the glycine positively modulates Env incorporation
into particles, as this residue was not disrupted.108,244 Further, if the YxxΦ sequence
affects virion Env by removing the protein from the cell surface and thus decreasing
its incorporation into particles, mutations that ablate functional portions of this motif
would be expected to increase virion Env. Alanine scanning mutagenesis could
confirm that Gly-720 is a positive regulator of Env content and that the YxxΦ motif
decreases virion Env.

A second function of the GYxxΦ motif appears to involve specific
localization of envelope on the surface of infected cells. We and others have
established that mutations to endocytosis motifs increase cell surface Env, a finding
confirmed by this study.66,76,108,244 Previously, cell surface Env has been positively
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correlated with virion Env content;63,71,108,109,240 thus the contradiction of increased
surface but decreased virion Env in SIVmac239ΔGY was surprising. An important
observation of our study is that, by imaging flow cytometry, all ΔGY-containing
mutants tested, including one containing a ΔQTH, have a lower percentage of cells
with punctate Env distribution compared to SIVmac239. There is evidence in HIV
that budding occurs preferentially from specific regions of the plasma membrane and
is controlled by Env, as polarized budding is abolished in the absence of
Env.88,89,232,333 A prior study specifically found that mutation of the membraneproximal tyrosine residue in HIV resulted in a reduced percentage of infected cells
displaying polarized distribution of p24.89

ΔGY may decrease Env recycling from the cell surface and/or specific
targeting of Env to sites of budding, which could result in increased protein on the
cell surface but a decrease in virion Env. The dual effect of removal of the glycine
(decreasing Env on virions) and the tyrosine motif (altering Env trafficking to sites of
budding) may result in significant defects to virion Env. However, failure of addition
of R722G and YFQL to rescue punctate Env distribution indicates that thr presence of
components of the signal is not equivalent to the wildtype sequence, suggesting that
correct positioning of the glycine relative to the YxxΦ sequence, or of the YxxΦ
sequence relative to the membrane spanning domain, may be required for additional
functions of the motif.
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Addition of R722G does raise Env levels on the cell surface, above
SIVmac239ΔGY levels, and rescues virion Env, but does not confer a wildtype Env
cell surface distribution. Raising the quantity of Env available on the cell surface
might increase Env on virions through passive incorporation, without explicitly
targeting Env to budding sites. Addition of ΔQTH (YFQL) lowers Env levels on cells
to be equivalent to SIVmac239ΔGY and maintains increased Env on virions, yet does
not rescue a wildtype punctate phenotype, implying that nonspecific incorporation
into virions is not the primary driver of rescue. The resolution of cell images from
imaging flow cytometry is relatively low, so it is possible that YFQL improves Env
targeting to sites of budding (though perhaps not as efficiently as the wildtype
sequence) but that small differences in distribution are less apparent due to the overall
increase in cell surface Env imparted by the R722G. Imaging of Env localization with
electron microscopy could improve resolution and address this limitation. Colocalization imaging of Env with cellular proteins known to be incorporated into
virions, such as CypA, could evaluate localization of mutant Envs relative to sites of
budding.334 It is also possible that CEMx174 cells, a human lymphocyte cell line, do
not perfectly recapitulate what occurs in macaque cells in vivo. Despite these
limitations, the model described would explain the ability of mutations in the GYxxΦ
domain to both positively and negatively regulate Env on particles and unifies the
apparently paradoxical alterations to cell surface and virion Env conferred by various
cytoplasmic tail mutations.
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The effects of cytoplasmic tail mutations on viral growth in vitro are less
clear. Acute SIVmac239ΔGY replication in vivo is on par with SIVmac239.222,223 In
contrast, we detected a small but reproducible decrease in peak replication of
SIVmac239ΔGY compared to SIVmac239 in PBMC cell culture. Although not
performed quantitatively, there appeared to be a delay in replication in CEMx174
culture as well (discussed in Ch. 2 Fig. 12), and prior studies in this cell line
demonstrated that SIVmac239 will outcompete SIVmac239ΔGY during a 35 day
culture.221 Control of replication of SIVmac239ΔGY after acute infection and its
inability to deplete gut CD4+ cells also implies some degree of immunologic
susceptibility that is incompletely rescued by additional gp41 mutations. In vitro,
ΔQTH mutations (creating YFQI or YFQL) were extremely deleterious to the virus
and nearly abrogated replication, but SIVmac239ΔGY YFQI and YFQL were rescued
to SIVmac239ΔGY-levels of replication by addition of R722G. Addition of S727P or
R722G to SIVmac239ΔGY alone did not result in significantly improved replication
in PBMCs, despite these mutations being selected for both in vitro (S727P) and in
vivo even in the absence of the ΔQTH. Two questions are thus raised by these
findings: 1) What replication advantage is rendered by R722G and S727P? and 2) by
what mechanism does R722G rescue replication of ΔQTH?

The first question could be explained by increases in Env on virions, which
correlates with increased infectivity, as the membrane-proximal tyrosine residue of
HIV has been directly shown to be important for both virion Env content and
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infectivity of particles.96,108,109,335 Greater infectivity would be an obvious advantage
to replication in vitro and in vivo, but we did not consistently observe improved
replication of SIVmac239ΔGY in PBMCs when R722G or S727P were added.
However, serial passage of SIVmac239ΔGY in CEMx174 cells resulted in selection
for S727P, indicating that this mutation is advantageous for replication in a human
cell line. One possibility is that variations in permissivity of host PBMCs to viral
replication resulted in inconsistencies in viral replication.336 We attempted to mitigate
this effect by performing growth assays in cultures of PBMCs pooled from three
independent donor animals. A mixed lymphocyte reaction resulting from mixing of
donor cells from major histocompatibility type-disparate animals could also affect
target cell availability, susceptibility to viral infection, or spread of virus, if cellular
immune responses are generated to varying degrees in culture.337 However, we
observed consistent results for comparisons between SIVmac239 and
SIVmac239ΔGY, implying that variation in susceptibility and release of chemokines
or activation of cellular immunity in vitro is likely playing a minor role.

It is also possible that R722G and S727P have an effect on the ability of the
virus to evade host immune responses, particularly humoral immunity, which would
not be evident in vitro. This theory is consistent with the ability of SIVmac239ΔGY
to replicate to high acute peaks in vitro, as humoral immune responses do not control
viremia in naïve animals during acute infection.57,338–340 Mutations in gp41,
particularly cytoplasmic tail truncations, have been well documented to increase
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neutralization resistance and increase infectivity.109,208,341 We have established that
neutralizing antibodies do not contribute to control of SIVmac239ΔGY in vivo, as
SIVmac239ΔGY-infected PTM controllers do not develop neutralizing antibody
activity against SIVmac239ΔGY.223 The possibility remains of non-neutralizing
antibody responses contributing to SIVmac239ΔGY control. Assays of antibodydependent cell-mediated cytotoxicity (ADCC), have yielded less conclusive results (J.
Hoxie, G. Ferrari, unpublished data). Supporting their possible contribution to control,
however, is the recent finding that mutations in the HIV and SIV membrane-proximal
tyrosine motif have been shown to increase susceptibility to ADCC by increasing
envelope exposure on infected cells.342 CD8+ cells are critical to host control of
SIVmac239ΔGY, as evidenced by rapid rebound of viremia following CD8 depletion
in controlling PTM and regain of control upon reconstitution of these cells, and this
may be due to their role mediating ADCC in vivo.223 The specific cell type and
mechanism responsible for control in SIVmac239ΔGY-infected animals is a point of
ongoing investigation. ADCC responses are a leading candidate for a mechanistic
explanation, and higher Env on R722G or S727P virions may increase resistance to
this response in vivo. This hypothesis is consistent with the lack of replication
enhancement observed in PBMCs in vitro versus the selection for these mutations in
animals.
The selection of S727P in vitro during serial passage of SIVmac239ΔGY
could be explained if this mutation does impart a small replication advantage that is
only evidenced over long term culture. PBMC growth assays were performed for 14
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days due to declining viability of target cells over this period. Serial passage in the
CEMx174 cell line occurred over a period of many weeks (approximately 3-5 days
per passage for a total of 20 passages), resulting in a large number of rounds of
replication in comparison to PBMC growth assays. The additive effect of small
differences in infectivity or replication efficiency over many rounds would also be
relevant in vivo, and again could explain discrepancies between performance of these
viruses in PBMCs in vitro versus in CEMx174 serial passage and in animals. As
S727P and R722G are never found in the same genome in vivo, R722G would not be
expected to arise with S727P in this assay.222,223 However, additional serial passage
experiments might yield the R722G instead of the S727P if these mutations confer
similar but non-synergistic advantages.

A final point is the possibility that these mutations could affect gp120
conformation, which could alter receptor or antibody binding and result in positive or
negative consequences for the virus. Truncation of the gp41 cytoplasmic tail has been
linked to changes in gp120 ectodomain conformation, although the mechanism
underlying this effect is not clear.212 At this time, specific investigations into the
conformation of gp120 in SIVmac239ΔGY and other mutants have not been made.
There is some evidence against this theory; SIVmac239ΔGY is not more
neutralization sensitive than SIVmac239 in assays using sera from SIVmac-infected
rhesus macaques.223 Additionally, we have not observed obvious defects in binding of
the monoclonal antibody 7D3, which binds a conformational epitope in the CCR5
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binding site of gp120, during flow cytometry staining.343 However, given the
evidence that ADCC may be important for control of this virus in vivo, assessment of
conformation via epitope mapping with monoclonal antibodies could be considered.

The second query regarding the relationship of R722G to the rescue of ΔQTH
is more complex. As discussed previously in Chapters 2 and 3, in addition to creating
novel YxxΦ motifs in Env, ΔQTH mutations affect the second exon of the Rev and
Tat proteins. In each of these, the deletion of the canonical second exon splice
acceptor site forces an alternative splicing pattern to occur. The effects of this
mutation are slightly different for YFQI and YFQL (Ch. 3, Fig. 12), but both delete
two amino acids from Rev (residues 25 and 26) and from Tat (residues 87 and 88). In
Rev, this deletion occurs in the first multimerization domain.260 Multimerization of
Rev is required for nuclear import and its function in mediating export of unspliced or
singly spliced viral mRNA from the nucleus.259,264,344 If the ΔQTH mutation ablates
functional residues and affects the ability of Rev to oligomerize, Rev function may be
substantially affected. Further, SIV Rev has been shown to be important for optimal
env expression.267 ΔQTH could therefore represent a second blow to virion Env levels
in addition to the effect of ΔGY. The dual hit of ΔGY and ΔQTH might reduce virion
Env to levels insufficient for efficient viral infectivity, producing the strongly
attenuated phenotype observed in PBMC growth assays.
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The tat open reading frame is also affected by ΔQTH, which produces a
deletion of residues 87 and 88. The Tat second exon was initially shown to be
dispensable for viral growth in vitro.345 However, subsequent work has demonstrated
that, at least for HIV, multiple functions depend on the Tat second exon. These
include efficient replication in vitro in peripheral blood lymphocytes via NF- κB
activation and LTR stimulation, delay of apoptosis in infected T cells, and modulation
of the induction of interferon stimulated genes (ISGs) in dendritic cells and
macrophages.256,257,346 It is also notable that the Tat second exon appears to be
important for efficient infection of monocyte-derived macrophages in vitro, which
could explain why ΔQTH mutants exhibit some improvements in pathogenicity but
still fail to infect macrophages to the extent of SIVmac239.255 While there are myriad
roles for the Tat second exon, ΔQTH does not overlap with mapped functional
domains in Tat, and so the specific effect of this mutation is not fully known.347
Interestingly, one investigation found that the Tat second exon is important for
chronic replication in vivo. Rhesus macaques infected with an SIVmac239 mutant
missing the second exon of Tat displayed a high peak viremia followed by a very low
set-point, similar to SIVmac239ΔGY in pig-tailed macaques. Multiple animals in this
study developed mutations to open the tat reading frame and restore the Tat second
exon, implying that its function is important in vivo.307 Thus, while it is likely that the
ΔQTH mutation has some effect on the function of Rev and Tat, we have not yet
evaluated the expression or function of these proteins in SIVmac239ΔGY ΔQTH
mutants and can only speculate as to the effect of this deletion.
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It is possible that the addition of R722G improves replication of YFQI and
YFQL by increasing total intracellular Env and compensating for a possible reduction
in Env transcripts due to the deletion in Rev. There is some preliminary evidence that
R722G does globally increase steady state intracellular Env levels (Scott Lawrence,
unpublished data). However, in transfected cell lines, ΔQTH does not substantially
decrease Env on virions below the level of SIVmac239ΔGY. We were not able to
assess Env levels on PBMCs for SIVmac239ΔGY + YFQI or YFQL due to very low
levels of infection of these cells. It is possible that SIVmac239ΔGY YFQI and YFQL
virions produced in PBMCs have very low levels of Env and that this explains their
poor replication. Initial infection in both PBMCs and CEMx174s (in which
SIVmac239ΔGY YFQI and YFQL did grow, albeit poorly) was established by viral
stocks produced in 293T cells, indicating that 293T-produced virions have adequate
Env levels to mediate initial infection. SIVmac239ΔGY YFQI and YFQL growth in
CEMx174 cells was sufficient to allow the R722G mutation to arise, indicating
replication levels that permitted evolution and selection for Env tail mutations. It is
possible that similar low level replication also occurred in PBMCs and that the length
of time and larger population of target cells in CEMx174 culture explains the
apparent improved replication in this cell type, i.e. that infection is not quantitatively
more efficient in CEMx174 cells than in PBMCs. It should be considered that, as
CEMx174 are a human-derived cell line lacking CCR5, the virus must use human
CD4 and alternative coreceptors such as GPR15 for entry.348 CEMx174 cells also
express CXCR4, and although SIVs are typically CCR5-tropic and do not acquire
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CXCR4 tropism, it is possible that discrepancies in coreceptor use could occur
between SIVmac239 and SIVmac239ΔGY-based mutants.204,349 We tested entry
dependence on CCR5 density of SIVmac239ΔGY compared to SIVmac239 and did
not appreciate differences between the two viruses, although the possibility of
alternative coreceptor use by ΔGY-containing mutants has not been fully explored.

To assess the effect of ΔQTH on viral function, the ΔQTH (YFQI and YFQL)
mutations could be introduced to SIVmac239 in the absence of ΔGY. Virion Env
content and growth of these viruses in CEMx174 cells and PBMCs could clarify
whether the observed growth defects are due to a double hit to Env of ΔGY and
ΔQTH, or if the Rev and Tat alterations might be deleterious independent of Env.
Mutations that affect only Rev and Tat, and not Env, could also be tested in the
context of ΔGY to better map determinants of the SIVmac239ΔGY ΔQTH growth
phenotype. Additional mechanistic studies are required to fully understand the effects
of gp41 mutations on Env function of SIVmac239, and may improve our
understanding of the benefit of these mutations in vivo.

Role of gp41 in Mediating Pathogenicity: Insights from env Evolution
The findings of this in vivo study with regard to effects of gp41 mutations on
viral natural history were somewhat unexpected. It is always difficult to make
concrete assertions when studies are performed in small numbers of animals.
However, overarching themes included 1) the acquisition of endocytosis and
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basolateral sorting motifs in progressing animals during chronic infection with
SIVmac239ΔGY R722G and 2) that the presence of the same motifs during early
infection did not appear to impart an advantage to the virus.

Both SIVmac239ΔGY R722G-infected progressors, which died before week
40 post-infection, developed confirmed or putative trafficking motifs in the region of
the SIVmac239ΔGY deletion. In one animal, a ΔQTH arose in a single genome at
week 10 post-infection, but during late infection this disappeared and was replaced by
three amino acid substitutions, one of which (P744L) created a novel dileucine motif.
The second animal developed a ΔQTH (residues 734-736 of Env) previously
observed in SIVmac239ΔGY-infected RhM progressors (YFQI), which became
nearly fixed by week 20 and had changed almost entirely to YFQL by week 34.
Neither sample could have been contaminated by samples from SIVmac239ΔGY
R722G YFQL-infected animals. Although the ΔQTH mutations creating the YFQI
and YFQL both delete residues 734-736, they are offset by one nucleotide, and YFQI
rather than YFQL was observed in each of the SIVmac239ΔGY R722G infected
progressors. We confirmed in Chapter 2 that YFQI and YFQL represent functional
endocytosis and basolateral sorting motifs. Assays for these functions, as described in
Chapter 2, are currently being performed on SIVmac239ΔGY containing the P744L
mutation in association with the other mutations that were observed (T735I and
Q739R). If this motif also confers endocytosis and/or basolateral sorting, we will
have powerful evidence that these functions are critical for the virus during long term
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infection. Reacquisition of these functions through separate mechanisms in multiple
animals would represent convergent evolution toward a common function. The
ΔQTH mutation is extremely unusual in that it affects three proteins in multiple
reading frames and requires deletion of nine nucleotides in a typically conserved
region of envelope. The P744L is selected early in infection, and results in the
introduction of a stop codon in the second exon of Tat. Tat truncations typically
revert in vivo, so evolution of a stop codon is a novel finding and suggests strong
selection pressure on Env in this context. Concerning ΔQTH, for such a large and
nonconservative deletion to become fixed in vivo also implies a significant benefit to
the virus, the mechanism of which is not fully understood. ΔQTH clearly contributes
to gain of function and likely is advantageous in vivo given the origin of this mutation
in animals. Selection during chronic infection favors the hypothesis that addition of
this mutation to the inoculum would result in an improvement in pathogenesis, i.e.
greater restoration of SIVmac239ΔGY defects such as targeting of mucosal CD4+
cells or macrophage infection, as well as ability to cause AIDS in macaques.
Conversely, fewer SIVmac239ΔGY R722G + YFQL animals progressed to AIDS
than SIVmac239ΔGY R722G alone. The apparent lack of advantage of the presence
of ΔQTH during early infection, coupled with its selection during chronic infection,
suggests that the function of this motif may be more important during the chronic
phase.
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A second possible consequence of disrupting Env targeting, which would
come into play much more strongly in vivo, is disturbance of virological synapses. As
discussed in Chapter 1, virological synapses are interactions that form between
surface Env on an infected cell and CD4 receptors on an uninfected target cell.117,295
In addition to permitting more efficient infection of target cells due to concentrated
presentation of virus, cell-to-cell spread through virological synapses also minimizes
exposure of viral antigen to the host immune system by allowing protected transfer of
virions between cells.117,271,295 This mechanism may permit replication to occur in
SIVmac239 infection even in the face of humoral immune responses and result in the
virus depleting target cells and the onset of AIDS. In contrast, a virus that was
efficient at cell-free spread but impaired in cell-to-cell replication might be
significantly hindered at the onset of humoral immunity. Although neutralizing
antibodies are not a factor in control of SIVmac239ΔGY or resistance to pathogenic
challenge viruses, the virus could be susceptible to non-neutralizing antibodies that
mediate ADCC. This is consistent with the finding that CD8 depletion of
SIVmac239ΔGY controllers results in a spike of viremia during depletion and that
control is regained when CD8+ cells are reconstituted.223 Thus, cell mediated
immunity, whether in the form of cytotoxic T lymphocytes, ADCC, or other
uncharacterized mechanisms, is clearly the primary driver of SIVmac239ΔGY control.
As such, avoidance of extracellular antigen exposure by decreasing Env on the cell
surface and facilitating cell-to-cell spread would potentially be beneficial for
propagation of SIVmac239ΔGY. This would be especially true during later infection
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when antibody responses are in play. Cell-to-cell spread is also thought to be
important in tissues; the gut lamina propria, for instance, is extremely cellular and has
high concentrations of potential target cells, as well as CD8+ T cells that could be
deleterious to viral spread.136 The relative ratio of virus to target cell may be lower in
tissues, favoring cell-to-cell spread and creating a greater disparity in propagation
efficiency of SIVmac239 versus SIVmac239ΔGY. Specific impairment of cell-to-cell
spread through virological synapses due to failure of Env targeting is a possible
explanation for SIVmac239ΔGY’s poor depletion of CD4+ T cells in gut despite its
ability to replicate to a robust acute peak.

Why, then, does ΔQTH not appear to be favorable for the virus during early
infection over the R722G alone? R722G may overcome the defect in virion Env
incorporation by increasing total levels on the cell surface, without specifically
targeting Env to sites of budding and virological synapse formation. In this model,
R722G would provide no improvement to the second proposed targeting function of
the tyrosine motif. Early during infection, this may be less important, and cell-free
spread sufficient for generating high acute peak viremia. Due to higher virion Env
levels, R722G alone may be more infectious than a virus with R722G and ΔQTH.
After adaptive immune responses are activated, evasion of antibody-mediated
immunity by cell-to-cell spread may be more important. This pressure would favor
evolution of trafficking motifs, as was observed in SIVmac239ΔGY R722G-infected
progressors. Ultimately, all progressors and the two viremic controllers (5/6 animals)
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were populated with viruses with Env proteins containing known or suspected
intracellular trafficking motifs. If R722G alone could not mediate this function, over
time, R722G progressors would be driven to select for endocytosis motifs that could
promote virological synapse formation and cell-to-cell spread, such as ΔQTH.
Dileucine motifs are not known to be involved in formation of virological synapses,
although it is possible that a dileucine-based signal could mediate basolateral sorting
or Env targeting to plasma membrane microdomains.

In summary, we have found evidence for the functional importance of the
gp41 membrane-proximal tyrosine motif both in vitro and in vivo. Residues in this
signal are involved in mediating incorporation of Env into virions, controlling
distribution of Env on the cell surface, and in directing endocytosis and trafficking of
this protein within the cell. These functions appear to coalesce to target Env to sites of
budding and perhaps virological synapse formation on the plasma membrane (Fig. 1).
We hypothesize that disruption of this motif impairs Env incorporation into virions as
well as cell-to-cell spread in vivo, rendering the virus more susceptible to control by
cellular and non-neutralizing antibody-mediated immune responses. In addition,
preservation of CD4+ T cells in GALT, possibly due to impaired mucosal spread as a
result of defects in synapse formation, results in robust polyfunctional cellular
immune responses from CD4+ T cells. These responses could function to provide
CD4+ help to CD8+ T cells, or could perform independently in a cytotoxic CD4+ killer
cell role. ThCTLs (cytotoxic CD4+ T cells) have been identified in HIV+ patients,
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Figure 4-1: Model for the role of the gp41 membrane-proximal tyrosine
motif in SIV pathogenesis.
Intracellular trafficking functions of the GYxx! motif are described in gray
boxes. Red boxes indicate implications of these functions for pathogenesis.
Known interactions with host proteins are listed as relevant.
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and similar SIV-specific cells with apparent cytotoxic capabilities (i.e.
granzyme) have been described in macaques infected with a live attenuated
SIV.282,325–327,350 Low level replication of SIVmac239ΔGY that provides continuous
antigenic stimulation is likely a contributor to the development of protective immune
responses and is consistent with prior findings that increased replication of live
attenuated vaccine strains correlates with stronger protection against challenge.181,351
Both CD4+ and CD8+ cellular responses may contribute to host control of viremia in
SIVmac239ΔGY infection and to protection from pathogenic challenge that has been
observed in these animals.

Selection pressure in vivo to repair the defect imparted by ΔGY has revealed
that functions of the GYxxΦ motif may be partially rescued by independent evolution
of components of this motif. However, at least in vivo, novel mutations do not appear
to function as efficiently as the wildtype sequence and, alone, are not sufficient to
restore SIVmac239-like pathogenesis to SIVmac239ΔGY. This incomplete rescue
may be due to the inability of novel motifs to mediate all functions of the SIVmac239
GYxxΦ (i.e. full rescue of some functions), or due to partial rescue of all functions
that is nonetheless inferior to SIVmac239. These studies have confirmed that the
membrane-proximal tyrosine motif of primate lentiviruses is intimately involved in
facilitating multiple aspects of viral pathogenesis, and that there is strong selection
pressure in vivo and in vitro to restore functions of the motif that are ablated by a
deletion in the motif. The contribution of the membrane-proximal tyrosine motif to
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gastrointestinal targeting should not be overlooked, though our studies have made
clear that this source of chronic immune activation is not required for development of
AIDS in macaques. Immune responses that are raised against SIVmac239ΔGY are
unique in their ability to prevent acquisition or facilitate control of pathogenic
challenge viruses, and further characterization of mechanisms underlying
SIVmac239ΔGY control can provide valuable information regarding correlates of
protection. Antibody mediated, neutralization-independent responses appear to be
capable of mediating protection in the absence of a neutralizing antibody response
and elicitation of such a response could represent a desirable goal for immunogen
design.

Future Directions
Future studies for the in vitro and in vivo aspects of this project have been
mentioned throughout this Chapter. In vitro, a pressing interest is to map the Env
incorporation function of the GYxxΦ domain. Assessment of virion Env levels of a
virus with only a Gly-720 deletion (SIVmac239ΔG) would confirm that this residue
is critical for mediating Env incorporation, as well as contributing to Env endocytosis.
Additionally, functional evaluation of the P744L mutant acquired by
SIVmac239∆GY R722G-infected animal KV73 is important for testing of our model.
P744L creates a dileucine motif ([DE]XXXL[LI]) in the region of the ΔGY mutation,
which could mediate endocytosis or intracellular Env trafficking. Examination of this
mutant in functional assays for virion and cellular Env content, endocytosis,
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subcellular localization, and basolateral sorting will provide critical information on a
potential model for convergent evolution of the cytoplasmic tail in vivo. If multiple
mutations arise in different animals that confer the same gain-of-function phenotype,
an extremely strong case can be made for the importance of these functions to the
virus during chronic infection. Additionally, the phenotype of SIVmac239 + ΔQTH
(without ΔGY) could provide insight into the effect of the Rev and Tat mutations on
viral function. Further specific studies to mutate only Rev and Tat in either
SIVmac239 or SIVmac239ΔGY while preserving the wildtype Env sequence at
amino acids 734-736 would be helpful to ascertain whether the effect of ΔQTH was
related primarily to changes in Env or in accessory proteins. SIVmac239 is functional
when using the noncanonical splice acceptor site A7, as occurs in ΔQTH.254 However,
ΔQTH also results in additional deletions to Rev and Tat, the effect of which has not
been characterized.

Another area of interest is in more specifically characterizing the effect of
ΔGY on Env distribution on infected cells. As the lipid envelope of HIV is enriched
for particular host plasma membrane lipids and proteins, HIV budding appears to
preferentially target host plasma membrane microdomains termed lipid rafts, with
gp41 being implicated in determining targeting.107 Sucrose gradient
ultracentrifugation could be used to separate raft-associated host protein fractions
from cytosolic fractions and the fraction enriched in SIV Env of SIVmac239 Env
compared to SIVmac239ΔGY.352,353 Differences in host protein fraction association
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would provide biochemical evidence for failure of Env targeting function in
SIVmac239ΔGY. Given the resolution limitations of the imaging flow cytometry
used in this thesis, imaging of virological synapses using higher resolution techniques
such as electron microscopy in SIVmac239 and SIVmac239ΔGY infected cell culture
would be particularly interesting.272 High resolution images of this structure would
allow us to definitively establish the ability of SIVmac239ΔGY and its derivatives to
target to sites of synapse formation. These assays could also be performed in PBMCs,
pre-sorted to identify SIV-infected cells, as a more physiologically relevant model.

In vitro results for the above assays may help determine the path forward for
in vivo studies. If the novel dileucine at amino acids 743 and 744 is determined to be
functional, a SIVmac239ΔGY with this mutation added could be used to inoculate
naïve macaques to characterize its ability to cause disease in vivo. Further studies in
pig-tailed macaques could also be conducted to determine whether an additional
cocktail of mutations could fully restore pathogenesis to SIVmac239ΔGY. For
example, addition of V67M, which arises in all SIVmac239ΔGY progressors and is
associated with macrophage tropism in SIVmac316, may affect macrophage infection
if included in the inoculum.222,223,287 Other commonly described mutations that may
improve replication of SIVmac239ΔGY include the E750G and R751G. R751G is
characterized in SIVmac239 and is unlikely to be a critical determinant of the
differential phenotype of SIVmac239ΔGY and SIVmac239.306 However, the additive
effects of several mutations may provide a small advantage to SIVmac239ΔGY in
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early infection and, in doing so, tip the competitive balance to allow viral escape from
host immune responses.

It would also be advisable to investigate SIVmac239ΔGY R722G±YFQL in
larger groups of pig-tailed macaques, and to perform MHC typing on these animals,
which was not done in the present study. It is possible that the single animal that
controlled SIVmac239ΔGY R722G may have had a viremia phenotype influenced by
controller MHC alleles.171–173,331 This animal had the lowest peak viremia and was the
only SIVmac239ΔGY R722G infected animal that remained alive, in contrast to the
other two animals that died prior to week 40 post-infection. Larger sample sizes and
MHC genotyping would reduce the possibility of confounding variables affecting our
assessment of in vivo pathogenesis of these viruses. Finally, for the original six
animals and for any additional animals, analysis of cellular and humoral immune
responses would provide valuable information for comparison to SIVmac239ΔGY
controllers and for SIVmac239ΔGY R722G±YFQL infected progressors versus
controllers. Differences in magnitude, breadth, or epitope targets in animals with
differing outcomes would help identify immune responses that correlate with control
of viremia.

SIVmac239ΔGY and its derivatives are valuable tools for characterizing the
functions and sequence requirements of the gp41 proximal tyrosine motif and for
mapping determinants of pathogenicity in env. This virus also holds promise as a live
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attenuated vaccine model, in which unprecedented protection against diverse
challenge strains has been elicited. We have confirmed that the membrane-proximal
GYxxΦ motif is a critical mediator of essential Env trafficking functions, and found
that residues within this motif make independent contributions to facilitate virion
assembly and spreading infection. Through mutational analysis, we determined that
components of this signal, while capable of restoring multiple functions of the
wildtype domain, are not equivalent to the SIVmac239 sequence in their ability to
produce a pathogenic infection. Identification of motifs and their associated functions
that correlate with restoration of each aspect of SIVmac239 natural history provides
insight to mechanisms of SIV pathogenesis. Thus, we have shown that the primate
lentivirus gp41 membrane-proximal GYxxΦ motif is indispensible for mediating Env
incorporation into virions, for trafficking of the protein within cells and at the cell
surface, and in resistance to immune responses in vivo, possibly related to formation
of the virological synapse and facilitation of cell-to-cell spread.
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